Aminoheteroaryl kinase inhibitors

JP2024506116A5Active Publication Date: 2024-12-04ALLORION THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023531615
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-03-17
Filing Date
2021-11-26
Publication Date
2024-12-04
Estimated Expiration
2041-11-26

AI Technical Summary

Technical Problem

Cyclin-dependent kinase 2 (CDK2) plays a crucial role in cell cycle progression and is frequently altered in various cancers, leading to chemotherapy resistance and poor outcomes, highlighting the need for selective CDK2 inhibitors to treat cancers with high cyclin E1 and/or E2 expression.

Method used

Development of novel heteroaryl compounds that selectively inhibit CDK2 over other kinases, providing therapeutic options for treating cancers characterized by cyclin E1 and/or E2 amplification or overexpression.

Benefits of technology

These compounds effectively inhibit CDK2 activity, offering potential treatments for breast, ovarian, and other cancers, including those resistant to CDK4/6 inhibitors, with minimal clinical toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022111621000001
    Figure 2022111621000001
  • Figure 2022111621000002
    Figure 2022111621000002
  • Figure 2022111621000003
    Figure 2022111621000003
Patent Text Reader

Abstract

Provided herein are novel compounds (e.g., of formula I or II), pharmaceutical compositions, and methods of use related to cyclin-dependent kinase (CDK).The compounds herein are typically CDK2 inhibitors that can be used to treat various diseases or disorders, such as cancer. TIFF2024506116000394.tif63170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to International Application No. PCT / CN2021 / 081236, filed March 17, 2021, and PCT / CN2020 / 132454, filed November 27, 2020, the contents of each of which are incorporated herein by reference in their entirety for all purposes.

[0002] Technical Field In various embodiments, the present disclosure relates generally to novel heteroaryl compounds, compositions comprising same, methods for preparing same, and methods of using same, e.g., to inhibit cyclin-dependent kinases and / or to treat or prevent various diseases or disorders described herein. [Background technology]

[0003] Cyclin-dependent kinases (CDKs) are a family of serine / threonine protein kinases that regulate cell cycle progression. Among CDKs, CDK2 is an essential driver for cells to transition from late G1 to the S and G2 phases. During late G1, CDK2 is activated upon binding to cyclin E. The cyclin E / CDK2 complex hyperphosphorylates RB, releasing E2F from RB and initiating transcription of genes required for the G1 / S transition. CDK2 then forms a complex with cyclin A to regulate S phase progression by activating proteins important for DNA replication and centrosome duplication, such as the DNA replication licensing protein (CDC6) and the centrosomal protein CP110 (Non-Patent Document 1).

[0004] Cyclin E1 is frequently amplified and / or overexpressed in human cancers. In high-grade serous ovarian cancer, cyclin E1 amplification is detected in approximately 20% of patients and is associated with chemotherapy resistance / refractory status (Non-Patent Document 2, Non-Patent Document 3). Ovarian cancer cell lines with amplified cyclin E1 are sensitive to reagents that either inhibit CDK2 activity or reduce cellular CDK2 protein levels, suggesting CDK2 dependency in these cyclin E1-amplified cells (Non-Patent Document 4). Poor outcomes and drug resistance have also been associated with high cyclin E1 expression in endometrial, gastric, breast, and other cancers (Non-Patent Document 5, Non-Patent Document 6, Non-Patent Document 7). Estrogen receptor (ER)-positive breast cancer cell lines with acquired resistance to the CDK4 / 6 inhibitor palvocyclib have elevated cyclin E1 expression and can become re-sensitive upon CDK2 knockdown (Non-Patent Document 8). High cyclin E1 levels have also been reported to be associated with poor response to palvocyclib and fulvestrant combination treatment in ER+ BC (CCNE1 high vs. CCNE1 low: median PFS for the palvocyclib + fulvestrant arm, 7.6 vs. 14.1 months; placebo + fulvestrant arm, 4.0 vs. 4.8 months), further highlighting the importance of CDK2 activity in mediating resistance to CDK4 / 6 inhibitors (Non-patent Document 9).

[0005] Cyclin E2 (CCNE2) overexpression has been reported to be associated with endocrine therapy resistance in breast cancer cells, and CDK2 inhibition has been reported to restore sensitivity to tamoxifen or CDK4 inhibitors in tamoxifen-resistant and CCNE2-overexpressing cells (Non-Patent Document 10, Non-Patent Document 11). Furthermore, cyclin E amplification has also been reported to contribute to trastuzumab resistance in HER2+ breast cancer (Non-Patent Document 12). Furthermore, cyclin E overexpression has been reported to play a role in basal-like and triple-negative breast cancer (TNBC) and inflammatory breast cancer (Non-Patent Document 13, Non-Patent Document 14). [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Tadesse et al.Targeting CDK2 in cancer: challenges and opportunities for therapy,Drug Discovery Today.2019;25(2):406-413 [Non-patent document 2] TCGA,Integrated genomic analyzes of ovarian carcinoma,Nature.2011;474:609-615 [Non-patent document 3] Nakayama et al;Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer,Cancer(2010)116:2621-34 [Non-patent document 4] Au-Yeung et al.Selective targeting of cyclin E1 amplified high grade serous ovarian cancer by clin-dependent kinase 2 and AKT inhibition,Clin.Cancer Res.2017;23(7):1862-1874 [Non-Patent Document 5] Noske et al.,Detection of CCNE1 / URI(19q12)amplification by in situ hybridization is common in high grade and type II endometrial cancer,Oncotarget(2017)8:14794-14805 [Non-patent document 6] Ooi et al., Gene amplification of CCNE1,CCND1 and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization,Hum Pathol.(2017)61:58-67 [Non-Patent Document 7] Keyomarsi et al.,Cyclin E and survival in patients with breast cancer.N Engl J Med.(2002)347:1566-75 [Non-patent document 8] Herrera-Abreu et al., Early adaptation and acquired resistance to CDK4 / 6 inhibition in estrogen receptor-positive breast cancer, Cancer Res. (2016)76:2301-2313 [Non-Patent Document 9] Turner et al.,Cyclin E1 expression and Palbociclib efficacy in previously treated hormone receptor positive metastatic breast cancer Clin Oncol.(2019)37(14):1169-1178 [Non-Patent Document 10] Caldon et al.,Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.Mol Cancer Ther.(2012)11:1488-99 [Non-Patent Document 11] Herrera-Abreu et al.,Early Adaptation and Acquired Resistance to CDK4 / 6 Inhibition in Estrogen Receptor-Positive Breast Cancer,Cancer Res.(2016)76:2301-2313 [Non-Patent Document 12] Scaltriti et al.Cyclin E amplification / overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients,Proc Natl Acad Sci.(2011)108:3761-6 [Non-Patent Document 13] Elsawaf & Sinn, Triple Negative Breast Cancer: Clinical and Histological Correlations, Breast Care(2011)6:273-278 [Non-Patent Document 14] Alexander et al.,Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer,Oncotarget(2017)8:14897-14911 Summary of the Invention [Means for solving the problem]

[0007] The importance of CDK2 in tumor proliferation pathways and the frequent altered CDK2 / cyclin E1 activity highlight CDK2 as a target for cancer therapy. CDK2 knockout mice survive with minimal defects, suggesting that CDK2 is not essential for normal cell proliferation (Berthet et al., CDK2 knockout mice are viable. Curr Biol. (2003) 13(20):1775-85). Furthermore, selective CDK2 inhibitors may be effective in treating patients with high tumor cyclin E1 and / or E2 expression while minimizing clinical toxicity. However, in certain embodiments, inhibiting CDK2 as well as other CDKs may also be clinically beneficial.

[0008] In various embodiments, the present disclosure relates to novel heteroaryl compounds that can, for example, selectively inhibit CDK2 over other CDKs and / or other kinases. The compounds and compositions herein are useful for treating various diseases or disorders, e.g., cancers, e.g., those characterized by amplification or overexpression of cyclin E1 (CCNE1) and / or cyclin E2 (CCNE2).

[0009] Certain embodiments of the present disclosure include a compound of Formula I or II, or a pharmaceutically acceptable salt thereof: [ka] wherein the variables are defined herein. In certain embodiments, the compound of formula I can have a subformula of I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB, as defined herein. In certain embodiments, the compound of Formula II can have the subformula II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4, as defined herein. In certain embodiments, the present disclosure also provides a specific compound selected from any of Examples 1-155, or any of the specific compounds disclosed in Tables 1A or 1B herein, or a pharmaceutically acceptable salt thereof.

[0010] In some embodiments, the present disclosure provides pharmaceutical compositions comprising one or more compounds of the present disclosure and, optionally, a pharmaceutically acceptable excipient. The pharmaceutical compositions can typically be formulated for oral administration.

[0011] In certain embodiments, the present disclosure also provides a method for inhibiting CDK activity, such as CDK2 activity, in a subject or biological sample. In certain embodiments, the method includes administering to the subject or biological sample an effective amount of one or more compounds of the present disclosure, e.g., compounds of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8A, IA-9A, IA-10A, IA-10B, IA-10C, IA-10D, IA-10E, IA-10F, IA-10H ... -8B, IA-9B, IA-10B, or IB), a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising same.

[0012] In certain embodiments, the present disclosure provides a method for treating or preventing a CDK-mediated disease or disorder in a subject in need thereof. In certain embodiments, the method comprises administering to the subject an effective amount of one or more compounds of the present disclosure or pharmaceutical compositions herein. In certain embodiments, the method comprises administering to the subject an effective amount of one or more compounds of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-1 0B, or IB), a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising same, to a subject.

[0013] In certain embodiments, the present disclosure also provides a method of treating or preventing cancer in a subject in need thereof, comprising administering an effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8A, IA-9A, IA-10A, IA-11A, IA-12A, IA-13A, IA-14A, IA-15A, IA-16A, IA-17A, IA-18A, IA-19A, IA-20A, IA-21A, IA-22A, IA-23A, IA-24A, IA-25A, IA-26A, IA-27A, IA-28A, IA-29A, IA-30A, IA-31A, IA-32A, IA-33A, IA-34A, IA-35A, IA-36A, IA-37A, IA-38A, IA-39A, IA-40A, IA-41A, IA-42A, IA-43A, IA-44A, IA-45A, IA-46A, IA-47A, IA-48A, IA-49A, IA-50A, IA-51A, and / or a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition described herein, is administered to a subject. In some embodiments, the cancer is characterized by amplification or overexpression of CCNE1 and / or CCNE2. In some embodiments, the cancer is selected from breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer (including NSCLC, SCLC, squamous cell carcinoma, or adenocarcinoma), esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer (including RCC), liver cancer (including HCC), pancreatic cancer, stomach (i.e., gastric) cancer, thyroid cancer, and combinations thereof. In some embodiments, the cancer is breast cancer selected from ER-positive / HR-positive, HER2-negative breast cancer; ER-positive / HR-positive, HER2-positive breast cancer; triple-negative breast cancer (TNBC); and inflammatory breast cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is breast cancer selected from endocrine therapy-resistant breast cancer, trastuzumab-resistant breast cancer, or breast cancer exhibiting primary or acquired resistance to CDK4 / CDK6 inhibition. In some embodiments, the cancer is advanced or metastatic breast cancer. In some embodiments, the cancer is ovarian cancer.

[0014] The administration in the methods herein is not limited to any particular route of administration. For example, in some embodiments, administration can be oral, nasal, transdermal, pulmonary, inhalation, buccal, sublingual, intraperitoneal, subcutaneous, intramuscular, intravenous, rectal, intrapleural, intrathecal, and parenteral. In some embodiments, administration is oral administration. In some embodiments, administration is parenteral injection, such as intravenous injection.

[0015] The compounds of the present disclosure can be used as monotherapy or in combination therapy. In some embodiments of the methods described herein, one or more compounds of the present disclosure can be administered as the only active ingredient. In some embodiments, the methods herein further include administering to the subject an additional therapeutic agent, for example, an additional anti-cancer agent described herein.

[0016] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention herein. DETAILED DESCRIPTION OF THE INVENTION

[0017] In various embodiments, the present disclosure provides compounds and compositions useful for inhibiting CDKs, such as CDK2, and / or treating or preventing various diseases or disorders described herein, e.g., cancer.

[0018] compound The compounds of the present disclosure are generally aminopyridine or aminopyrimidine derivatives represented by Formula I or II described herein. The compounds herein can typically inhibit CDK2. In some embodiments, the compounds herein can selectively inhibit CDK2 over other CDKs. For example, as shown in the Examples section herein, certain exemplified compounds have been shown to be more potent at inhibiting CDK2 over CDK1 with greater than 10-fold, and up to about 30-fold or greater selectivity.

[0019] Formula I In certain embodiments, the present disclosure provides a compound of Formula I, or a pharmaceutically acceptable salt thereof: [ka] (In the formula: L 1 is an optionally substituted arylene (e.g., phenylene), an optionally substituted heteroarylene (e.g., 5- or 6-membered heteroarylene), an optionally substituted heterocyclylene (e.g., 4- to 8-membered heterocyclylene), or an optionally substituted carbocyclylene (e.g., C 3~8 carbocyclylene); R 1 But SO2R 10 , SO2NR 11 R 12 , S(O)(NH)R 10 , or C(O)NR 11 R 12 or R 1 is hydrogen or NR 11 R 12 and; X is N or CR 13 and; L 2 is the bond, -N(R 14 )- or -O-; L 3 is a bond, optionally substituted C 1~4 Alkylene or optionally substituted C 1~4 is heteroalkylene; R 2 is hydrogen, optionally substituted C 3~8 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted 4-10 membered heterocyclyl, optionally substituted phenyl, or optionally substituted 5-10 membered heteroaryl; R 3 is hydrogen, halogen (e.g., F), CN, C(O)NR 11 R 12 , optionally substituted C 1~6 Alkyl, optionally substituted C 2~4 Alkenyl, optionally substituted C 2~4 Alkynyl, optionally substituted C1~4 Heteroalkyl, OR A , C.O.R. B , COOR A , N.R. 11 R 12 , optionally substituted C 3~8 carbocyclyl, optionally substituted 4-10 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl; R 4 is hydrogen, halogen (e.g., F), optionally substituted C 1~6 Alkyl or NR 11 R 12 and; or L 2 and R 3 together with the intervening atoms form an optionally substituted 4- to 8-membered ring structure; or R 3 and R 4 together with the intervening atoms form an optionally substituted 4- to 8-membered ring structure; where: R 10 is arbitrarily substituted C 1~6 alkyl (e.g., C optionally substituted with carbocycle, heterocycle, or heteroaryl) 1~4 alkyl), optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl (e.g., 5- or 6-membered heteroaryl), or optionally substituted 4- to 10-membered heterocyclyl; R 11 and R 12 each occurrence independently represents hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl (e.g., 5- or 6-membered heteroaryl), optionally substituted 4- to 10-membered heterocyclyl; or a nitrogen protecting group; or R 11 and R 12 may be joined to form an optionally substituted 4- to 10-membered heterocyclyl or 5- or 6-membered heteroaryl; R A is hydrogen, optionally substituted C 1~6Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl (e.g., 5- or 6-membered heteroaryl), optionally substituted 4- to 10-membered heterocyclyl; or an oxygen protecting group; R B is hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted 4- to 10-membered heterocyclyl, or optionally substituted heteroaryl (e.g., 5- or 6-membered heteroaryl); R 13 is hydrogen, F, CN, -OH, optionally substituted C 1~4 Alkyl, optionally substituted C 1~4 Heteroalkyl, optionally substituted C 3~8 carbocyclyl, or optionally substituted 4-10 membered heterocyclyl; R 14 is hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl (e.g., 5- or 6-membered heteroaryl), optionally substituted 4- to 10-membered heterocyclyl; or a nitrogen protecting group. to provide.

[0020] In certain embodiments, compounds of Formula I (including any of the applicable subformulas described herein) may contain one or more asymmetric centers and / or axial chirality and therefore may exist in various stereoisomers, e.g., enantiomers and / or diastereomers. In certain embodiments, compounds of Formula I may exist in the form of individual enantiomers and / or diastereomers, if applicable, or mixtures of stereoisomers (including racemic mixtures and mixtures enriched in one or more stereoisomers). In certain embodiments, compounds of Formula I (including any of the applicable subformulas described herein) may exist as isolated individual enantiomers substantially free of other enantiomers (e.g., less than 20%, less than 10%, less than 5%, less than 1%, or undetectable amounts by weight, HPLC, or SFC area, or both). In certain embodiments, compounds of Formula I (including any of the applicable subformulas described herein) may also exist as mixtures of stereoisomers in any ratio, such as racemic mixtures, if applicable.

[0021] In certain embodiments, compounds of Formula I (including any of the applicable subformulas described herein) may exist as isotopically labeled compounds, particularly deuterated analogs, in which one or more of the hydrogen atoms of a compound of Formula I has been replaced with a deuterium atom having an abundance greater than its natural abundance, e.g., if the compound has a CH3 group, a CD3 analog.

[0022] It should be apparent to one skilled in the art that in some cases, compounds of Formula I may exist as a mixture of tautomers. The present disclosure is not limited to any particular tautomer. Rather, the present disclosure encompasses all such tautomers, whether or not explicitly depicted or referred to.

[0023] Typically, X in formula I is N and the compound of formula I has the formula IA: [ka] wherein L 1 , L 2, L 3 , R 1 , R 2 , R 3 , and R 4 in any combination, including any of those described herein.

[0024] In one embodiment, X in formula I is CR 13 wherein R 13 is defined herein. For example, in one embodiment, R 13 can be hydrogen, and the compound of formula IB: [ka] wherein L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , and R 4 in any combination, including any of those described herein.

[0025] Various groups can be represented by L in Formula I. 1 For example, in one embodiment, L in Formula I is 1 In some embodiments, L in Formula I can be an optionally substituted phenylene. 1 can be an optionally substituted 5- or 6-membered heteroarylene, e.g., having 1 to 3 ring heteroatoms independently selected from N, O, and S. In some embodiments, L in formula I 1 can be an optionally substituted 4- to 8-membered heterocyclylene, e.g., a monocyclic or bicyclic (e.g., fused, bridged, or spiro bicyclic) 4- to 8-membered heterocyclylene having 1 to 2 ring heteroatoms independently selected from N, O, and S. In some embodiments, L in Formula I 1 is an arbitrarily substituted C 3~8 The carbocyclylene can be, for example, a monocyclic or bicyclic (eg, fused, bridged, or spiro bicyclic) carbocyclylene.

[0026] In certain embodiments, L in Formula I (e.g., any of the subformulas described herein, e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB, as applicable) 1 but, [ka] is selected from: When valences allow, n is 0, 1, 2, 3, or 4; R 100 each occurrence independently represents halogen (e.g., F or Cl), CN, OH, optionally substituted C 1~4 Alkyl, optionally substituted C 1~4 Alkoxy and optionally substituted C 1~4 Typically, n is 0, 1, or 2.

[0027] In certain embodiments, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 is unsubstituted phenylene, pyridylene, piperidinylene, or cyclohexylene. For example, in certain embodiments, L 1 but, [ka] is.

[0028] In certain embodiments, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 but, [ka] is selected from: n is 1 or 2; R 100 each occurrence independently represents C optionally substituted with F, Cl, CN, OH, F 1~4 alkyl, C optionally substituted with F 1~4 C optionally substituted with alkoxy and F 1~4 heteroalkyl.

[0029] In certain embodiments, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 is phenylene, pyridylene, piperidinylene, or cyclohexylene, each of which can be optionally further substituted, for example, mono- or di-substituted. For example, in certain embodiments, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 but, [ka] is selected from: R 100 is F, Cl, CN, OH, methyl, fluorine-substituted methyl such as CF3, methoxy, or fluorine-substituted methoxy. In any of the embodiments herein, unless specified or contradicted by context, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 but, [ka] In any of the embodiments herein, unless specified or contradicted by context, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) may be selected from: 1 but, [ka] It could be.

[0030] R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 The group is typically a sulfone, sulfonamide, sulfonimine, or amide. For example, in some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But SO2R 10 where R 10 is defined herein. In certain embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But SO2NR 11 R 12 where R 11 and R 12 is defined herein. In certain embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But S(O)(NH)R 10 where R 10is defined herein. In some embodiments, R in Formula I (e.g., Formula IA or IB) 1 But C(O)NR 11 R 12 where R 11 and R 12 is defined herein.

[0031] In certain more specific embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But SO2R 10 where R 10 is arbitrarily substituted C 1~4 Alkyl, optionally substituted C 3~6 cycloalkyl, or an optionally substituted 4-8 membered heterocyclyl having 1 or 2 ring heteroatoms independently selected from N, O, and S. In certain more specific embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But SO2R 10 where R 10 is an optionally substituted 5- or 6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, O, and S.

[0032] In some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But SO2R 10 where R 10 But C 1~4 Alkyl, (C 1~4 alkylene) j -C 3~6cycloalkyl or having 1 or 2 ring heteroatoms independently selected from N, O, and S (C 1~4 alkylene) j - 4 to 8 membered monocyclic heterocyclyl, or R 10 However, (C 1~4 alkylene) j -(5- or 6-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O, and S); where j is 0 or 1, and C 1~4 alkylene is a straight or branched alkylene chain optionally substituted with F; where C 1~4 Alkyl, C 3~6 Each of cycloalkyl, 5- or 6-membered heteroaryl, and 4- to 8-membered monocyclic heterocyclyl is oxo, F, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 In some embodiments, j is 0. In some embodiments, j is 1. In some embodiments, R 10 C optionally substituted with 1 to 3 F such as CH2F, CF3 1~4 In one embodiment, R 10 may be optionally substituted, -(C 1~4 Alkylene)-C 3~6 cycloalkyl, for example, CH2-cyclopropyl. In some embodiments, R 10 may be optionally substituted, -(C 1~4alkylene)-(4- to 8-membered monocyclic heterocyclyl), for example, —CH-tetrahydrofuranyl. 10 may be a 5- or 6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, O, and S, such as pyrazole, imidazole, triazole, etc., which may be, for example, C 1~4 In any of the embodiments herein, unless specified or contradicted by context, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 In some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) can be SOMe. 1 but, [ka] In some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) can be selected from: 1 but, [ka] In some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) can be selected from: 1 but, [ka] may be selected from:

[0033] In some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But S(O)(NH)R 10 , i.e., [ka] wherein R 10 is arbitrarily substituted C 1~4 Alkyl, optionally substituted C 3~6 cycloalkyl, or an optionally substituted 4- to 8-membered heterocyclyl having 1 or 2 ring heteroatoms independently selected from N, O, and S, or an optionally substituted 5- or 6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, O, and S.

[0034] In certain more specific embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But S(O)(NH)R 10 , i.e., [ka] wherein R 10 But C 1~4 Alkyl, (C 1~4 alkylene) j -C 3~6 Cycloalkyl, having 1 or 2 ring heteroatoms independently selected from N, O, and S (C 1~4 alkylene) j - 4 to 8 membered monocyclic heterocyclyl, or R 10 However, (C 1~4 alkylene) j -(5- or 6-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O, and S); where j is 0 or 1, and C 1~4 alkylene is a straight or branched alkylene chain optionally substituted with F; where C 1~4 Alkyl, C 3~6 Each of cycloalkyl, 5- or 6-membered heteroaryl, and 4- to 8-membered monocyclic heterocyclyl is oxo, F, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 In some embodiments, j is 0. In some embodiments, j is 1. In any of the embodiments herein, unless specified or contradicted by context, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 can be S(O)(NH)Me.

[0035] In some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But SO2NR 11 R 12 where R 11 and R 12 are independently hydrogen, optionally substituted C 1~4 Alkyl, optionally substituted C3~6 cycloalkyl, or an optionally substituted 4-8 membered heterocyclyl having 1 or 2 ring heteroatoms independently selected from N, O, and S. In certain embodiments, R 11 and R 12 is hydrogen and R 11 and R 12 For example, in some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But SO2NR 11 R 12 where R 11 and R 12 is hydrogen and R 11 and R 12 The other is hydrogen, optionally substituted C 1~4 Alkyl, optionally substituted C 3~6 cycloalkyl or an optionally substituted 4-8 membered heterocyclyl having 1 or 2 ring heteroatoms independently selected from N, O, and S.

[0036] In certain more specific embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But SO2NR 11 R 12 where R 11 and R 12 are independently hydrogen, C 1~4 Alkyl, (C 1~4 alkylene) j -C 3~6 Cycloalkyl, having 1 or 2 ring heteroatoms independently selected from N, O, and S (C 1~4 alkylene) j - 4- to 8-membered monocyclic heterocyclyl; where j is 0 or 1, and C 1~4alkylene is a straight or branched alkylene chain optionally substituted with F; where C 1~4 Alkyl, C 3~6 Each of cycloalkyl and 4- to 8-membered monocyclic heterocyclyl is oxo, deuterium, F, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 In some embodiments, j is 0. In some embodiments, j is 1. In some embodiments, R 11 and R 12 is hydrogen and R 11 and R 12 and the other is described herein. In some embodiments, R 11 and R 12 is methyl or CD3, and R 11 and R 12 and the other is described herein. In some embodiments, R 11 and R 12 In one embodiment, both of R 11 and R 12 is hydrogen and R 11 and R 12 the other is C optionally substituted with 1 to 3 F and / or deuterium 1~4 alkyl, such as CH, isopropyl, tert-butyl, CD, etc. In some embodiments, R 11 and R 12 is hydrogen and R 11 and R12 The other is C 3~6 Cycloalkyl, for example, cyclopropyl or cyclobutyl, which may be optionally substituted, for example, with one or two F. In certain embodiments, R 11 and R 12 is hydrogen and R 11 and R 12 and the other is a 4- to 8-membered monocyclic heterocyclyl having 1 to 3 ring heteroatoms independently selected from N, O, and S, such as oxetane, tetrahydrofuran, tetrahydropyran, piperidine, etc., which is, for example, C 1~4 It may be optionally substituted with alkyl (e.g., methyl). In some embodiments, R 11 and R 12 is hydrogen and R 11 and R 12 The other is -(C 1~4 alkylene)-(4-8 membered monocyclic heterocyclyl having 1-3 ring heteroatoms independently selected from N, O, and S), such as —CH— (oxetane), which is, for example, C 1~4 It may be optionally substituted with alkyl (eg, methyl).

[0037] In some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But SO2NR 11 R 12 where R 11 and R 12 are combined to form R 11 and R 12 and R form an optionally substituted 4-8 membered heterocyclyl having, in addition to the nitrogen atom to which they are both attached, zero or one ring heteroatom selected from N, O, and S. For example, in some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1But SO2NR 11 R 12 where R 11 and R 12 are combined to form R 11 and R 12 and form a 4-8 membered monocyclic heterocyclyl having, in addition to the nitrogen atom to which both are attached, zero or one ring heteroatom selected from N, O, and S, such as morpholinyl or piperazinyl, which is substituted with oxo, deuterium, F, G, 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 It is cycloalkyl.

[0038] In certain preferred embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 In certain preferred embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 but, [ka] In certain preferred embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 but, [ka] may be selected from:

[0039] In some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But C(O)NR 11 R 12 where R 11 and R 12 are independently hydrogen, optionally substituted C 1~4 Alkyl, optionally substituted C 3~6 cycloalkyl, or an optionally substituted 4-8 membered heterocyclyl having 1 or 2 ring heteroatoms independently selected from N, O, and S. In certain embodiments, R 11 and R 12 is hydrogen and R 11 and R 12 For example, in some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But C(O)NR 11 R 12 where R 11 and R 12 is hydrogen and R 11 and R 12 The other is hydrogen, optionally substituted C 1~4 Alkyl, optionally substituted C 3~6cycloalkyl or an optionally substituted 4-8 membered heterocyclyl having 1 or 2 ring heteroatoms independently selected from N, O, and S.

[0040] For example, in some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But C(O)NR 11 R 12 where R 11 and R 12 are independently hydrogen, C 1~4 Alkyl, (C 1~4 alkylene) j -C 3~6 Cycloalkyl, having 1 or 2 ring heteroatoms independently selected from N, O, and S (C 1~4 alkylene) j - 4- to 8-membered monocyclic heterocyclyl; where j is 0 or 1, and C 1~4 alkylene is a straight or branched alkylene chain optionally substituted with F; where C 1~4 Alkyl, C 3~6 Each of cycloalkyl and 4- to 8-membered monocyclic heterocyclyl is oxo, deuterium, F, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6In some embodiments, j is 0. In some embodiments, j is 1. In some embodiments, R 11 and R 12 is hydrogen and R 11 and R 12 For example, in some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 can be C(O)NHMe.

[0041] In some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But C(O)NR 11 R 12 where R 11 and R 12 are combined to form R 11 and R 12 and R form an optionally substituted 4-8 membered heterocyclyl having, in addition to the nitrogen atom to which they are attached, zero or one ring heteroatom selected from N, O, and S. For example, in some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 But C(O)NR 11 R 12 where R 11 and R 12 are combined to form R 11 and R 12 and form a 4-8 membered monocyclic heterocyclyl having, in addition to the nitrogen atom to which they are attached, 0 or 1 ring heteroatom selected from N, O, and S, which is oxo, deuterium, F, G 1 , OH, OG 1 , NH2, NH(G 1), and N(G 1 )(G 1 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 For example, in some embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) is cycloalkyl. 1 but, [ka] It could be.

[0042] Compounds of Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) can be prepared by the addition of L 1 and R 1 In any of the embodiments herein, unless specified or contradicted by context, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) may be any of various combinations of L, I ... 1 -R 1 but, [ka] or L 1 -R 1 but, [ka] is.

[0043] In any of the embodiments herein, unless specified or contradicted by context, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) 1 -R 1 but, [ka] In any of the embodiments herein, unless specified or contradicted by context, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, or IB) may be selected from: 1 -R 1 but, [ka] In one embodiment, L in formula I 1 -R 1 but, [ka] In one embodiment, L in formula I 1 -R 1 but, [ka] It could be.

[0044] In certain preferred embodiments, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, or IB) 1-R 1 but, [ka] may be selected from:

[0045] In certain preferred embodiments, L in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB) 1 -R 1 Where applicable, the piperidine ring, e.g. [ka] may contain

[0046] For example, in certain embodiments, the compound of formula IA can be characterized as having a formula represented by any of the following formulas IA-1, IA-2, IA-3, or IA-4: [ka] In the formula, L 2 , L 3 , R 2 , R 3 , and R 4 includes any of those described herein in any combination.

[0047] In certain embodiments, L in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB) 2 can be a bond, in which case L 3 -R 2 is attached directly to the pyridine or pyrimidine ring in Formula I.

[0048] In certain embodiments, L in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB) 2 can be -O-.

[0049] In certain embodiments, L in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB) 2 But -N(R 14 )-, where R 14 is defined herein. For example, in one embodiment, R 14 can be hydrogen. In some embodiments, R 14 But, oxo, F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 ) optionally replaced by C 1~4 alkyl, where G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 It is cycloalkyl.

[0050] In certain embodiments, L in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB) 3 can be a bond, in which case R 2 But, L 2 or L 2 If is also a bond, R 2 is attached directly to the pyridine or pyrimidine ring in Formula I.

[0051] In certain embodiments, L in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB) 3 is arbitrarily substituted C 1~4 It can be alkylene, for example, CH2.

[0052] In certain embodiments, L in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB) 3 is, for example, an optionally substituted C 1~4 It may be heteroalkylene.

[0053] Various groups can be represented by R in Formula I. 2 For example, in one embodiment, R 2 can be hydrogen. In some embodiments, R 2 is arbitrarily substituted C 3~8 In some embodiments, R 2 is arbitrarily substituted C 3~8In some embodiments, R 2 can be an optionally substituted 4-10 membered heterocyclyl, e.g., a monocyclic or bicyclic (e.g., fused, bridged, or spiro bicyclic) heterocyclyl, having 1 or 2 ring heteroatoms independently selected from N, O, and S. In certain embodiments, R 2 may be optionally substituted phenyl. In some embodiments, R 2 can be an optionally substituted 5-10 membered heteroaryl, for example, a 5 or 6 membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, O, and S.

[0054] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 But, oxo, F, G 1 , CN, OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 C substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from 3~8 alkyl, where G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6In any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0055] In any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0056] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 But, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 C optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from 3~8 cycloalkyl, where G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 It is cycloalkyl.

[0057] In certain preferred embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 But C 3~6 Cycloalkyl, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from F, methyl, ethyl, hydroxyethyl (e.g., —CHCHOH or —CH(OH)CH), —C(O)CH, OH, —CHOH, fluorine-substituted methyl (e.g., —CFH), and fluorine-substituted ethyl (e.g., —CHCFH). In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 But C 3~6Cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, which is substituted with one or two substituents independently selected from OH, —CHCHOH, —CH(OH)CH), —CHOH, —CFH, and —CHCFH, and optionally further substituted with F, methyl, or ethyl.

[0058] In certain preferred embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 spiro, fused, or bridged C 6~8 Cycloalkyl, for example [ka] and optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from F, methyl, ethyl, hydroxyethyl (e.g., —CHCHOH or —CH(OH)CH), —C(O)CH, OH, —CHOH, fluorine-substituted methyl (e.g., —CFH), and fluorine-substituted ethyl (e.g., —CHCFH). In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 spiro, fused, or bridged C 6~8 Cycloalkyl, for example [ka] which is substituted with one or two substituents independently selected from OH, —CHCHOH, —CH(OH)CH), —CHOH, —CFH, and —CHCFH, and optionally further substituted with F, methyl, or ethyl.

[0059] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 may be a 4- to 10-membered heterocyclyl having 1 to 4 ring heteroatoms independently selected from N, O, and S, which may be oxo, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 wherein two substituents of a 4- to 10-membered heterocyclyl, together with an intervening atom, can optionally be joined to form a fused, bridged, or spirocyclic structure.

[0060] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 is a 4- to 8-membered heterocyclyl having 1 to 2 ring heteroatoms independently selected from N, O, and S, which is oxo, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 It is cycloalkyl.

[0061] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 may be a 4-8 membered monocyclic, saturated or partially unsaturated heterocyclyl having 1-2 ring heteroatoms independently selected from N, O, and S, such as pyrrolidine, piperidine, azepane, etc., which is not limited to oxo, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 wherein two substituents of a 4- to 8-membered heterocyclyl, together with an intervening atom, can optionally be joined to form a fused, bridged, or spirocyclic structure.

[0062] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 can be a 4- to 6- or 7-membered monocyclic heterocyclyl having 1 to 2 ring heteroatoms independently selected from N, O, and S, such as oxetane, azetidine, tetrahydrofuran, tetrahydropyran, oxepane, pyrrolidine, piperidine, etc., which is optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from oxo, F, methyl, ethyl, hydroxyethyl (e.g., —CHCHOH or —CH(OH)CH), —C(O)CH, OH, —CHOH, fluorine-substituted methyl (e.g., —CFH), and fluorine-substituted ethyl (e.g., —CHCFH). In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2can be a 4- to 6- or 7-membered monocyclic heterocyclyl having 1 to 2 ring heteroatoms independently selected from N, O, and S, such as oxetane, azetidine, tetrahydrofuran, tetrahydropyran, oxepane, pyrrolidine, piperidine, etc., which is substituted by one or two substituents independently selected from OH, —CHCHOH, —CH(OH)CH), —CHOH, —CFH, and —CHCFH, and optionally further substituted by F, methyl, or ethyl.

[0063] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from: m is 0, 1, 2, 3, or 4; R 101 Each occurrence of is independently oxo, F, CN, G 1 , G 2 , OH, OG 1 , and OG 2 where G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2each occurrence is independently a 4- to 6-membered heterocyclyl having 1 to 2 ring heteroatoms independently selected from N, O, and S, phenyl, or a 5- or 6-membered heteroaryl having 1 to 4 ring heteroatoms independently selected from N, O, and S, which are each independently selected from F, CN, G 1 , OH, and OG 1 wherein two R 101 may be optionally joined, together with the intervening atoms, to form a fused, bridged, or spirocyclic structure. In some embodiments, m may be 0, 1, 2, or 3. For example, in some embodiments, m is 0, i.e., the heterocyclyl is unsubstituted. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, R 101 Each occurrence of is independently F, OH, CN, C 1~4 Alkyl (e.g., methyl, ethyl, propyl, etc.), phenyl, cyclopropyl, hydroxymethyl (-CHOH), methoxy, fluorine-substituted methoxy, fluorine-substituted C 1~4 Alkyl, for example, fluorine-substituted methyl, such as CF2H, or fluorine-substituted ethyl (eg, CH2CF2H).

[0064] In certain preferred embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0065] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 Also, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 phenyl optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G1 ), wherein two optional substituents of the phenyl group, together with the intervening atom, may optionally be joined to form a fused ring structure.

[0066] For example, in certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be, wherein: m is 0, 1, 2, or 3; R 101 Each occurrence of F, CN, G 1 , G 2 , OH, OG 1 , O.G. 2 , NH2, NH(G 1 ), NH(G 2 ), N(G 1 )(G 1 ), and N(G 1 )(G 2 ), where G 1 Each occurrence of independently represents F, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl or F, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 each occurrence is independently a 4- to 6-membered heterocyclyl having 1 to 2 ring heteroatoms independently selected from N, O, and S, phenyl, or a 5- or 6-membered heteroaryl having 1 to 4 ring heteroatoms independently selected from N, O, and S, which are each independently selected from F, CN, G1 , OH, and OG 1 wherein two R 101 may be optionally joined together with the intervening atoms to form a fused ring structure. In some embodiments, m may be 0, 1, 2, or 3. For example, in some embodiments, m is 0, i.e., the phenyl is unsubstituted. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, R 101 Each occurrence of is independently F, OH, CN, C 1~4 Alkyl (e.g., methyl, ethyl, propyl, etc.), cyclopropyl, cyclobutyl, oxetanyl, C 1~4 Alkoxy (e.g., methoxy), fluorine-substituted C 1~4 Alkoxy, for example, fluorine-substituted methoxy, fluorine-substituted C 1~4 alkyl, for example, fluorine-substituted methyl, for example, CFH, or fluorine-substituted ethyl (e.g., CHCFH). In certain preferred embodiments, R 101 Each time it appears, F, C 1~4 It is alkyl (for example, methyl, ethyl, n-propyl, etc.), OH, cyclopropyl, cyclobutyl, oxetanyl, or CN.

[0067] In certain preferred embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0068] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 can also be a 5-10 membered heteroaryl having 1-4 ring heteroatoms independently selected from N, O, and S, which can be F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1, NH2, NH(G 1 ), and N(G 1 )(G 1 ), wherein two optional substituents of a heteroaryl group, together with an intervening atom, may optionally be joined to form a fused ring structure.

[0069] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 may be a 5- or 6-membered heteroaryl having 1 to 4 ring heteroatoms independently selected from N, O, and S, such as pyridyl (e.g., 2-, 3-, or 4-pyridyl), pyrazole, etc., which may be selected from F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 wherein two optional substituents of a heteroaryl group, together with an intervening atom, may optionally be joined to form a fused ring structure. In any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0070] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 may be an 8-10 membered bicyclic heteroaryl having 1-4 ring heteroatoms independently selected from N, O, and S, such as indolyl, indazolyl, etc., which may be F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G.1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 ), wherein two optional substituents of a heteroaryl group, together with an intervening atom, may optionally be joined to form a fused ring structure.

[0071] In any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] [ka] may be selected from:

[0072] In any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0073] In any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0074] In any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0075] In any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0076] In any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), R 2 but, [ka] may be selected from:

[0077] R in Formula I 2 , L 2 and L 3 For example, in one embodiment, in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), L 2 can be -O-, L 3 is optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from a bond, F, OH, and protected OH; 1~4 It can be alkylene (e.g., CH). For example, in certain embodiments, a compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized by having Formula I-1 or I-2: [ka] In the formula, L 1 , R 1 , R 2 , R 3 , and R 4 includes any of those described herein in any combination.

[0078] In some embodiments, in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), L 2 -N(R 14 )-, where R 14 is defined herein, and L 3 is optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from a bond, F, OH, and protected OH;1~4 It can be alkylene (e.g., CH). For example, in certain embodiments, a compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized by having Formula I-3 or I-4: [ka] In the formula, L 1 , R 1 , R 2 , R 3 , R 4 and R 14 includes any of those described herein in any combination. Typically, R in formula I-3 or I-4 14 is hydrogen or C 1~4 It is alkyl (eg, methyl).

[0079] In certain preferred embodiments, the compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having formula I-1, I-2, I-3, or I-4, wherein R 2 But, oxo, F, G 1 , CN, OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 C substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from 3~8 alkyl, where G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where C 3~8Two optional substituents of an alkyl may optionally be joined together with intervening atoms to form a ring structure, e.g., spiro-C 3~6 In any of the embodiments herein, unless specified or contradicted by context, in Formula I-1, I-2, I-3, or I-4, R 2 But the following [ka] may be selected from: In any of the embodiments herein, unless specified or contradicted by context, in formula I-1, I-2, I-3, or I-4, R 2 But the following: [ka] may be selected from:

[0080] In certain preferred embodiments, the compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having formula I-1, I-2, I-3, or I-4, wherein R 2 But, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 C optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from 3~8 cycloalkyl, where G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 In some embodiments, in formula I-1, I-2, I-3, or I-4, R 2 But C 3~6 Cycloalkyl can be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, which is optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from F, methyl, ethyl, hydroxyethyl (e.g., —CHCHOH or —CH(OH)CH), —C(O)CH, OH, —CHOH, fluorine-substituted methyl (e.g., —CFH), and fluorine-substituted ethyl (e.g., —CHCFH). In certain embodiments, in Formula I-1, I-2, I-3, or I-4, R 2 spiro, fused, or bridged C 6~8 Cycloalkyl, for example [ka]

[0033] For example, in any of the embodiments herein, unless specified or contradicted by context, in Formula I-1, I-2, I-3, or I-4, R 2 But the following: [ka] may be selected from:

[0081] In any of the embodiments herein, unless specified or contradicted by context, in formula I-1, I-2, I-3, or I-4, R 2 But the following: [ka] may be selected from:

[0082] In any of the embodiments herein, unless specified or contradicted by context, in formula I-1, I-2, I-3, or I-4, R 2 But the following: [ka] may be selected from:

[0083] In any of the embodiments herein, unless specified or contradicted by context, in formula I-1, I-2, I-3, or I-4, R 2 But the following: [ka] may be selected from:

[0084] In any of the embodiments herein, unless specified or contradicted by context, in formula I-1, I-2, I-3, or I-4, R 2 But the following: [ka] may be selected from:

[0085] In one preferred embodiment, in formula I-1, I-2, I-3 or I-4, R 2 But the following: [ka] may be selected from:

[0086] In one preferred embodiment, in formula I-1, I-2, I-3 or I-4, R 2 But the following: [ka] may be selected from:

[0087] In one preferred embodiment, in formula I-1, I-2, I-3 or I-4, R 2 But the following: [ka] may be selected from:

[0088] As shown in the Examples section, compounds of Formula I-1, I-2, I-3, or I-4 have been found to be potent CDK2 inhibitors, with several of the Examples exhibiting greater than 10-fold selectivity over CDK1. In particular, a representative compound, Example 9, exhibited greater than 30-fold selectivity over CDK1. Additional compounds with greater than 10-fold selectivity over CDK1 are also shown in the Examples herein.

[0089] In some embodiments, a compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be represented by Formula I-2-1: [ka] wherein L 1 , R 1 , R 3 , and R 4 In certain embodiments, the compound of formula I-2-1 can be characterized as having the formula I-2-1-S1, I-2-1-S2, I-2-1-S3, or I-2-1-S4: [ka] In certain embodiments, any of the compounds of formulae I-2-1-S1, I-2-1-S2, I-2-1-S3, and I-2-1-S4 can be present as a substantially pure stereoisomer, e.g., substantially free of other possible stereoisomers (e.g., less than 10%, less than 5%, less than 1%, or undetectable amounts by weight or by HPLC or SFC area). For example, in certain embodiments, the compound of formula I-2-1-S1 can be a substantially pure stereoisomer, and of the four possible stereoisomers, the combined amount of the corresponding stereoisomers of formulae I-2-1-S2, I-2-1-S3, and I-2-1-S4 can be present in less than 10%, less than 5%, less than 1%, or undetectable amounts by weight or by HPLC or SFC area. In certain embodiments, the compound of formula I-2-1 may also exist as a mixture of any two or more of the corresponding formulae I-2-1-S1, I-2-1-S2, I-2-1-S3, and I-2-1-S4 in any ratio.

[0090] In certain preferred embodiments, the compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having formula I-1, I-2, I-3, or I-4, wherein R 2 is a 4- to 8-membered heterocyclyl having 1 to 2 ring heteroatoms independently selected from N, O, and S, which is oxo, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 In some embodiments, in formula I-1, I-2, I-3, or I-4, R 2 is a 4-6 membered monocyclic heterocyclyl having 1-2 ring heteroatoms independently selected from N, O, and S, e.g., oxetane, azetidine, tetrahydrofuran, tetrahydropyran, pyrrolidine, piperidine, etc., which is optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from oxo, F, methyl, ethyl, hydroxyethyl (e.g., —CHCHOH or —CH(OH)CH), —C(O)CH, OH, —CHOH, fluorine-substituted methyl (e.g., —CFH), and fluorine-substituted ethyl (e.g., —CHCFH). For example, in certain embodiments, in Formula I-1, I-2, I-3, or I-4, R 2 but, [ka] may be selected from:

[0091] In certain preferred embodiments, the compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having formula I-1, I-2, I-3, or I-4, wherein R 2 may also be a 5- or 6-membered heteroaryl having 1 to 4 ring heteroatoms independently selected from N, O, and S, such as pyridyl (e.g., 2-, 3-, or 4-pyridyl), pyrazole, etc., which may be selected from F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 wherein two optional substituents of a heteroaryl group, together with an intervening atom, may optionally be joined to form a fused ring structure. For example, in certain embodiments, in Formula I-1, I-2, I-3, or I-4, R 2 But also, [ka] may be selected from:

[0092] In some embodiments, in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), L 2 and L 3 are both bonds, then R 2 is directly attached to the pyridine or pyrimidine ring of Formula I. For example, in some embodiments, a compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be attached to a compound of Formula I-5: [ka] wherein L 1 , R 1 , R 2 , R 3 , and R 4 includes any of those described herein in any combination.

[0093] In certain embodiments, a compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having Formula I-5, wherein R 2 may be a 4- to 10-membered heterocyclyl having 1 to 4 ring heteroatoms independently selected from N, O, and S, which may be oxo, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 wherein the two optional substituents of the 4- to 10-membered heterocyclyl, together with the intervening atoms, can optionally be joined to form a fused, bridged, or spiro ring structure.

[0094] In certain preferred embodiments, the compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having Formula I-5, wherein R 2 is a 4-8 membered monocyclic, saturated or partially unsaturated heterocyclyl having 1-2 ring heteroatoms independently selected from N, O, and S, such as pyrrolidine, piperidine, azepane, etc., which is not oxo, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1, C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 wherein the two optional substituents of a 4- to 8-membered heterocyclyl, together with the intervening atoms, can optionally be joined to form a fused, bridged, or spiro ring structure.

[0095] In certain preferred embodiments, the compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having Formula I-5, wherein R 2 but, [ka] may be selected from: m is 0, 1, 2, 3, or 4; R 101 Each occurrence of is independently oxo, F, CN, G 1 , G 2 , OH, OG 1 , and OG 2 where G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 each occurrence is independently a 4- to 6-membered heterocyclyl having 1 to 2 ring heteroatoms independently selected from N, O, and S, phenyl, or a 5- or 6-membered heteroaryl having 1 to 4 ring heteroatoms independently selected from N, O, and S, which are each independently selected from F, CN, G 1 , OH, and OG 1 wherein two R 101 may be optionally joined, together with the intervening atoms, to form a fused, bridged, or spirocyclic structure. In some embodiments, m may be 0, 1, 2, or 3. For example, in some embodiments, m is 0, i.e., the heterocyclyl is unsubstituted. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, R 101 Each occurrence of is independently F, OH, CN, C1~4 Alkyl (e.g., methyl, ethyl, propyl, etc.), phenyl, cyclopropyl, hydroxymethyl (-CHOH), methoxy, fluorine-substituted methoxy, fluorine-substituted C 1~4 Alkyl, for example, fluorine-substituted methyl, such as CF2H, or fluorine-substituted ethyl (eg, CH2CF2H).

[0096] In any of the embodiments herein, unless specified or contradicted by context, in Formula I-5, R 2 but, [ka] may be selected from:

[0097] In certain embodiments, a compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having Formula I-5, wherein R 2 But, F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 phenyl optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 ), wherein two optional substituents of the phenyl group, together with the intervening atom, may optionally be joined to form a fused ring structure.

[0098] For example, in one preferred embodiment, in formula I-5, R 2 but, [ka] may be, wherein: m is 0, 1, 2, or 3; R 101 Each occurrence of F, CN, G 1 , G 2 , OH, OG 1 , O.G. 2 , NH2, NH(G 1 ), NH(G 2 ), N(G 1 )(G 1 ), and N(G 1 )(G 2 ), where G 1 Each occurrence of independently represents F, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl or F, OH, and C 1~4C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 each occurrence is independently a 4- to 6-membered heterocyclyl having 1 to 2 ring heteroatoms independently selected from N, O, and S, phenyl, or a 5- or 6-membered heteroaryl having 1 to 4 ring heteroatoms independently selected from N, O, and S, which are each independently selected from F, CN, G 1 , OH, and OG 1 wherein two R 101 may be optionally joined together with the intervening atoms to form a fused ring structure. In some embodiments, m may be 0, 1, 2, or 3. For example, in some embodiments, m is 0, i.e., the phenyl is unsubstituted. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, R 101 Each occurrence of is independently F, OH, CN, C 1~4 Alkyl (e.g., methyl, ethyl, propyl, etc.), cyclopropyl, cyclobutyl, oxetanyl, C 1~4 Alkoxy (e.g., methoxy), fluorine-substituted C 1~4 Alkoxy, for example, fluorine-substituted methoxy, fluorine-substituted C 1~4 alkyl, for example, fluorine-substituted methyl, for example, CFH, or fluorine-substituted ethyl (e.g., CHCFH). 101 Each time it appears, F, C 1~4 It is alkyl (for example, methyl, ethyl, n-propyl, etc.), OH, cyclopropyl, cyclobutyl, oxetanyl, or CN.

[0099] In any of the embodiments herein, unless specified or contradicted by context, in Formula I-5, R 2 but, [ka] may be selected from:

[0100] In certain preferred embodiments, the compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having Formula I-5, wherein R 2 can also be a 5-10 membered heteroaryl having 1-4 ring heteroatoms independently selected from N, O, and S, which can be F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1, NH2, NH(G 1 ), and N(G 1 )(G 1 ), wherein two optional substituents of a heteroaryl group, together with an intervening atom, may optionally be joined to form a fused ring structure.

[0101] In certain preferred embodiments, the compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having Formula I-5, wherein R 2 may be a 5- or 6-membered heteroaryl having 1 to 4 ring heteroatoms independently selected from N, O, and S, such as pyridyl (e.g., 2-, 3-, or 4-pyridyl), pyrazole, etc., which may be selected from F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G 2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 wherein two optional substituents of a heteroaryl group, together with an intervening atom, may optionally be joined to form a fused ring structure. For example, in one embodiment, in Formula I-5, R 2 but, [ka] may be selected from:

[0102] In certain preferred embodiments, the compound of Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, IA-5, IA-6, IA-7, IA-8, IA-9, or IA-10) can be characterized as having Formula I-5, wherein R 2 may be an 8-10 membered bicyclic heteroaryl having 1-4 ring heteroatoms independently selected from N, O, and S, such as indolyl, indazolyl, etc., which may be F, CN, G 1 , OH, COOH, C(O)-G 1 , O.G. 1 , C(O)-OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), C(O)-N(G 1 )(G 1 ), G 2 , O.G. 2 , NH(G 2 ), N(G 1 )(G 2 ), C(O)-NH(G2 ), and C(O)-N(G 1 )(G 2 Optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 cycloalkyl; where G 2 is independently 4-6 membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, each of which is selected from oxo (if applicable), F, CN, G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 ), wherein two optional substituents of a heteroaryl group, together with an intervening atom, may optionally be joined to form a fused ring structure.

[0103] In certain preferred embodiments, the compound of formula I-5 can be characterized as having formula I-5-1 or I-5-2: [ka] In the formula, L 1 , R 1 , R 3 , R 4 , m, and R 101 includes any of those described herein in any combination.

[0104] Various groups can be represented by R in Formula I. 3 For example, in one embodiment, R 3 is hydrogen. In one embodiment, R 3is halogen (e.g., F). In some embodiments, R 3 is CN. In one embodiment, R 3 is C(O)NR 11 R 12 where R 11 and R 12 is defined herein, for example, R 11 and R 12 and R may both be hydrogen. 3 is arbitrarily substituted C 3~8 In one embodiment, R 3 is an optionally substituted 4-10 membered heterocyclyl having 1 or 2 ring heteroatoms independently selected from N, O, and S. In certain embodiments, R 3 is an optionally substituted 5-10 membered heteroaryl having 1-4 ring heteroatoms independently selected from N, O, and S.

[0105] In any of the embodiments herein, unless specified or contradicted by context, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB) 3 is C optionally substituted with hydrogen, F, Cl, Br, F 1~4 For example, in certain embodiments, a compound of Formula I can be characterized as having a formula represented by formula IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, or IA-10B: [ka] [ka] In the formula, L 2 , L 3 , R 2, R 10 , R 11 , and R 12 In certain embodiments according to formula IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, or IA-10A, R 11 and R 12 are optionally substituted with hydrogen, F and / or deuterium; 1~4 Alkyl or C optionally substituted with F and / or deuterium 3~6 In certain embodiments according to formula IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, or IA-10A, R 11 and R 12 is hydrogen and R 11 and R 12 the other of which is optionally substituted with hydrogen, F and / or deuterium 1~4 Alkyl or C optionally substituted with F and / or deuterium 3~6 In certain preferred embodiments according to formula IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, or IA-10A, R 11 and R 12 is hydrogen and R 11 and R 12 The other is hydrogen, methyl, CD3, ethyl, isopropyl, cyclopropyl, cyclobutyl, [ka] In certain preferred embodiments according to formula IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, or IA-10B, R 10 C optionally substituted with 1 to 3 F 1~4 alkyl, for example, CH, CHF, CF, etc. In certain preferred embodiments according to formula IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, or IA-10B, R 10is a 5- or 6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, O, and S, such as pyrazole, imidazole, triazole, etc. (which may be, for example, C 1~4 alkyl (e.g., methyl), e.g., [ka] is.

[0106] In certain embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB) 3 is an arbitrarily substituted C 1~4 In some embodiments, R 3 is deuterium, F, CN, or OR C C substituted with one or more, for example, 1 to 3, substituents independently selected from 1~4 alkyl, where R C Each occurrence of represents independently hydrogen, deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 For example, in one embodiment, R 3 can be methyl, CD3, CH2-OMe, CH2-OCD3, ethyl, CHF2, CF2CH3, CH2CH2F, CH2CF2H, or CF3.

[0107] In certain embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB) 3 is an arbitrarily substituted C 2~4 Alkenyl, for example [ka] It could be.

[0108] In certain embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB) 3 is an arbitrarily substituted C 2~4 Alkynyl, for example [ka] It could be.

[0109] In certain embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB) 3 is OR A For example, in one embodiment, R 3 OR A and R A are hydrogen, deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 It is cycloalkyl.

[0110] In certain embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB) 3 is C(O)R B For example, in one embodiment, R 3 is C(O)R B and R B are hydrogen, deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 It is cycloalkyl.

[0111] In certain embodiments, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB) 3 Also, C 3~6 and cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, etc.), 4-6 membered heterocyclyl having 1-2 ring heteroatoms independently selected from N, O, and S, such as oxetanyl, tetrahydrofuranyl, or 5-6 membered heteroaryl having 1-4 ring heteroatoms independently selected from N, O, and S, such as thiazolyl, which may each be oxo (where applicable), deuterium, F, CN, G, 1 , OH, OG 1 , NH2, NH(G 1 ), N(G 1 )(G 1 ), C(O)-NH2, C(O)-NH(G 1 ), and C(O)-N(G 1 )(G 1) optionally substituted with 1 to 3 substituents independently selected from G 1 Each occurrence of represents independently deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 It is cycloalkyl.

[0112] In any of the embodiments herein, unless specified or contradicted by context, R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB) 3 teeth, [ka] may be selected from:

[0113] R in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB) 4 is typically hydrogen. In one embodiment, R in formula I 4 may also be halogen (e.g., F), optionally substituted C 1~6 Alkyl or NR 11 R 12 For example, in one embodiment, R in Formula I can be 4 is NH2.

[0114] In certain embodiments, in Formula I (e.g., Formula IA, IA-1, IA-2, IA-3, IA-4, or IB), L, if applicable, 2 and R 3may also be joined, together with the intervening atoms, to form an optionally substituted 4- to 8-membered ring structure, such as a 4- to 8-membered heterocyclic structure or a 5- or 6-membered heteroaryl structure.

[0115] In certain embodiments, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB), R 3 and R 4 can also be joined together with the intervening atoms to form an optionally substituted 4- to 8-membered ring structure, e.g., a 4- to 8-membered heterocyclic structure or a 5- or 6-membered heteroaryl structure. For example, in any of the embodiments herein, unless specified or contradicted by context, in Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, or IB), R 3 and R 4 is bonded together with intervening atoms to: [ka] It may form one of:

[0116] Formula II In certain embodiments, the present disclosure provides a compound of formula II, or a pharmaceutically acceptable salt thereof: [ka] (In the formula: L 1 is an optionally substituted arylene (e.g., phenylene), an optionally substituted heteroarylene (e.g., 5- or 6-membered heteroarylene), an optionally substituted heterocyclylene (e.g., 4- to 8-membered heterocyclylene), or an optionally substituted carbocyclylene (e.g., C 3~8 carbocyclylene); R 1 But SO2R 10 , SO2NR 11 R 12 , S(O)(NH)R 10 , or C(O)NR 11 R 12 or R 1 is hydrogen or NR 11 R 12 and; X is N or CR 13 and; Ring A is an optionally substituted carbocycle or an optionally substituted heterocycle having one or more (e.g., 1 or 2) ring heteroatoms independently selected from O, N, and S; Q is hydrogen, OR A , optionally substituted C 1~4 Alkyl, halogen, CN, or COR B and; R 3 is hydrogen, halogen (e.g., F), CN, C(O)NR 11 R 12 , optionally substituted C 1~6 Alkyl, optionally substituted C 2~4 Alkenyl, optionally substituted C 2~4 Alkynyl, optionally substituted C 1~4 Heteroalkyl, OR A , C.O.R. B , COOR A , N.R. 11 R 12 , optionally substituted C 3~8 carbocyclyl, optionally substituted 4-10 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl; R 4 is hydrogen, halogen (e.g., F), optionally substituted C 1~6 Alkyl or NR 11 R 12 and; or R 3 and R 4 together with the intervening atoms form an optionally substituted 4- to 8-membered ring structure; where: R 10is arbitrarily substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl (e.g., 5- or 6-membered heteroaryl), or optionally substituted 4- to 10-membered heterocyclyl; R 11 and R 12 each occurrence independently represents hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl (e.g., 5- or 6-membered heteroaryl), optionally substituted 4- to 10-membered heterocyclyl; or a nitrogen protecting group; or R 11 and R 12 may be joined to form an optionally substituted 4- to 10-membered heterocyclyl or 5- or 6-membered heteroaryl; R A each occurrence independently represents hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl (e.g., 5- or 6-membered heteroaryl), optionally substituted 4- to 10-membered heterocyclyl; or an oxygen protecting group; R B each occurrence independently represents hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted 4- to 10-membered heterocyclyl, or optionally substituted heteroaryl (e.g., 5- or 6-membered heteroaryl); R 13 is hydrogen, F, CN, -OH, optionally substituted C 1~4 Alkyl, optionally substituted C 1~4 Heteroalkyl, optionally substituted C 3~8carbocyclyl, or optionally substituted 4- to 10-membered heterocyclyl. For clarity, it should be understood that ring A depicted in formula II (including any applicable subformulas) contains at least two ring carbon atoms bonded to each of the O atom and Q groups depicted in formula II.

[0117] In certain embodiments, a compound of Formula II (including any of the applicable subformulas described herein) can exist in various stereoisomers, e.g., enantiomers and / or diastereomers. In certain embodiments, a compound of Formula II can exist in the form of an individual enantiomer and / or diastereomer, if applicable, or a mixture of stereoisomers (including racemic mixtures and mixtures enriched in one or more stereoisomers). In certain embodiments, a compound of Formula II (including any of the applicable subformulas described herein), if applicable, can exist as an isolated individual enantiomer substantially free of the other enantiomer (e.g., less than 20%, less than 10%, less than 5%, less than 1%, or undetectable amounts by weight, HPLC, or SFC area, or both). In certain embodiments, a compound of Formula II (including any of the applicable subformulas described herein), if applicable, can also exist as a mixture of stereoisomers in any ratio, such as a racemic mixture.

[0118] It should be apparent to one skilled in the art that in some cases, compounds of Formula II may exist as a mixture of tautomers. The present disclosure is not limited to any particular tautomer. Rather, the present disclosure encompasses all such tautomers, whether or not explicitly depicted or referred to.

[0119] In certain embodiments, compounds of Formula II (including any of the corresponding subformulas described herein) may exist as isotopically labeled compounds, particularly deuterated analogs, in which one or more of the hydrogen atoms of a compound of Formula II have been replaced with a deuterium atom having an abundance greater than its natural abundance, e.g., a CD analog when the compound has a CH group.

[0120] Typically, X in formula II is N, and the compound of formula II has formula II-A: [ka] wherein L 1 , R 1 , rings A, Q, R 3 , and R 4 may include any of those described herein in any combination. For example, the variable L 1 , R 1 , R 3 , and R 4 may include any of those defined herein with formula I in any combination.

[0121] A variety of ring structures are suitable for Ring A in Formula II. For example, in one embodiment, Ring A is an optionally substituted C 4~10 Cycloalkyl or an optionally substituted 4-10 membered heterocycle having 1-4 ring heteroatoms independently selected from O, S, and N. Ring A can be monocyclic or polycyclic, which can include fused, bridged, or spiro ring structures. For example, in one embodiment, ring A is an optionally substituted monocyclic C 4~8 In some embodiments, Ring A can be, for example, an optionally substituted fused, bridged, or spiro bicyclic C 6~10 In some embodiments, ring A can be an optionally substituted monocyclic 4- to 8-membered heterocycle, for example, having one ring heteroatom selected from O and N. In some embodiments, ring A is an optionally substituted fused, bridged, or spiro bicyclic 6- to 10-membered heterocycle, for example, having one or two ring heteroatoms independently selected from O, S, and N. When further substituted, ring A is typically selected from oxo, halogen (e.g., F), CN, G 1 , C(O)H, C(O)G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G1 ) may be substituted with 1 to 3 substituents each independently selected from G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 In some embodiments, ring A can also be deuterated, for example, with one or more ring CH2 groups substituted with CD2 groups.

[0122] A variety of groups are suitable as Q for Formula II. In some embodiments, Q is OR A For example, in one embodiment, Q is OR A where R A are hydrogen, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 In certain preferred embodiments, Q in formula II (e.g., any of the relevant subformulas) is OH.

[0123] In some embodiments, Q is optionally substituted C 1~4 Alkyl, e.g., fluorine-substituted C 1~4 Alkyl or hydroxyl substituted C 1~4 It can be alkyl, for example, CH2OH.

[0124] In some embodiments, Q can be halogen, such as F or CN. In some embodiments, Q can also be COR B For example, in some embodiments, Q can be COR B where R B are hydrogen, F, CN, OH, and C 1~4C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 It is cycloalkyl.

[0125] In some embodiments, Q is selected from the group consisting of F, CN, C(O)H, C(O)—(C optionally substituted with F). 1~4 C optionally substituted with alkyl, CHOH, F 1~4 C optionally substituted with alkyl or F 1~4 It may be alkoxy.

[0126] In some embodiments, in Formula II (e.g., II-A), [ka] but, [ka] may be selected from:

[0127] In some embodiments, in Formula II (e.g., II-A), [ka] but, [ka] may be selected from:

[0128] In one preferred embodiment, in Formula II (e.g., II-A), [ka] but, [ka] may be selected from:

[0129] In one preferred embodiment, in Formula II (e.g., II-A), [ka] but, [ka] may be selected from:

[0130] In certain embodiments, the compound of Formula II has a subformula of Formula II-1 or II-2, or a deuterated analog thereof: [ka] wherein: n1 and n2 are independently 0, 1, 2, or 3; Z is CR 21 R 22 , O, or NR 23 and p is 0, 1, 2, 3, or 4, where valences permit; R 20 each occurrence independently represents oxo, halogen (e.g., F), CN, G 1 , C(O)H, C(O)G 1 , OH, OG 1 , NH2, NH(G 1 ), and N(G 1 )(G 1 ), where G 1 Each occurrence of represents independently F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 is cycloalkyl, or two geminal R 20 form an oxo group, or two R 20 together with the intervening atoms form an optionally substituted ring system; R21 and R 22 are each independently hydrogen or R 20 and or R 21 and R 22 together form an oxo group or an optionally substituted ring structure, or one R 20 R containing groups 21 and R 22 together with the intervening atoms form an optionally substituted ring system; R 23 is hydrogen or R 20 and or R 23 and one R 20 the groups, together with the intervening atoms, form an optionally substituted ring system; Here, Q and L 1 , R 1 , R 3 and R 4 includes any of those described herein in any combination. For clarity, the variable R 21 , R 22 , and R 23 is R 20 However, R depicted in formula II-1 or II-2 may have the same definition as 20 In other words, the integer p refers to possible substitution of the ring at any available position other than the Z group.

[0131] Typically, n2 in formula II-1 or II-2 is 1.

[0132] Typically, n1 in formula II-1 or II-2 is 0, 1, or 2.

[0133] In some embodiments, n1 and n2 are such that the ring is a 4- to 8-membered ring, for example, a 4-, 5-, 6-, or 7-membered ring.

[0134] In some embodiments, Z in formula II-1 or II-2 is CH2, O, or NR 23 where R 23is optionally substituted with 1 to 3 substituents independently selected from hydrogen or F, CN, and OH; 1~4 It is alkyl.

[0135] In a preferred embodiment, Z in formula II-1 or II-2 is CH2.

[0136] In a preferred embodiment, Z in formula II-1 or II-2 is CF2.

[0137] The compounds of formula II-1 or II-2 can exist in deuterated form. For example, in certain preferred embodiments, the hydrogen in the Z group can be replaced with deuterium, i.e., the Z group in formula II-1 or II-2 can be CD2.

[0138] In a preferred embodiment, Z in formula II-1 or II-2 is O.

[0139] The integer p in Formula II-1 or II-2 is typically 0 to 2. For example, in some embodiments, p in Formula II-1 or II-2 is 0. In some embodiments, p in Formula II-1 or II-2 is 1 or 2.

[0140] In some embodiments, p in formula II-1 or II-2 is 1 or 2, and R 20 each occurrence independently represents halogen (e.g., F), CN, G 1 , C(O)H, C(O)G 1 , OH, or OG 1 For example, in some embodiments, p in formula II-1 or II-2 is 1 or 2, and R 20 each occurrence independently represents halogen (e.g., F), CN, G 1 , C(O)H, C(O)G 1 , OH, or OG 1 where G 1 C optionally substituted with 1 to 3 F 1~4 It is alkyl.

[0141] A variety of groups are suitable for use as Q in Formula II-2, including any of the definitions of Q described herein. In some embodiments, Q in Formula II-2 is selected from the group consisting of F, CN, C(O)H, C(O)—(C optionally substituted with F), C(O)—(C ... 1~4 C optionally substituted with alkyl, CHOH, F 1~4 C optionally substituted with alkyl or F 1~4 It may be alkoxy.

[0142] In one preferred embodiment, in formula II-1 [ka] The part is [ka] may be selected from:

[0143] In one preferred embodiment, in formula II-1 [ka] The part is [ka] may be selected from:

[0144] In one preferred embodiment, in formula II-1 [ka] The part is [ka] In a preferred embodiment, in formula II-1 [ka] The part is [ka] In a preferred embodiment, in formula II-1 [ka] The part is [ka] In a preferred embodiment, in formula II-1 [ka] The part is [ka] In a preferred embodiment, in formula II-1 [ka] The part is [ka] In a preferred embodiment, in formula II-1 [ka] The part is [ka] In a preferred embodiment, in formula II-1 [ka] The part is [ka] In a preferred embodiment, in formula II-1 [ka] The part is [ka] In a preferred embodiment, in formula II-1 [ka] The part is [ka] In one embodiment, in formula II-1, [ka] The part is [ka] In a preferred embodiment, in formula II-1 [ka] The part is [ka] In one embodiment, in formula II-1 [ka] The part is [ka] In one embodiment, in formula II-1 [ka] The part is [ka] is.

[0145] The compounds of formula II-1 or II-2 can exist in various stereoisomers, e.g., racemates, substantially pure individual stereoisomers, mixtures enriched in one or more stereoisomers, or mixtures of stereoisomers in any ratio. For example, in certain embodiments, the compounds of formula II-1 can be characterized as having formula II-1-S1, II-1-S2, II-1-S3, or II-1-S4: [ka] where the variables n1, n2, Z, and R 20 ,p,L 1 , R 1 , R 3 , and R 4In some embodiments, the compound of any of Formulas II-1-S1, II-1-S2, II-1-S3, or II-1-S4 may be present as a substantially pure stereoisomer (the stereoisomer as depicted), e.g., substantially free of other possible stereoisomers (e.g., less than 10%, less than 5%, less than 1%, or undetectable amounts by weight and / or by HPLC or SFC area). For example, in some embodiments, the compound of Formula II-1-S1 may be a substantially pure stereoisomer, and the combined amount of the corresponding stereoisomers of Formulas II-1-S2, II-1-S3, and II-1-S4, of the four possible stereoisomers, may be present in less than 10%, less than 5%, less than 1%, or undetectable amounts by weight and / or by HPLC or SFC area. In certain embodiments, the compound of formula II-1 can also exist as a mixture of any two or more of the corresponding formulae II-1-S1, II-1-S2, II-1-S3, or II-1-S4 in any ratio, for example, a racemic mixture of II-1-S1 and II-1-S2 or a racemic mixture of II-1-S3 and II-1-S4. Exemplary methods for separating stereoisomers are provided in the Examples section herein. In certain preferred embodiments, the compound of formula II-1 can be characterized as a cis isomer, which can exist as the corresponding stereoisomer of formula II-1-S1 or II-1-S2, or a mixture thereof in any ratio, for example, a racemic mixture or a mixture enriched in the stereoisomer of formula II-1-S1 or II-1-S2 having an enantiomeric excess of about 50% or more, such as about 80% or more, about 90% or more, about 95% or more, etc.

[0146] In certain embodiments, the compound of formula II-2 can be characterized as having formula II-2-S1, II-2-S2, II-2-S3, or II-2-S4: [ka] where the variables n1, n2, Z, and R 20 , p, Q, L 1 , R 1 , R 3, and R 4 In some embodiments, the compound of any of Formulas II-2-S1, II-2-S2, II-2-S3, or II-2-S4 can be present as a substantially pure stereoisomer (the stereoisomer as depicted), e.g., substantially free of other possible stereoisomers (e.g., less than 10%, less than 5%, less than 1%, or undetectable amounts by weight and / or by HPLC or SFC area). For example, in some embodiments, the compound of Formula II-2-S1 can be a substantially pure stereoisomer, and the combined amount of the corresponding stereoisomers of Formulas II-2-S2, II-2-S3, and II-2-S4, of the four possible stereoisomers, can be present in less than 10%, less than 5%, less than 1%, or undetectable amounts by weight and / or by HPLC or SFC area. In certain embodiments, the compound of Formula II-2 can also exist as a mixture of any two or more of the corresponding formulae II-2-S1, II-2-S2, II-2-S3, or II-2-S4 in any ratio, for example, a racemic mixture of II-2-S1 and II-2-S2 or a racemic mixture of II-2-S3 and II-2-S4. Exemplary methods for separating stereoisomers are provided in the Examples section herein. In certain preferred embodiments, the compound of Formula II-2 can also be characterized as a cis isomer, which can exist as the corresponding stereoisomer of Formula II-2-S1 or II-2-S2, or a mixture thereof in any ratio, for example, a racemic mixture or a mixture enriched in the stereoisomer of Formula II-2-S1 or II-2-S2 having an enantiomeric excess of about 50% or more, such as about 80% or more, about 90% or more, or about 95% or more.

[0147] The variable L for Formula II and any of the corresponding sub-formulas 1 , R 1 , R 3 , and R 4includes any of those described herein in any combination, including any of those described herein with Formula I and subformulas thereof. For example, in some embodiments, L in Formula II (e.g., II-A, II-1, or II-2) 1 -R 1 teeth, [ka] or L 1 -R 1 but, [ka] In some embodiments, L in Formula II (e.g., II-A, II-1, or II-2) is 1 -R 1 teeth, [ka] In some embodiments, L in Formula II (e.g., II-A, II-1, or II-2) can be selected from: 1 -R 1 teeth, [ka] In some embodiments, L in Formula II (e.g., II-A, II-1, or II-2) can be selected from: 1 -R 1 teeth, [ka] is selected from.

[0148] In some embodiments, R in Formula II (e.g., II-A, II-1, or II-2) 3 is C optionally substituted with hydrogen, F, Cl, Br, deuterium and / or F 1~4 For example, in some embodiments, R in Formula II (e.g., II-A, II-1, or II-2) is 3 is C optionally substituted with 1 to 3 F 1~4In some embodiments, R in Formula II (e.g., II-A, II-1, or II-2) can be alkyl, such as methyl, CD, ethyl, CHF, CFCH, CHCHF, CHCFH, or CF. 3 can be methyl, CD, CH-OMe, CH-OCD, ethyl, CHF, CFCH, CHCHF, CHCFH, or CF. In some embodiments, R in Formula II (e.g., II-A, II-1, or II-2) 3 is OR A where R A is defined herein, for example, R A are hydrogen, deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 In some embodiments, R in Formula II (e.g., II-A, II-1, or II-2) is cycloalkyl. 3 is C(O)R B where R B is defined herein, for example, R B are hydrogen, deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or deuterium, F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 In some embodiments, R in Formula II (e.g., II-A, II-1, or II-2) is cycloalkyl. 3 teeth, [ka] In a preferred embodiment, R in Formula II (e.g., II-A, II-1, or II-2) is selected from 3In a preferred embodiment, R in Formula II (e.g., II-A, II-1, or II-2) is 3 is F, Cl, or Br. In a preferred embodiment, R in Formula II (e.g., II-A, II-1, or II-2) 3 In some preferred embodiments, R in Formula II (e.g., II-A, II-1, or II-2) is CF. 3 In some preferred embodiments, R in Formula II (e.g., II-A, II-1, or II-2) is methyl or ethyl. 3 is CHF2, CF2CH3, CH2CH2F, or CH2CF2H. In a preferred embodiment, R in Formula II (e.g., II-A, II-1, or II-2) 3 In some preferred embodiments, R in Formula II (e.g., II-A, II-1, or II-2) is cyclopropyl. 3 teeth, [ka] In a preferred embodiment, R in Formula II (e.g., II-A, II-1, or II-2) is 3 teeth, [ka] Typically, R in Formula II (e.g., II-A, II-1, or II-2) 4 is hydrogen. 4 In some embodiments, R in Formula II (e.g., II-A, II-1, or II-2) can be NH. 3 and R 4can be joined to form a 5- or 6-membered heteroaryl structure having 1-3 ring heteroatoms independently selected from N, O, and S, which is optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from F, CN, OH, and 4- to 6-membered heterocyclyl having 1-2 ring heteroatoms independently selected from N, O, and S, and optionally substituted with 1-3 substituents independently selected from oxo, F, CN, and OH. For example, in some embodiments, R 3 and R 4 are combined, [ka] Form.

[0149] In certain embodiments, the present disclosure also provides a compound selected from Table 1A or Table 1B below, a deuterated analog thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: Table 1A. List of compounds [ka] [ka] [ka] [ka] [ka] [ka] Table 1B. List of compounds [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] The compounds of Tables 1A and 1B may exist in various stereoisomers, e.g., individual isomers, individual enantiomers and / or diastereomers, if applicable, or as mixtures of stereoisomers (including racemic mixtures and mixtures enriched in one or more stereoisomers). In certain embodiments, if applicable, the compounds shown in Tables 1A or 1B may exist as isolated individual enantiomers that are substantially free of other enantiomers (e.g., less than 20%, less than 10%, less than 5%, less than 1%, or undetectable amounts by weight, by HPLC or SFC area, or both). In certain embodiments, if applicable, the compounds shown in Tables 1A or 1B may also exist as mixtures of stereoisomers in any ratio, such as racemic mixtures.

[0150] In certain embodiments, the genera of compounds described herein exclude, where applicable, any specifically known single compounds that precede the present disclosure. In certain embodiments, where applicable, any subgenera or species of compounds that precede the present disclosure that are all within the genus of compounds described herein may be excluded from such genus herein.

[0151] Synthesis method The compounds of the present disclosure may be readily synthesized by one of ordinary skill in the art in light of the present disclosure, and exemplary syntheses are also provided in the Examples section.

[0152] The synthesis of a compound of Formula I shown in Scheme 1 is exemplary. As shown in Scheme 1, a compound of Formula I can typically be prepared from a compound of S-2 by a series of coupling reactions. For example, in some embodiments, a compound of S-2 can first be reacted with an amine S-1 to form a compound of S-3. Typically, the G in S-2 1A is a leaving group as described herein, such as a halogen, e.g., Cl, and G in S-1 1B is typically hydrogen. Conditions for coupling compounds S-1 and S-2 include any of the conditions known for similar transformations. Exemplary conditions are provided in the Examples section herein. Compound S-3 can then be reacted with S-4 to form a compound of Formula I. L 2 is O or NR 14 or R 2 -L 3 -L 2 represents a heterocycle attached to the pyridine or pyrimidine ring in formula I via a ring nitrogen, typically G in S-3 2A is a leaving group as described herein, such as a halogen, e.g., F, Cl, etc., and G in S-4 2B is typically hydrogen. Conditions for coupling compounds S-3 and S-4 include any of the conditions known for similar transformations. Exemplary conditions are provided in the Examples section herein. In certain embodiments, G in S-3 2Acan be a leaving group as described herein, such as a halogen, and G in S-4 2B can be a coupling partner such as a boronic acid / ester, tin, zinc, etc., and S-4 reacts with S-3 under appropriate conditions (e.g., palladium-catalyzed cross-coupling reaction) to give R 2 -L 3 -L 2 The variable L in the formula in Scheme 1 is 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 and X include any of those described herein in any combination. While Scheme 1 depicts one particular sequence for coupling various compounds with S-2 to provide compounds of Formula I, the disclosure is not limited to this sequence of coupling. For example, in one embodiment, the synthetic method begins with coupling S-2 with S-4 to provide R 2 -L 3 -L 2 The resulting compound can then be reacted by sequential coupling with S-1 and S-4 to give compounds of formula I. Compounds of S-2 may be commercially available or can be generally prepared according to various heteroaryl-forming methods and / or subsequent transformations known in the art. Coupling partners S-1 and S-4 are generally commercially available or can be readily prepared by one skilled in the art in light of the present disclosure.

[0153] [ka] As will be apparent to one skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, many protecting groups are described in "Protective Groups in Organic Synthesis", 4th ed. P.G.M.Wuts; T.W. Greene, John Wiley, 2007, and the references cited therein. The reagents for the reactions described herein are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the reagents are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA) and Sigma (St. Louis, Missouri, USA). Others are described in Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplement (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (Wiley, 7 th These compounds may be prepared by procedures described in standard references such as "The Organic Synthesis of Benzyl Alcohols" (Wiley-VCH, 1999), "The Organic Synthesis of Benzyl Alcohols," and "Larock's Comprehensive Organic Transformations" (Wiley-VCH, 1999), and any revised editions available at the time of this application, or obvious modifications thereof.

[0154] Pharmaceutical Composition Certain embodiments relate to pharmaceutical compositions comprising one or more compounds of the present disclosure.

[0155] The pharmaceutical composition may optionally contain a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B). , IA-9B, IA-10B, or IB), a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), Examples 1-155, or any of the specific compounds disclosed in Tables 1A or 1B herein, or a pharmaceutically acceptable salt thereof), and a pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients are known in the art. Non-limiting examples of suitable excipients include, for example, encapsulating materials or additives such as antioxidants, binders, buffers, carriers, coating agents, colorants, diluents, disintegrants, emulsifiers, bulking agents, fillers, flavoring agents, humectants, lubricants, flavorings, preservatives, propellants, release agents, sterilizing agents, sweeteners, solubilizers, wetting agents, and mixtures thereof. See also Remington's The Science and Practice of Pharmacy, 21st Edition, A.R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, Md., 2005; incorporated herein by reference), which discloses various excipients used to formulate pharmaceutical compositions and known techniques for their preparation.

[0156] The pharmaceutical composition may include any one or more of the compounds of the present disclosure. For example, in certain embodiments, the pharmaceutical composition may include any one or more of the compounds of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, I In some embodiments, the pharmaceutical composition may comprise, for example, a therapeutically effective amount of a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), Examples 1-155, or any of the specific compounds disclosed in Tables 1A or 1B herein, or a pharmaceutically acceptable salt thereof. In any of the embodiments described herein, the pharmaceutical composition may comprise a therapeutically effective amount (e.g., for treating breast cancer or ovarian cancer) of a compound selected from any of Examples 1-155, or any of the specific compounds disclosed in Tables 1A or 1B herein, or a pharmaceutically acceptable salt thereof. In a preferred embodiment, the pharmaceutical composition may comprise a compound selected from the compounds of Examples 1 to 155 having a CDK2 / cyclin E1 IC50 level designated as "A" or "B" in Table 2 herein, preferably "A".

[0157] The pharmaceutical compositions herein may be formulated for delivery via any of the known routes of delivery, including, but not limited to, oral, nasal, transdermal, pulmonary, by inhalation, buccal, sublingual, intraperitoneal, subcutaneous, intramuscular, intravenous, intrarectal, intrapleural, intrathecal or parenteral administration.

[0158] In certain embodiments, the pharmaceutical composition may be formulated for oral administration. Oral formulations may be presented as discrete units, such as capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Excipients for preparing compositions for oral administration are known in the art. Non-limiting examples of suitable excipients include agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomer, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, crospovidone, diglycerides, ethanol, ethyl cellulose, ethyl laurate, methyl cellulose ... laureate), ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, peanut oil, hydroxypropyl methylcellulose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethylcellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acid, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water, and mixtures thereof.

[0159] In some embodiments, the pharmaceutical composition is formulated for parenteral administration (such as intravenous injection or infusion, subcutaneous or intramuscular injection). Parenteral formulations can be, for example, aqueous solutions, suspensions, or emulsions. Excipients for preparing parenteral formulations are known in the art. Non-limiting examples of suitable excipients include 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, peanut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, USP or isotonic sodium chloride solution, water, and mixtures thereof.

[0160] The compounds of the present disclosure may be used alone, in combination with each other, or in combination with one or more additional therapeutic agents, for example, in combination with additional anti-cancer therapeutic agents such as mitotic inhibitors, alkylating agents, antimetabolites, antitumor antibiotics, antiangiogenic agents, topoisomerase I and II inhibitors, plant alkaloids, hormonal agents and antagonists, growth factor inhibitors, radiation, signal transduction inhibitors such as inhibitors of protein tyrosine kinases and / or serine / threonine kinases, cell cycle inhibitors, biological response modifiers, enzyme inhibitors, antisense oligonucleotides or oligonucleotide derivatives, cytotoxic agents, immuno-oncology agents, and the like. In certain embodiments, one or more compounds of the present disclosure may be used in combination with one or more targeting agents, such as inhibitors of PI3 kinase, mTOR, PARP, IDO, TDO, ALK, ROS, MEK, VEGF, FLT3, AXL, ROR2, EGFR, FGFR, Src / Abl, RTK / Ras, Myc, Raf, PDGF, AKT, c-Kit, erbB, CDK4 / CDK6, CDK5, CDK7, CDK9, SMO, CXCR4, HER2, GLS1, EZH2, or Hsp90, or an immunomodulatory agent, such as a PD-1 or PD-L1 antagonist, an OX40 agonist, or a 4-1BB agonist. In some embodiments, one or more compounds of the present disclosure may be used in combination with standard therapeutic agents such as tamoxifen, docetaxel, paclitaxel, cisplatin, capecitabine, gemcitabine, vinorelbine, exemestane, letrozole, fulvestrant, anastrozole, or trastuzumab. Suitable additional anticancer therapeutic agents include any known in the art, such as those approved for appropriate cancers by regulatory agencies such as the US Food and Drug Administration. Some examples of suitable additional anticancer therapeutic agents include those described in International Publication No. 2020 / 157652, US Patent Application Publication No. 2018 / 0044344, International Publication No. 2008 / 122767, etc., the contents of each of which are incorporated herein by reference in their entirety.

[0161] When used in combination with one or more additional therapeutic agents, the compounds of the present disclosure or pharmaceutical compositions herein can be administered to a subject simultaneously with such additional therapeutic agents or sequentially in any order. In some embodiments, a pharmaceutical composition can contain one or more compounds of the present disclosure and one or more additional therapeutic agents in a single composition. In some embodiments, a pharmaceutical composition containing one or more compounds of the present disclosure can be included in a kit that also contains a separate pharmaceutical composition containing one or more additional therapeutic agents.

[0162] A pharmaceutical composition may contain various amounts of a compound of the present disclosure, depending on various factors, such as the intended use and efficacy and selectivity of the compound. In some embodiments, a pharmaceutical composition contains a therapeutically effective amount of a compound of the present disclosure. In some embodiments, a pharmaceutical composition contains a therapeutically effective amount of a compound of the present disclosure and a pharmaceutically acceptable excipient. As used herein, a therapeutically effective amount of a compound of the present disclosure is an amount effective to treat a disease or disorder described herein, such as breast cancer or ovarian cancer, which may depend on the recipient of the treatment, the disorder, condition or disease being treated and their severity, the composition containing the compound, the timing of administration, the route of administration, the duration of treatment, the efficacy of the compound, its clearance rate, and whether another drug is co-administered.

[0163] Method of Treatment / Use The compounds of the present disclosure have various utilities. For example, the compounds of the present disclosure can be used as therapeutically effective substances for the treatment and / or prevention of CDK2-mediated diseases or disorders. Accordingly, some embodiments of the present disclosure also relate to methods of using one or more compounds of the present disclosure or pharmaceutical compositions herein for treating or preventing CDK2-mediated diseases or disorders in a subject in need thereof, for example, for treating cancer in a subject in need thereof.

[0164] In certain embodiments, the present disclosure provides a method of inhibiting abnormal cell growth in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutical composition described herein. In certain embodiments, the abnormal cell growth is cancer characterized by amplification or overexpression of cyclin E1 (CCNE1) and / or cyclin E2 (CCNE2). In certain embodiments, the subject is identified as having a cancer characterized by amplification or overexpression of CCNE1 and / or CCNE2.

[0165] In certain embodiments, the present disclosure also provides a method for inhibiting CDK activity in a subject or biological sample. In certain embodiments, the present disclosure provides a method for inhibiting CDK2 activity in a subject or biological sample, comprising administering to the subject or biological sample an effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, I and / or a compound of Formula II (e.g., a compound of Formula II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition described herein.

[0166] In certain embodiments, the present disclosure provides a method for treating or preventing a CDK-mediated, particularly a CDK2-mediated, disease or disorder in a subject in need thereof. In certain embodiments, the method includes administering an effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA- 10B, or IB), a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof), or an effective amount of a pharmaceutical composition described herein, is administered to a subject. In one embodiment, the CDK2-mediated disease or disorder is cancer. In one embodiment, the cancer is characterized by amplification or overexpression of CCNE1 and / or CCNE2.

[0167] In certain embodiments, the present disclosure also provides a method of treating or preventing cancer in a subject in need thereof, comprising administering an effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, and / or a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), Examples 1-155, or any of the specific compounds disclosed in Tables 1A or 1B herein, or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition described herein, is administered to a subject. In some embodiments, the cancer is characterized by amplification or overexpression of CCNE1 and / or CCNE2. In some embodiments, the subject is identified as having a cancer characterized by amplification or overexpression of CCNE1 and / or CCNE2. In certain embodiments, the cancer is selected from breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer (including NSCLC, SCLC, squamous cell carcinoma, or adenocarcinoma), esophageal cancer, head and neck cancer, colorectal cancer, renal cancer (including RCC), liver cancer (including HCC), pancreatic cancer, stomach (i.e., gastric) cancer, thyroid cancer, and combinations thereof. In certain embodiments of the methods herein, the cancer is breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, liver cancer, pancreatic cancer, and / or gastric cancer.

[0168] In some embodiments of the methods herein, the cancer is breast cancer, such as ER-positive / HR-positive, HER2-negative breast cancer; ER-positive / HR-positive, HER2-positive breast cancer; triple-negative breast cancer (TNBC); or inflammatory breast cancer. In some embodiments, the breast cancer can be endocrine therapy-resistant breast cancer, trastuzumab-resistant breast cancer, or breast cancer that exhibits primary or acquired resistance to CDK4 / CDK6 inhibition. In some embodiments, the breast cancer can be advanced or metastatic breast cancer. In some embodiments, the breast cancer described herein is characterized by amplification or overexpression of CCNE1 and / or CCNE2.

[0169] In some embodiments of the methods herein, the cancer is ovarian cancer, hi some embodiments, the ovarian cancer is characterized by amplification or overexpression of CCNE1 and / or CCNE2.

[0170] In some embodiments of the methods herein, the cancer is a blood cancer such as leukemia. In some embodiments of the methods herein, the cancer is chronic lymphocytic leukemia, such as relapsed or refractory chronic lymphocytic leukemia (CLL).

[0171] In some embodiments of the methods herein, the cancer is acute myeloid leukemia. In some embodiments of the methods herein, the cancer is relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.

[0172] In any of the embodiments described herein, unless otherwise specified or contradicted, the cancers herein may be characterized by amplification or overexpression of CCNE1 and / or CCNE2.

[0173] In certain embodiments, the present disclosure also provides a method of treating breast cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA- and inflammatory breast cancer. In some embodiments, the breast cancer is selected from ER-positive / HR-positive, HER2-negative breast cancer; ER-positive / HR-positive, HER2-positive breast cancer; triple-negative breast cancer (TNBC); and inflammatory breast cancer. In some embodiments, the breast cancer is selected from endocrine therapy-resistant breast cancer, trastuzumab-resistant breast cancer, or breast cancer exhibiting primary or acquired resistance to CDK4 / CDK6 inhibition. In certain embodiments, the breast cancer is advanced or metastatic breast cancer. In certain embodiments, the breast cancer is characterized by amplification or overexpression of CCNE1 and / or CCNE2.

[0174] In certain embodiments, the present disclosure also provides a method of treating ovarian cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8A, IA-9A, IA-10A, IA-11A, IA-12A, IA-13A, IA-14A, IA-15A, IA-16A, IA-17A, IA-18A, IA-19A, IA-20A, IA-21A, IA-22A, IA-23A, IA-24A, IA-25A, IA-26A, IA-27A, IA-28A, IA-29A, IA-30A, IA-31A, IA-32A, IA-33A, IA-34A, IA-35A, IA-36A, IA-37A, IA-38A, IA-39A, IA-40A, IA-41A, IA-42A, IA-43A, IA-44A, IA-45A, IA-46A, IA-47A, IA-48A, IA-49A, IA-50A, IA-5 and / or a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition described herein, is provided. In some embodiments, the ovarian cancer is characterized by amplification or overexpression of CCNE1 and / or CCNE2.

[0175] In certain embodiments, the present disclosure also provides a method of treating leukemia in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8A, IA-9A, IA-10A, IA-11A, IA-12A, IA-13A, IA-14A, IA-15A, IA-16A, IA-17A, IA-18A, IA-19A, IA-20A, IA-21A, IA-22A, IA-23A, IA-24A, IA-25A, IA-26A, IA-27A, IA-28A, IA-29A, IA-30A, IA-31A, IA-32A, IA-33A, IA-34A, IA-35A, IA-36A, IA-37A, IA-38A, IA-39A, IA-40A, IA-41A, IA-42A, IA-43A, IA-44A, IA-45A, IA-46A, IA-47A, IA-48A, IA-49A, IA-50A, IA-5 and / or a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition described herein, is administered to a subject. In some embodiments, the leukemia is characterized by amplification or overexpression of CCNE1 and / or CCNE2.

[0176] In certain embodiments, the present disclosure also provides a method of treating chronic lymphocytic leukemia, such as relapsed or refractory chronic lymphocytic leukemia (CLL), in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5A, IA-6B, IA-7C, IA-8D, IA-9D, IA-10E, IA-10F, IA-10H ... and / or a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof), or an effective amount of a pharmaceutical composition described herein, is provided.

[0177] In certain embodiments, the present disclosure also provides a method of treating acute myeloid leukemia, such as relapsed or refractory acute myeloid leukemia, in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6A, IA-7B, IA-8A, IA-9B, IA-10B, IA-10C, IA-10D, IA-10E, IA-10F, IA-10H ... and / or a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof), or an effective amount of a pharmaceutical composition described herein, is provided.

[0178] In certain embodiments, the present disclosure also provides a method of treating myelodysplastic syndrome in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, and / or a compound of Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4), any of Examples 1-155, or any of the specific compounds disclosed in Table 1A or 1B herein, or a pharmaceutically acceptable salt thereof), or an effective amount of a pharmaceutical composition described herein, is provided.

[0179] In a preferred embodiment, the compound of the present disclosure for the methods herein has a CDK2 / cyclin E1 IC50 of less than 100 nM, more preferably less than 10 nM, measured / calculated according to Biological Example 1 herein. In a preferred embodiment, the compound of the present disclosure for the methods herein is selected from the compounds of Examples 1-155 having a CDK2 / cyclin E1 IC50 level designated as "A" or "B" in Table 2 herein, preferably "A".

[0180] The administration in the methods herein is not limited to any particular route of administration. For example, in some embodiments, administration can be oral, nasal, transdermal, pulmonary, inhalation, buccal, sublingual, intraperitoneal, subcutaneous, intramuscular, intravenous, rectal, intrapleural, intrathecal, and parenteral. In some embodiments, administration is oral administration. In some embodiments, administration is parenteral injection, such as intravenous injection.

[0181] The compounds of the present disclosure can be used as monotherapy or in combination therapy. In some embodiments of the methods described herein, they can be administered as the only active ingredient. In some embodiments of the methods described herein, one or more compounds of the present disclosure can also be co-administered to a subject in need thereof with an additional therapeutic agent, either simultaneously or sequentially in any order. The additional therapeutic agent can typically be an additional anti-cancer therapeutic agent, such as a mitotic inhibitor, an alkylating agent, an antimetabolite, an antitumor antibiotic, an anti-angiogenic agent, a topoisomerase I and II inhibitor, a plant alkaloid, a hormone agent and antagonist, a growth factor inhibitor, radiation, a signal transduction inhibitor, such as an inhibitor of protein tyrosine kinase and / or serine / threonine kinase, a cell cycle inhibitor, a biological response modifier, an enzyme inhibitor, an antisense oligonucleotide or oligonucleotide derivative, a cytotoxic agent, an immuno-oncology agent, or the like. In some embodiments, the additional anti-cancer agent is an endocrine therapy agent, such as an aromatase inhibitor, a SERD, or a SERM. In certain embodiments, one or more compounds of the present disclosure may be administered in combination with one or more targeting agents, such as inhibitors of PI3 kinase, mTOR, PARP, IDO, TDO, ALK, ROS, MEK, VEGF, FLT3, AXL, ROR2, EGFR, FGFR, Src / Abl, RTK / Ras, Myc, Raf, PDGF, AKT, c-Kit, erbB, CDK4 / CDK6, CDK5, CDK7, CDK9, SMO, CXCR4, HER2, GLS1, EZH2, or Hsp90, or an immunomodulatory agent, such as a PD-1 or PD-L1 antagonist, an OX40 agonist, or a 4-1BB agonist. In certain embodiments, one or more compounds of the present disclosure may be administered in combination with a standard of care agent such as tamoxifen, docetaxel, paclitaxel, cisplatin, capecitabine, gemcitabine, vinorelbine, exemestane, letrozole, fulvestrant, anastrozole, or trastuzumab. Suitable additional anti-cancer therapeutic agents include any known in the art, such as those approved for the appropriate cancer by regulatory agencies, such as the US Food and Drug Administration.Some examples of suitable additional anti-cancer therapeutic agents also include those described in WO 2020 / 157652, U.S. Patent Application Publication No. 2018 / 0044344, WO 2008 / 122767, and the like, the contents of each of which are incorporated herein by reference in their entirety.

[0182] Dosage regimens, including dosages, for the methods described herein may vary and may be adjusted depending on the recipient of the treatment, the disorder, condition, or disease being treated and its severity, the composition containing the compound, the timing of administration, the route of administration, the duration of treatment, the potency of the compound, its clearance rate, and whether another drug is co-administered.

[0183] definition It is intended to be understood that appropriate atom valences are maintained for all moieties and combinations thereof.

[0184] It is also intended to be understood that a particular embodiment of a variable moiety herein may be the same or different from another particular embodiment having the same identifier.

[0185] Suitable groups for the variables in compounds of Formula I or II, or subformulas thereof, are independently selected, where applicable. Non-limiting useful groups for the variables in compounds of Formula I or II, or subformulas thereof, include any of the respective groups, individually or in any combination, as shown in the Examples or in the specific compounds described in Tables 1A or 1B herein, where applicable. Examples include the variable R 1 In certain embodiments, compounds of Formula I or II can be prepared by using the formula R 1 R relating to any of the groups 1 In certain embodiments, the compound of Formula I or II may contain at least one other variable (e.g., L) according to a specific compound described in the Examples or Table 1A or 1B herein. 1) in certain compounds shown in the Examples or described in Table 1A or 1B herein, 1 R relating to any of the groups 1 group, where R 1 and at least one other variable may be from the same compound or a different compound. Any such combination is contemplated and is within the scope of the present disclosure.

[0186] The described embodiments of the present disclosure may be combined. Such combinations are contemplated and within the scope of the present disclosure. For example, when L of Formula I (e.g., Formula I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, IA-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB) is 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 , and any one or more of the definitions of X, if applicable, L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 and any one or more other definitions of X, and compounds resulting from this combination are considered to be within the scope of the present disclosure.

[0187] symbol, [ka] Whether used as a bond or shown perpendicular to (or across) a bond, indicates the point at which the shown moiety is attached to the remainder of the molecule. As will be understood by those of skill in the art, one or more directly bonded groups may be used with the symbol, [ka] It should be noted that the number of pixels may be greater than 1.

[0188] Definitions of certain functional groups and chemical terms are explained in more detail below. Chemical elements are defined in accordance with the Periodic Table of the Elements, CAS edition, Handbook of Chemistry and Physics, 75 th Ed., inside cover, and specific functional groups are generally defined as described therein. Further general principles of organic chemistry and specific functional groups and reactivity are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5 th Edition, John Wiley&Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987. The present disclosure is in no way intended to be limited by the exemplary recitation of substituents described herein.

[0189] The compounds described herein may contain one or more asymmetric centers and therefore may exist in various stereoisomers, such as enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, or geometric isomers, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-performance liquid chromatography (HPLC), chiral supercritical fluid chromatography (SFC), and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present disclosure further encompasses the compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers, including racemic mixtures. Where stereochemistry is specifically depicted, it should be understood that, unless otherwise contradicted by context, the compound may exist predominantly as the stereoisomer depicted, with less than 20%, less than 10%, less than 5%, less than 1%, or an undetectable amount of other stereoisomers, e.g., by weight, by HPLC or SFC area, or both. The presence and / or amount of stereoisomers can be determined by one of skill in the art in light of the present disclosure, such as by use of chiral HPLC or chiral SFC. As will be understood by one of skill in the art, " *" is shown in a chemical structure herein, unless the context specifically contradicts it, the corresponding asymmetric center should be shown as being enantiomerically pure or enriched in either of its forms, or as being enantiomerically pure or enriched in the form as depicted, e.g., by weight, by HPLC or SFC area, or both, containing less than 20%, less than 10%, less than 5%, less than 1%, or an undetectable amount of the other stereoisomer. Also, where the stereochemistry is not specifically depicted, " * " is not used in a chemical structure, unless the context specifically contradicts it, it is to be understood that such structure includes the corresponding compound in any stereoisomeric form, including individual isomers and mixtures of various isomers, including racemic mixtures, substantially free of other isomers.

[0190] When a range of values ​​is listed, it is intended to encompass each value and subrange within the range. For example, "C 1~6 ” is C1, C2, C3, C4, C5, C6, C 1~6 , C 1~5 , C 1~4 , C 1~3 , C 1~2 , C 2~6 , C 2~5 , C 2~4 , C 2~3 , C 3~6 , C 3~5 , C 3~4 , C 4~6 , C 4~5 , and C 5~6 is intended to encompass:

[0191] As used herein, the term "compounds of the disclosure" refers to compounds of formula I (e.g., I-1, I-2, I-3, I-4, I-5, I-2-1, I-2-1-S1, I-2-1-S2, I-2-1-S3, I-2-1-S4, I-5-1, I-5-2, IA, IA-1, IA-2, IA-3, IA-4, IA-5A, IA-6A, IA-7A, I A-8A, IA-9A, IA-10A, IA-5B, IA-6B, IA-7B, IA-8B, IA-9B, IA-10B, or IB), Formula II (e.g., II-A, II-1, II-2, II-1-S1, II-1-S2, II-1-S3, II-1-S4, II-2-S1, II-2-S2, II-2-S3, or II-2-S4). or any of the specific compounds disclosed in Tables 1A or 1B herein, its isotopically labeled compounds (such as deuterated analogs in which one or more hydrogen atoms have been replaced with deuterium atoms having an abundance greater than their natural abundance, e.g., if the compound has a CH group, a CD analog), its possible positional isomers, possible geometric isomers, possible stereoisomers (including diastereoisomers, enantiomers, and racemic mixtures), its tautomers, its conformers, its pharmaceutically acceptable esters, and / or its possible pharmaceutically acceptable salts (e.g., acid addition salts such as HCl salts or base addition salts such as Na salts). For clarity, the compounds of Examples 1-155 refer to compounds in the Examples section designated by the integers 1, 2, etc. through 155 only, or may be further followed by the designation "a," "b," "c," or "d," where applicable, for the corresponding stereoisomer. See, for example, Examples 1-23 and Table A herein. Collectively, Examples 1-155 should be understood to include Example Numbers 1-155, as well as those designated by an Example Number followed by "a," "b," "c," or "d." Illustrated syntheses and characterizations of Examples 1-155 are provided in the Examples section. Detailed illustrative procedures are provided in the illustrative Examples, e.g., 1-23. Hydrates and hydrates of the compounds of the present disclosure are contemplated compositions of the present disclosure, where the compounds are bound to water or solvent, respectively.

[0192] The compounds of the present disclosure may exist in isotopically enriched or enriched forms containing one or more atoms with an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature. The isotopes may be radioactive or non-radioactive. Isotopes of atoms such as, but not limited to, hydrogen, carbon, phosphorus, sulfur, fluorine, chlorine, and iodine include: 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 32 P, 35 S, 18 F, 36 Cl, and 125 I. Compounds that contain other isotopes of these and / or other atoms are within the scope of this invention.

[0193] As used herein, the phrase "administration" of a compound, "administering" a compound, or other variations thereof, means providing a compound or a prodrug of a compound to an individual in need of treatment.

[0194] As used herein, the term "alkyl" by itself or as part of another group refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon. In certain embodiments, alkyl refers to an alkyl group having 1 to 12 carbon atoms (i.e., C 1~12 alkyl) or the number of carbon atoms indicated. In one embodiment, the alkyl group is a linear C 1~10 In another embodiment, the alkyl group is a branched C 3~10 In another embodiment, the alkyl group is a linear C 1~6 In another embodiment, the alkyl group is a branched C 3~6 In another embodiment, the alkyl group is a linear C 1~4 It is an alkyl group. For example, C 1~4Alkyl groups include methyl, ethyl, propyl (n-propyl), isopropyl, butyl (n-butyl), sec-butyl, tert-butyl, and iso-butyl. As used herein, the term "alkylene," when used by itself or as part of another group, refers to a divalent group derived from an alkyl group. For example, non-limiting straight-chain alkylene groups include -CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-, -CH2-CH2-, and the like.

[0195] As used herein, the term "alkenyl" by itself or as part of another group refers to a straight or branched chain aliphatic hydrocarbon containing one or more, e.g., one, two, or three, carbon-carbon double bonds. In one embodiment, an alkenyl group is 2~6 In another embodiment, the alkenyl group is C 2~4 Alkenyl groups. Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.

[0196] As used herein, the term "alkynyl" by itself or as part of another group refers to a straight or branched chain aliphatic hydrocarbon containing one or more, e.g., one to three, carbon-carbon triple bonds. In one embodiment, an alkynyl has one carbon-carbon triple bond. In one embodiment, an alkynyl group is a C 2~6 In another embodiment, the alkynyl group is C 2~4 Alkynyl groups. Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.

[0197] As used herein, the term "alkoxy" when used by itself or as part of another group refers to R a1 is alkyl, a1 Refers to the radical of

[0198] As used herein, the term "cycloalkoxy" by itself or as part of another group refers to R a1 is cycloalkyl, a1 Refers to the radical of

[0199] As used herein, the term "haloalkyl" by itself or as part of another group refers to an alkyl substituted with one or more fluorine, chlorine, bromine, and / or iodine atoms. In a preferred embodiment, a haloalkyl is an alkyl group substituted with one, two, or three fluorine atoms. In one embodiment, a haloalkyl group is selected from the group consisting of C 1~10 In one embodiment, the haloalkyl group is C 1~6 In one embodiment, the haloalkyl group is C 1~4 It is a haloalkyl group.

[0200] As used herein, the term "heteroalkyl," by itself or in combination with another term, unless otherwise specified, means a stable straight- or branched-chain alkyl group having, for example, 2 to 14 carbons in the chain, e.g., 2 to 10 carbons, in which one or more of the carbons are replaced with a heteroatom selected from S, O, P, and N, where the nitrogen, phosphine, and sulfur atoms can be optionally oxidized and the nitrogen heteroatom can be optionally quaternized. The heteroatoms S, O, P, and N can be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. When a heteroalkyl is described as substituted, the substituents can replace one or more hydrogen atoms bonded to the carbon atoms and / or heteroatoms of the heteroalkyl. In certain embodiments, a heteroalkyl is a C 1~4 Heteroalkyl refers to heteroalkyl as defined herein having 1 to 4 carbon atoms. 1~4Examples of heteroalkyl include, but are not limited to, C heteroalkyl, e.g., -CH-CH-N(CH)-CH, C heteroalkyl, e.g., -CH-CH-O-CH, -CH-CH-NH-CH, -CH-S-CH-CH, -CH-CH-S(O)-CH, -CH-CH-S(O)-CH, C heteroalkyl, e.g., -CH-CH-OH, -CH-CH-NH, -CH-NH(CH), -O-CH-CH, and C heteroalkyl, e.g., -CH-OH, -CH-NH, -O-CH. Similarly, the term "heteroalkylene" by itself or as part of another substituent refers to a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH-CH-O-CH-CH- and -O-CH-CH-NH-CH-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Furthermore, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is drawn. When "heteroalkyl" is recited followed by a recitation of a specific heteroalkyl group, such as -NR'R", it will be understood that the terms heteroalkyl and -NR'R" are not overlapping or mutually exclusive. Rather, the specific heteroalkyl group is recited to add clarity. Thus, the term "heteroalkyl" should not be construed herein to exclude specific heteroalkyl groups, such as -NR'R".

[0201] "Carbocyclyl" or "carbocyclic" when used by itself or as part of another group refers to a ring system having at least three carbon atoms, e.g., 3 to 10 ring carbon atoms ("C 3~10"carbocyclyl" refers to the radical of a non-aromatic cyclic hydrocarbon group having 1 or 2 carbon atoms, and 0 heteroatoms. Carbocyclyl groups can be either monocyclic ("monocyclic carbocyclyl") or contain fused, bridged, or spiro ring systems, such as bicyclic ring systems ("bicyclic carbocyclyl"), and can be saturated or partially unsaturated. Non-limiting exemplary carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclopentenyl, and cyclohexenyl. As used herein, the term "carbocyclylene" when used by itself or as part of another group refers to a divalent radical derived from a carbocyclyl group, as defined herein.

[0202] In some embodiments, a "carbocyclyl" is fully saturated, which is also referred to as a cycloalkyl. In some embodiments, a cycloalkyl can have from 3 to 10 ring carbon atoms ("C 3~10 In preferred embodiments, the cycloalkyl is a monocyclic ring. As used herein, the term "cycloalkylene" by itself or as part of another group refers to a cycloalkyl group, such as [ka] It refers to a divalent group derived from

[0203] "Heterocyclyl" or "heterocyclic," by itself or as part of another group, refers to the radical of a three- or more-membered, e.g., 3- to 14-membered, non-aromatic ring system having ring carbon atoms and at least one ring heteroatom, e.g., 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment can be at a carbon or nitrogen atom, where valence allows. Heterocyclyl groups can be either monocyclic ("monocyclic heterocyclyl") or fused, bridged, or spiro ring systems, e.g., bicyclic ring systems ("bicyclic heterocyclyl"), and can be saturated or partially unsaturated. Heterocyclyl bicyclic ring systems can contain one or more heteroatoms in one or both rings, and the point of attachment can be on any ring. As used herein, the term "heterocyclylene" by itself or as part of another group refers to a divalent radical derived from a heterocyclyl group, as defined herein. The heterocyclyl or heterocyclylene can be optionally linked to the remainder of the molecule through a carbon or nitrogen atom.

[0204] Exemplary 3-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azirdinyl, oxiranyl, and thiiranyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl. Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocycles) include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.Exemplary 6-membered heterocyclyl groups (also referred to herein as 6,6-bicyclic heterocycles) fused to an aryl ring include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

[0205] "Aryl" when used by itself or as part of another group refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic arrangement) having 6 to 14 ring carbon atoms and 0 heteroatoms provided in the aromatic ring system ("C 6~14 In some embodiments, an aryl group has 6 ring carbon atoms ("C aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C 10 Aryl"; e.g., naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms ("C 14 "Aryl"; e.g., anthracyl). As used herein, the term "arylene" by itself or as part of another group refers to a divalent radical derived from an aryl group, as defined herein.

[0206] "Aralkyl," when used by itself or as part of another group, refers to an alkyl substituted with one or more aryl groups, preferably one aryl group. Examples of aralkyls include benzyl, phenethyl, and the like. When an aralkyl is described as being optionally substituted, either the alkyl or aryl portion of the aralkyl can be optionally substituted.

[0207] "Heteroaryl," by itself or as part of another group, refers to a radical of a 5- to 14-membered monocyclic, bicyclic, or tricyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π-electrons shared in a cyclic arrangement) having ring carbon atoms and at least one, preferably 1 to 4, ring heteroatoms provided in the aromatic ring system, each heteroatom independently selected from nitrogen, oxygen, and sulfur ("5- to 14-membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment can be at a carbon or nitrogen atom, as valence permits. Heteroaryl bicyclic ring systems can contain one or more heteroatoms in one or both rings. In bicyclic heteroaryl groups in which one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, etc.), the point of attachment can be on either ring, i.e., either the ring with the heteroatom (e.g., 2-indolyl) or the ring without the heteroatom (e.g., 5-indolyl). As used herein, the term "heteroarylene" by itself or as part of another group refers to a divalent radical derived from a heteroaryl group, as defined herein.

[0208] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0209] "Heteroaralkyl" by itself or as part of another group refers to an alkyl substituted with one or more heteroaryl groups, preferably one heteroaryl group. When a heteroaralkyl is described as optionally substituted, either the alkyl or heteroaryl portion of the heteroaralkyl can be optionally substituted.

[0210] "Optionally substituted" groups, such as optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl groups, refer to the respective groups being unsubstituted or substituted. Generally, the term "substituted," whether preceded by the term "optionally," means that at least one hydrogen atom present in the group (e.g., a carbon or nitrogen atom) is replaced with an acceptable substituent, e.g., a substituent that, upon substitution, results in a stable compound, e.g., a compound that does not spontaneously undergo transformation, such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a "substituted" group has a substituent at one or more substitutable positions of the group; when more than one position in any given structure is substituted, the substituents can be the same or different at each position. Typically, when substituted, an optionally substituted group herein can be substituted with 1 to 5 substituents. Substituents may be carbon atom, nitrogen atom, oxygen atom, or sulfur atom substituents, each of which may be optionally isotopically labeled, e.g., deuterated, if applicable. Two of the optional substituents may be linked to form a ring structure, such as an optionally substituted cycloalkyl, heterocyclyl, aryl, or heteroaryl ring. Substitution may occur on any available carbon, oxygen, or nitrogen atom to form a spirocyclic ring. Typically, substitutions herein do not result in OO, ON, SS, SN (excluding SO-N bonds), heteroatom-halogen, or -C(O)-S bonds or three or more consecutive heteroatoms (excluding O-SO-O, O-SO-N, and N-SO-N), except that such bonds or portions of the linkage may be tolerated if they are in a stable aromatic system.

[0211] In a broad aspect, the permissible substituents herein include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, heteroatoms such as nitrogen can have hydrogen substituents and / or any permissible substituents of organic compounds described herein that satisfy the valences of the heteroatoms. Substituents can include any substituent described herein, for example, halogen, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (such as thioester, thioacetate, or thioformate), alkoxy, cycloalkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, aryl, or heteroaryl, each of which can be optionally substituted.

[0212] Exemplary substituents include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, heteroaryl, -alkylene-aryl, -arylene-alkyl, -alkylene-heteroaryl, -alkenylene-heteroaryl, -alkynylene-heteroaryl, -OH, hydroxyalkyl, haloalkyl, -O-alkyl, -O-haloalkyl, -alkylene-O-alkyl, -O-aryl, -O-alkylene-aryl, acyl, -C(O)-aryl, halo, -NO, -CN, -SF, -C(O)OH, -C(O)O-alkyl, -C(O)O-aryl, -C(O)O-alkylene-aryl, -S(O)-alkyl, -S(O)-alkyl, -S(O)-aryl, -S(O)-aryl, -S(O)-heteroaryl, -S(O) -heteroaryl, -S-alkyl, -S-aryl, -S-heteroaryl, -S-alkylene-aryl, -S-alkylene-heteroaryl, -S(O)2-alkylene-aryl, -S(O)2-alkylene-heteroaryl, cycloalkyl, heterocycloalkyl, -OC(O)-alkyl, -OC(O)-aryl, -OC(O)-cycloalkyl, -C(=N-CN)-NH2, -C(=NH)-NH2, -C(=NH)-NH(alkyl), -N(Y1)(Y2), -alkylene-N(Y1)(Y2), -C(O)N(Y1)(Y2) and -S(O)2N(Y1)(Y2), where Y1 and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and -alkylene-aryl.

[0213] Some examples of suitable substituents include, but are not limited to, (C1-C8) alkyl groups, (C2-C8) alkenyl groups, (C2-C8) alkynyl groups, (C3-C 10) cycloalkyl groups, halogens (F, Cl, Br or I), halogenated (C1-C8) alkyl groups (such as, but not limited to, -CF3), -O-(C1-C8) alkyl groups, -OH, -S-(C1-C8) alkyl groups, -SH, -NH(C1-C8) alkyl groups, -N((C1-C8) alkyl) groups, -NH2, -C(O)NH2, -C(O)NH(C1-C8) alkyl groups, -C(O)N((C1-C8) alkyl) groups, -NHC(O)H, -NHC(O)(C1-C8) alkyl groups, -NHC(O)(C3-C8) cycloalkyl groups, -N((C -N((C1-C8)alkyl)C(O)H, -N((C1-C8)alkyl)C(O)(C1-C8)alkyl group, -NHC(O)NH2, -NHC(O)NH(C1-C8)alkyl group, -N((C1-C8)alkyl)C(O)NH2 group, -NHC(O)N((C1-C8)alkyl)2 group, -N((C1-C8)alkyl)C(O)N((C1-C8)alkyl)2 group, -N((C1-C8)alkyl)C(O)NH((C1-C8)alkyl), -C(O)H, -C(O)(C1-C8)alkyl group, -CN, -NO2, -S(O)(C1-C8)alkyl group, -S(O)2(C1-C8) alkyl group, -S(O)2N((C1-C8) alkyl)2 group, -S(O)2NH(C1-C8) alkyl group, -S(O)2NH(C3-C8) cycloalkyl group, -S(O)2NH2 group, -NHS(O)2(C1-C8) alkyl group, -N((C1-C8) alkyl)S(O)2(C1-C8) alkyl group, -(C1-C8) alkyl-O-(C1-C8) alkyl group, -O-(C1-C8) alkyl-O-(C1-C8) alkyl group, -C(O)OH, -C(O)O(C1-C8) alkyl group, NHOH, NHO(C -C1-C8) alkyl groups, -O-halogenated (C1-C8) alkyl groups (such as, but not limited to, -OCF3), -S(O)2-halogenated (C1-C8) alkyl groups (such as, but not limited to, -S(O)2CF3), -S-halogenated (C1-C8) alkyl groups (such as, but not limited to, -SCF3), -(C1-C6) heterocycles (such as, but not limited to, pyrrolidine, tetrahydrofuran, pyran, or morpholine), -(C1-C6) heteroaryls (such as, but not limited to, tetrazole, imidazole, furan, pyrazine, or pyrazole),-phenyl, -NHC(O)O-(C1-C6)alkyl group, -N((C1-C6)alkyl)C(O)O-(C1-C6)alkyl group, -C(=NH)-(C1-C6)alkyl group, -C(=NOH)-(C1-C6)alkyl group, and -C(=NO-(C1-C6)alkyl)-(C1-C6)alkyl group.

[0214] Exemplary carbon atom substituents include, but are not limited to, deuterium, halogen, -CN, -NO2, -N3, hydroxyl, alkoxy, cycloalkoxy, aryloxy, amino, monoalkylamino, dialkylamino, amido, sulfonamido, thiol, acyl, carboxylic acid, ester, sulfone, sulfoxide, alkyl, haloalkyl, alkenyl, alkynyl, C 3~10 Carbocyclyl, C 6~10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, etc. For example, exemplary carbon atom substituents include F, Cl, —CN, —SOH, —SOH, —OH, —OC 1~6 Alkyl, -NH2, -N(C 1~6 alkyl)2, -NH(C 1~6 alkyl), -SH, -SC 1~6 Alkyl, -C(=O)(C 1~6 alkyl), -CO2H, -CO2(C 1~6 alkyl), -OC(=O)(C 1~6 alkyl), -OCO2(C 1~6 alkyl), -C(=O)NH2, -C(=O)N(C 1~6 alkyl)2, -OC(=O)NH(C 1~6 alkyl), -NHC(=O)(C 1~6 alkyl), -N(C 1~6 alkyl)C(=O)(C 1~6 alkyl), -NHCO2(C 1~6 alkyl), -NHC(=O)N(C 1~6 alkyl)2, -NHC(=O)NH(C 1~6 alkyl), -NHC(=O)NH2, -NHSO2(C 1~6 alkyl), -SO2N(C 1~6 alkyl)2, -SO2NH(C1~6 alkyl), -SO2NH2, -SO2C 1~6 Alkyl, -SO2OC 1~6 Alkyl, -OSO2C 1~6 Alkyl, -SOC 1~6 Alkyl, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~10 Carbocyclyl, C 6~10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl; or two geminal substituents may be joined to form =O.

[0215] Nitrogen atoms can be substituted or unsubstituted, as valence allows, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, acyl groups, esters, sulfones, sulfoxides, C 1~10 Alkyl, C 1~10 Haloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 Alternatively, two substituents attached to a nitrogen atom may be joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl may be further substituted as defined herein. In certain embodiments, the substituent present on the nitrogen atom is a nitrogen protecting group (also called an amino protecting group). Nitrogen protecting groups are well known in the art and are described in Protective Groups in Organic Synthesis, T.W. Greene and P.G.M. Buts, 399-402, incorporated herein by reference. rdedition, John Wiley & Sons, 1999. Exemplary nitrogen protecting groups include, but are not limited to, those that form carbamates, such as carbobenzyloxy (Cbz), p-methoxybenzylcarbonyl (Moz or MeOZ), tert-butyloxycarbonyl (BOC), Troc, 9-fluorenylmethyloxycarbonyl (Fmoc), etc., those that form amides, such as acetyl, benzoyl, etc., those that form benzylamines, such as benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, etc., those that form sulfonamides, such as tosyl, nosyl, etc., and others, such as p-methoxyphenyl.

[0216] Exemplary oxygen atom substituents include, but are not limited to, acyl groups, esters, sulfonates, C 1~10 Alkyl, C 1~10 Haloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 and 5- to 14-membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl may be further substituted as defined herein. In certain embodiments, the oxygen atom substituent present on the oxygen atom is an oxygen protecting group (also called a hydroxyl protecting group). Oxygen protecting groups are well known in the art and are described in Protective Groups in Organic Synthesis, T.W. Greene and P.G.M. Buts, 3001, incorporated herein by reference. rdedition, John Wiley & Sons, 1999. Exemplary oxygen protecting groups include, but are not limited to, those that form alkyl ethers or substituted alkyl ethers, such as methyl, allyl, benzyl, substituted benzyls, such as 4-methoxybenzyl, methoxylmethyl (MOM), benzyloxymethyl (BOM), 2-methoxyethoxymethyl (MEM), and the like; those that form silyl ethers, such as trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), t-butyldimethylsilyl (TBDMS), and the like; those that form acetals or ketals, such as tetrahydropyranyl (THP); those that form esters, such as formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, and the like; and those that form carbonates or sulfonates, such as methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts).

[0217] Unless otherwise expressly stated, combinations of substituents and / or variables are permissible only if such combinations result in chemically permissible and stable compounds. A "stable" compound is one that can be prepared and isolated and whose structure and properties will retain or remain essentially unchanged for a period of time sufficient to permit use of the compound for the purposes described herein (e.g., therapeutic administration to a subject).

[0218] In certain embodiments, each "optionally substituted" alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkynyl, carbocyclic, carbocyclylene, cycloalkyl, cycloalkylene, alkoxy, cycloalkoxy, heterocyclyl, or heterocyclylene herein is independently unsubstituted or substituted with deuterium, F, Cl, -OH, protected hydroxyl, oxo (where applicable), NH, protected amino, NH(C 1~4alkyl) or its protected derivatives, N(C 1~4 Alkyl ((C 1~4 alkyl), C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 1~4 Alkoxy, C 3~6 Cycloalkyl, C 3~6 and cycloalkoxy, phenyl, 5- or 6-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, 3- to 7-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from O, S, and N, wherein each of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxyphenyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, three, or four substituents independently selected from deuterium, F, —OH, oxo (if applicable), C 1~4 Alkyl, Fluoro-substituted C 1~4 Alkyl (e.g., CF3), C 1~4 Alkoxy and Fluoro Substituted C 1~4 In certain embodiments, each "optionally substituted" aryl, arylene, heteroaryl, or heteroarylene group herein is independently unsubstituted or substituted with deuterium, F, Cl, -OH, -CN, NH, protected amino, NH(C 1~4 alkyl) or its protected derivatives, N(C 1~4 Alkyl ((C 1~4 alkyl), -S(=O)(C 1~4 alkyl), -SO2(C 1~4 alkyl), C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 1~4 Alkoxy, C 3~6 Cycloalkyl, C 3~6and cycloalkoxy, phenyl, 5- or 6-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, 3- to 7-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from O, S, and N, wherein each of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, phenyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, three, or four substituents independently selected from deuterium, F, —OH, oxo (where applicable), C 1~4 Alkyl, Fluoro-substituted C 1~4 Alkyl, C 1~4 Alkoxy and Fluoro Substituted C 1~4 Optionally substituted with 1, 2, or 3 substituents independently selected from alkoxy.

[0219] "Halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).

[0220] The term "pharmaceutically acceptable salt" refers to salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art.

[0221] The term "tautomer" or "tautomerism" refers to two or more interconvertible compounds resulting from tautomerization. The exact ratio of tautomers depends on several factors, including, for example, temperature, solvent, and pH. Tautomerization is known to those skilled in the art. Exemplary tautomerizations include keto-enol, amide-imide, lactam-lactim, enamine-imine, and enamine-(different enamine) tautomerizations.

[0222] The term "subject" (also referred to herein as "patient") as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

[0223] As used herein, the terms "treat," "treating," "treatment," and the like refer to eliminating, alleviating, or ameliorating a disease or condition and / or its associated symptoms. Although not excluded, treating a disease or condition does not require that the disease, condition, or its associated symptoms be completely eliminated. As used herein, the terms "treat," "treating," "treatment," and the like may also include "prophylactic treatment," which refers to reducing the likelihood of recurrence of a disease or condition, or the recurrence of a previously controlled disease or condition, in a subject who does not have, but is at risk of, or susceptible to, recurrence of the disease or condition or recurrence of a disease or condition. The term "treat" and synonyms contemplate administering a therapeutically effective amount of a compound described herein to a subject in need of such treatment.

[0224] The term "effective amount" refers to an amount of a compound or combination of compounds described herein sufficient to carry out the intended use, including, but not limited to, the prevention or treatment of disease. A therapeutically effective amount may vary depending on the intended use (in vitro or in vivo), or the subject and condition being treated (e.g., the subject's weight, age, and sex), the severity of the condition, the method of administration, etc., and can be readily determined by one of ordinary skill in the art. The term also applies to a dose that induces a particular response in target cells and / or tissues. The specific dose will vary depending on the particular compound selected, the dosing regimen to be followed, whether the compound is administered in combination with other compounds, the timing of administration, the tissue to which it is administered, and the physical delivery system by which the compound is delivered.

[0225] As used herein, the singular forms "a," "an," and "the" include plural referents unless expressly stated or unless it is clear from the context that this is not intended.

[0226] The term "and / or" when used herein in phrases such as "A and / or B" is intended to include both A and B; A or B; A alone; and B alone. Similarly, the term "and / or" when used in phrases such as "A, B, and / or C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A alone; B alone; and C alone.

[0227] Headings and subheadings are used for convenience and / or formal compliance only, do not limit the present technology, and are not referred to in connection with the interpretation of the description of the present technology. Features described under one heading or one subheading of the present disclosure may be combined with features described under other headings or subheadings in various embodiments. Furthermore, not all features under a single heading or a single subheading may necessarily be used together in an embodiment.

[0228] (Example) The various starting materials, intermediates, and compounds of the embodiments herein may be isolated and purified, if desired, using conventional techniques, such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Characterization of these compounds may be performed using conventional methods, such as by melting point, mass spectrum, nuclear magnetic resonance, and various other spectroscopic analyses. Abbreviations used in the Examples section should be understood to have their ordinary meaning in the art unless otherwise indicated or clearly contradicted by context. The Examples are illustrative only and do not limit the claimed invention in any way.

[0229] Exemplary embodiments of steps for synthesizing the products described herein are described in further detail below. Some of the examples described herein can be prepared by separation from the corresponding racemic mixture. As will be understood by those skilled in the art, the compounds described in the Examples section, immediately prior to a chiral separation step, e.g., by supercritical fluid chromatography (SFC), exist in the form of racemates and / or stereoisomeric mixtures, and bold, but not wedged, bonds are used in chemical structure diagrams to indicate relative stereochemistry. It should be understood that the enantiomeric excess ("ee") reported for these examples is merely representative of the exemplary procedures herein and is not limiting; one skilled in the art will understand that such enantiomers with different ees, such as higher ees, can be obtained in light of the present disclosure.

[0230] In some illustrative examples, the synthesis of deuterated compounds is shown. Where applicable, it should be understood that the corresponding non-deuterated (i.e., natural abundance) compounds were prepared by the same methods but by using the corresponding non-deuterated starting materials or intermediates.

[0231] Synthesis of cis-1-methylcyclopentane-1,2-diol (Intermediate I) [ka] To a solution of 1-methylcyclopent-1-ene (IA, 9.20 g, 112 mmol) in t-BuOH (90 mL) and HO (30 mL) was added potassium dioxide dioxoosmium dihydrate (2.06 g, 5.60 mmol), 4-methylmorpholine N-oxide (NMO) (18.3 g, 157 mmol), and pyridine (9.0 mL, 112 mmol). The reaction mixture was stirred at 85 °C for 5 h. Upon completion, the mixture was filtered through a short pad of Celite®, and the filtrate was quenched with saturated NaHSO solution (20 mL) and concentrated under reduced pressure to give a residue that was separated using silica gel column chromatography to give cis-1-methylcyclopentane-1,2-diol (Intermediate I, 11.9 g, 91%) as an oil. 1 H NMR (400MHz, DMSO-d6) δ 4.36(d,J=5.5Hz, 1H), 3.83(s,1H), 3.48-3.34(m,1H), 1.81-1.33(m,6H), 1.09(s,3H).

[0232] Synthesis of cis-4,4-difluoro-1-methylcyclopentane-1,2-diol (Intermediate II) [ka] To a mixture of cyclopent-3-en-1-ol (II-A, 5.00 g, 59.4 mmol) and 1H-imidazole (4.45 g, 65.4 mmol) in DMF (50 mL), chlorotriisopropylsilane (11.5 g, 59.4 mmol) was added dropwise. The mixture was stirred at room temperature for 12 hours. The resulting mixture was diluted with water (100 mL) and extracted with n-hexane (50 mL × 3). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, and concentrated under reduced pressure to give cyclopent-3-en-1-yloxy)triisopropylsilane (II-B, 14.5 g, crude) as a yellow oil. 1H NMR (500MHz, CDCl3)δ 5.68(s,2H), 4.67-4.62(m,1H), 2.65(dd,J=7.0, 1.9Hz, 1H), 2.61(dd,J=7.0, 1.7Hz, 1H), 2.37(t,J=2.7Hz, 1H), 2.33(t,J=2.9Hz, 1H), 1.13-1.08(m,21H).

[0233] To a solution of (cyclopent-3-en-1-yloxy)tris(propan-2-yl)silane (II-B, 5.00 g, crude product from above) in t-BuOH (50 mL) was added potassium osmate (0.38 g, 1.04 mmol), 4-methylmorpholine N-oxide (NMO) (3.41 g, 29.1 mmol), pyridine (1.67 mL, 20.8 mmol), and water (15 mL). The reaction mixture was stirred at 85 °C for 5 h. The resulting mixture was concentrated to give a residue, which was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (10:1 to 1:1) to give cis-4-((triisopropylsilyl)oxy)cyclopentane-1,2-diol (II-C, 3.2 g) as a yellow oil. 1 H NMR (500MHz, CDCl3) δ 4.54-4.50(m,1H), 4.28(t,J=4.9Hz, 2H), 2.73(s,2H), 2.04-1.99(m,2H), 1.95-1.90(m,2H), 1.08-1.03(m,21H).

[0234] To a mixture of cis-4-((triisopropylsilyl)oxy)cyclopentane-1,2-diol (II-C, 2.20 g, 8.01 mmol) and (4-fluorophenyl)boronic acid (0.11 g, 0.80 mmol) in N,N-dimethylformamide (20 mL) was added potassium carbonate (1.66 g, 12.0 mmol) and (bromomethyl)benzene (2.06 g, 12.0 mmol). The mixture was stirred at room temperature under a N atmosphere for 12 hours. The resulting mixture was diluted with water (100 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, and concentrated under reduced pressure to give a residue, which was subjected to silica gel column chromatography eluted with petroleum ether / ethyl acetate (1:0 to 10:1) to give cis-2-(benzyloxy)-4-((triisopropylsilyl)oxy)cyclopentan-1-ol (II-D, 1.70 g, 58%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.41-7.30(m,5H), 4.63(d,J=11.7Hz, 1H), 4.60-4.52(m,2H), 4.31(q, J=4.7Hz, 1H), 4.13- 4.10(m,1H), 2.16-2.07(m,2H), 1.94-1.90(m,1H), 1.86-1.81(m,1H), 1.08-1.40(m,21H).

[0235] To a solution of cis-2-(benzyloxy)-4-((triisopropylsilyl)oxy)cyclopentan-1-ol (II-D, 1.20 g, 3.29 mmol) in dichloromethane (20 mL) was added Dess-Martin periodinane (2.79 g, 6.58 mmol) at 0 °C, and the resulting mixture was stirred at room temperature for 5 h. After completion, the reaction mixture was quenched with saturated sodium thiosulfate solution (30 mL), diluted with water (50 mL), and then extracted with dichloromethane (50 mL × 3). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, and concentrated under reduced pressure to give a residue, which was subjected to silica gel column chromatography eluted with petroleum ether / ethyl acetate (1:0 to 10:1) to give 2-(benzyloxy)-4-((triisopropylsilyl)oxy)cyclopentan-1-one (II-E, 1.00 g, 84%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.48-7.29(m,5H), 4.91(d,J=11.7Hz, 1H), 4.77-4.57(m,2H), 4.21(t,J=8.6Hz, 1 H), 2.57-2.52(m,1H), 2.39-2.33(m,2H), 2.06-2.00(m,1H), 1.10-0.97(m,21H).

[0236] To a solution of 2-(benzyloxy)-4-{[tris(propan-2-yl)silyl]oxy}cyclopentan-1-one (II-E, 2.30 g, 6.34 mmol) in dry THF (20 mL) was added dropwise methylmagnesium bromide (1 M in THF, 12.7 mL, 12.7 mmol) at 0 °C. The mixture was then stirred at room temperature for 1 h. After completion, the resulting mixture was diluted with saturated ammonium chloride solution (10 mL) and water (20 mL) and then extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure to give a residue. The residue was subjected to silica gel column chromatography eluted with petroleum ether / ethyl acetate (1:0 to 1:1) to give 2-(benzyloxy)-1-methyl-4-((triisopropylsilyl)oxy)cyclopentan-1-ol (II-F, 1.50 g, 63%) as a yellow oil.

[0237] A mixture of 2-(benzyloxy)-1-methyl-4-((triisopropylsilyl)oxy)cyclopentan-1-ol (II-F, 1.20 g, 3.17 mmol) and palladium (10% on carbon, 0.2 g) in methanol (12 mL) was stirred at room temperature under 1 atmosphere of H. The resulting mixture was filtered, and the filtrate was concentrated to give a residue that was subjected to silica gel column chromatography eluted with petroleum ether / ethyl acetate (10:1 to 0:1) to give cis-1-methyl-4-((triisopropylsilyl)oxy)cyclopentane-1,2-diol (II-G, 650 mg, 71%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 4.59-4.53(m,1H), 4.15-4.13(m,1H), 3.85(s,1H), 2.41-2.36(m,1H), 1.98-1.95(m,2H), 1.87-1.75(m,2H), 1.32(s,3H), 1.08-1.06(m,21H).

[0238] A mixture of cis-1-methyl-4-((triisopropylsilyl)oxy)cyclopentane-1,2-diol (II-G, 500 mg, 1.73 mmol), (dimethoxymethyl)benzene (395 mg, 2.60 mmol), and pyridinium p-toluenesulfonate (PPTS) (10 mg, 0.055 mmol) in dichloromethane (3 mL) was stirred at room temperature for 4 h. The resulting mixture was concentrated to give a residue, which was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (100:1 to 2:1) to give cis-triisopropyl((3a-methyl-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-yl)oxy)silane (II-H, 350 mg, 54%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.50-7.48(m,2H), 7.42-7.37(m,3H), 5.71(s,1H), 4.77-4.71(m,1H), 4.27(d,J=5.6Hz, 1H), 2.43-2.3 9(m,1H), 2.35-2.30(m,1H), 1.77-7.71(m,J=1H), 1.57-1.54(m,1H), 1.52(s,3H), 1.09-1.08(m,21H).

[0239] A mixture of cis-triisopropyl((3a-methyl-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-yl)oxy)silane (II-H, 350 mg, 0.93 mmol) and tetrabutylammonium fluoride (1 M in THF, 5 mL) was stirred at 60° C. for 1 hour. The mixture was concentrated under reduced pressure to give a residue, which was subjected to silica gel column chromatography eluted with petroleum ether / ethyl acetate (10:1 to 1:1) to give cis-3a-methyl-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-ol (II-I, 170 mg, 85%) as a yellow oil. 1H NMR (500MHz, CDCl3)δ 7.50(dd,J=6.5, 3.0Hz, 2H), 7.41-7.39(m,3H), 5.72(s,1H), 4.75-4.69(m,1H), 4.30(d,J=5.7H z, 1H), 2.49-2.45(m,1H), 2.41-2.37(m,1H), 1.75-1.69(m,1H), 1.54(s,3H), 1.53-1.48(m,1H).

[0240] To a solution of cis-3a-methyl-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-ol (II-I, 150 mg, 0.68 mmol) in dichloromethane (4 mL) was added Dess-Martin periodinane (347 mg, 0.80 mmol) at 0 °C. The mixture was stirred at room temperature for 12 h. The resulting mixture was filtered. The filter cake was washed with ethyl acetate (20 mL). The filtrate was concentrated to give a residue, which was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (20:1 to 3:1) to give cis-3a-methyl-2-phenyltetrahydro-5H-cyclopenta[d][1,3]dioxol-5-one (II-J, 120 mg, 80%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.49-7.44(m,2H), 7.41-7.39(m,3H), 5.96(s,1H), 4.55(dd,J=5.0, 3.2Hz, 1H), 2.83-2.79(m,1H), 2.75-2.70(m,2H), 2.50-2.47(m,1H), 1.64(s,3H).

[0241] A mixture of cis-3a-methyl-2-phenyltetrahydro-5H-cyclopenta[d][1,3]dioxol-5-one (II-J, 380 mg, 1.74 mmol) and bis(2-methoxyethyl)aminosulfur trifluoride (BAST) (0.96 mL, 5.22 mmol) in dichloromethane (2 mL) was stirred at room temperature for 48 hours. The resulting mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure to give a residue that was subjected to silica gel column chromatography eluted with petroleum ether / ethyl acetate (50:1 to 1:1) to give cis-5,5-difluoro-3a-methyl-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxole (II-K, 290 mg, 69%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.59-7.54(m,2H), 7.46-7.34(m,3H), 5.80(s,1H), 4.39(d,J=6.6Hz, 1H), 2.75-2 .65(m,1H), 2.62-2.56(m,1H), 2.48-2.36(m,1H), 2.23-2.15(m,1H), 1.57(s,3H).

[0242] A mixture of cis-5,5-difluoro-3a-methyl-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxole (II-K, 290 mg, 1.20 mmol), palladium (10% on carbon, 20 mg), and acetic acid (35 μL, 0.60 mmol) in methanol (10 mL) was stirred under 1 atmosphere of H2 at room temperature for 12 hours. The resulting mixture was filtered. The filtrate was concentrated to give a residue, which was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (10:1 to 0:1) to give cis-4,4-difluoro-1-methylcyclopentane-1,2-diol (Intermediate II, 160 mg, 89%) as a yellow oil. 1 H NMR (500MHz, CDCl3) δ 4.01-3.93(m,1H), 2.57-2.11(m,4H), 1.38(s,3H).

[0243] Synthesis of cis-1-methylcyclopentane-4,4-d2-1,2-diol (intermediate III) [ka] A mixture of cis-4-((triisopropylsilyl)oxy)cyclopentane-1,2-diol (II-C, 6.00 g, 21.9 mmol), (dimethoxymethyl)benzene (4.99 g, 32.8 mmol), and pyridinium p-toluenesulfonate (PPTS) (1.10 g, 4.37 mmol) in dichloromethane (60 mL) was stirred at room temperature for 4 h. The mixture was concentrated under reduced pressure to give a residue, which was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (1:0 to 3:1) to give cis-triisopropyl((2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-yl)oxy)silane (III-A, 8.90 g, crude) as a yellow oil.

[0244] A mixture of cis-triisopropyl((2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-yl)oxy)silane (III-A, 8.00 g, crude product from above) and tetrabutylammonium fluoride (TBAF) (1 M in THF, 50.0 mL, 50.0 mmol) was stirred at 60° C. for 1 h. The reaction mixture was concentrated under reduced pressure to give a residue, which was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (10:1 to 1:1) to give cis-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-ol (III-B, 350 mg) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.50-7.48(m,2H), 7.42-7.40(m,3H), 5.63(s,1H), 4.72(dd,J=4.1, 1.9Hz, 2H), 4.70-4.63(m,1H), 2.39-2.35(m,2H), 1.67-1.62(m,2H).

[0245] To a mixture of cis-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-ol (III-B, 4.30 g, 20.9 mmol) and sodium bicarbonate (5.25 g, 62.6 mmol) in dichloromethane (40 mL) was added Dess-Martin periodinane (10.6 g, 25.0 mmol) at 0 °C. The mixture was stirred at room temperature for 12 h. The reaction mixture was filtered. The filtrate was concentrated under reduced pressure to give a residue, which was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (20:1 to 3:1) to give cis-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-ol (III-C, 3.10 g, 73%) as a yellow oil. 1 H NMR (500MHz, CDCl3) δ 7.49-7.46(m,2H), 7.44-7.38(m,3H), 5.88(s,1H), 4.96-4.94(m,2H), 2.67-2.63(m,4H).

[0246] To a solution of cis-2-phenyl-hexahydrocyclopenta[d][1,3]dioxol-5-one (III-C, 2.00 g, 9.79 mmol) in methanol (20 mL) was added sodium borodeuteride (1.91 g, 9.79 mmol) at 0 °C. The mixture was stirred at room temperature for 4 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was subjected to silica gel column chromatography eluted with petroleum ether / ethyl acetate (10:1 to 1:1) to give cis-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-d-5-ol (III-D, 2 g, 98%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.56-7.54(m,2H), 7.42-7.41(m,3H), 5.74(s,1H), 4.85-4.83(m,2H), 2.48-2.43(m,1H), 2.35-2.31(m,2H), 1.88-1.84(m,2H).

[0247] To a mixture of cis-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-d-5-ol (III-D, 2.90 g, 15.0 mmol) and 4-dimethylaminopyridine (1.88 g, 15.4 mmol) in pyridine (30 mL) was added tosyl chloride (4.07 g, 26.6 mmol). The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure to give a residue, which was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (10:1 to 1:1) to give cis-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-yl-5-d-4-methylbenzenesulfonate (III-E, 4.10 g, 81%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.81-7.71(m,2H), 7.59-7.52(m,2H), 7.40-7.36(m,1H), 7.33(dd,J=8.1, 6.4Hz, 2H), 7.30-7.27(m,2H), 5.67(s,1H), 4.75(dd,J=4 .4, 1.7Hz, 2H), 2.44(s,3H), 2.43(d,J=1.2Hz, 1H), 2.40(d,J=1.5Hz, 1H), 1.96(dd,J=4.4, 1.9Hz, 1H), 1.92(dd,J=4.5, 1.8Hz, 1H).

[0248] To a solution of cis-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-yl-5-d4-methylbenzenesulfonate (III-E, 1.00 g, 2.77 mmol) in THF (10 mL) was added lithium aluminum deuteride (460 mg, 11.1 mmol) at 0 °C. The mixture was stirred at 50 °C for 12 h. Sodium sulfate decahydrate was added to the reaction mixture until effervescence ceased, followed by the addition of ethyl acetate (50 mL). The mixture was filtered, and the filtrate was concentrated to give a residue that was subjected to silica gel column chromatography eluted with petroleum ether / ethyl acetate (1:0 to 3:1) to give cis-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxole-5,5-d2 (III-F, 443 mg, 83%) as a yellow oil. 1H NMR (500MHz, CDCl3) δ 7.54-7.52(m,2H), 7.47-7.33(m,3H), 5.64(s,1H), 4.71-4.70(m,2H), 2.08-2.06(m,2H), 1.56-1.47(m,2H).

[0249] A mixture of cis-2-phenyltetrahydro-4H-cyclopenta[d][1,3]dioxole-5,5-d2 (III-F, 440 mg, 1.22 mmol), palladium (10% on carbon, 500 mg), and acetic acid (770 μL, 1.35 mmol) in methanol (20 mL) was stirred at room temperature under 1 atmosphere of H2 for 12 hours. The reaction mixture was filtered. The filtrate was concentrated under reduced pressure to give cis-cyclopentane-4,4-d2-1,2-diol (III-G, 580 mg, 82%) as a yellow oil. 1 H NMR (500MHz, CDCl3) δ 4.08-4.05(m,2H), 1.92-1.85(m,2H), 1.73-1.63(m,2H).

[0250] To a mixture of cis-cyclopentane-4,4-d2-1,2-diol (III-G, 190 mg, 1.82 mmol) and (4-fluorophenyl)boronic acid (25 mg, 0.20 mmol) in DMF (2 mL) was added K2CO3 (378 mg, 2.74 mmol) and (bromomethyl)benzene (468 mg, 2.74 mmol). The mixture was stirred at room temperature under a N2 atmosphere for 12 h. The reaction mixture was diluted with water (50 mL) and then extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, and concentrated to give a residue. The residue was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (1:0 to 3:1) to give cis-2-(benzyloxy)cyclopentan-4,4-d2-1-ol (III-H, 270 mg, 77%) as a yellow oil. 1H NMR (500MHz, CDCl3)δ 7.41-7.36(m,4H), 7.34-7.32(m,1H), 4.64(d,J=11.8Hz, 1H), 4.57(d,J=11.8Hz, 1H), 4.13-4.10(m,1H), 3.86-3.82(m,1H), 1.90-1.84(m,1H), 1.81-1.73(m,3H).

[0251] To a mixture of cis-2-(benzyloxy)cyclopentan-4,4-d2-1-ol (III-H, 260 mg, 1.34 mmol) and sodium bicarbonate (337 mg, 4.02 mmol) in dichloromethane (5 mL) was added Dess-Martin periodinane (681 mg, 1.61 mmol) at 0 °C. The mixture was stirred at room temperature for 12 h. The reaction mixture was diluted with saturated aqueous sodium sulfite (20 mL) and water (20 mL). The mixture was extracted with dichloromethane (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and concentrated under reduced pressure to give a residue. The residue was subjected to silica gel column chromatography eluting with petroleum ether / ethyl acetate (1:0 to 3:1) to give 2-(benzyloxy)cyclopentan-1-one-4,4-d2 (III-I, 190 mg, 73%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.42-7.34(m,4H), 7.35-7.29(m,1H), 4.86(d,J=11.9Hz, 1H), 4.71(d,J =11.9Hz, 1H), 3.81-3.84(m,1H), 2.33-2.21(m,3H), 1.87-1.83(m,1H).

[0252] To a solution of 2-(benzyloxy)cyclopentan-1-one-4,4-d2 (III-I, 190 mg, 0.99 mmol) in tetrahydrofuran (4 mL) was added dropwise methylmagnesium bromide (0.66 mL, 1.98 mmol) at 0 °C. The mixture was stirred at 0 °C for 2 h. The reaction mixture was diluted with saturated aqueous ammonium chloride (10 mL) and water (20 mL). The mixture was extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, and then concentrated under reduced pressure to give a residue, which was subjected to silica gel column chromatography eluted with petroleum ether / ethyl acetate (10:1 to 1:1) to give cis-2-(benzyloxy)-1-methylcyclopentan-4,4-d2-1-ol (III-J, 70 mg, 34%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.41-7.34(m,4H), 7.35-7.30(m,1H), 4.68(d,J=11.8Hz, 1H), 4.54(d,J=11.8Hz, 1H), 3.5 1(t,J=6.5Hz, 1H), 1.94-1.90(m,1H), 1.84-1.76(m,2H), 1.59-1.56(m,1H), 1.28(s,3H).

[0253] A mixture of cis-2-(benzyloxy)-1-methylcyclopentan-4,4-d2-1-ol (III-J, 70 mg, 0.30 mmol) and palladium (10% on carbon, 70 mg) in methanol (5 mL) was stirred at room temperature under 1 atmosphere of H2. Upon completion, the reaction mixture was filtered, and the filtrate was concentrated to give cis-1-methylcyclopentane-4,4-d2-1,2-diol (Intermediate III, 30 mg, 75%) as a yellow oil.

[0254] Synthesis of cis-3-methyltetrahydrofuran-3,4-diol (intermediate IV) [ka] To a solution of 2,5-dihydrofuran (IV-A, 2.10 g, 30.0 mmol) in tert-butanol (27 mL) was added potassium dioxide dioxoosmium dihydrate (552 mg, 1.50 mmol), 4-methylmorpholine N-oxide (NMO) (4.80 g, 42.0 mmol), pyridine (2.40 mL, 30.0 mmol), and water (9 mL). The reaction mixture was stirred at 85 °C for 5 h. Upon completion, the mixture was filtered through a Celite pad, and the filtrate was quenched with saturated aqueous NaHSO (10 mL). The reaction mixture was concentrated under reduced pressure and then purified using silica gel column chromatography eluting with methanol / dichloromethane (0–6%) to give cis-tetrahydrofuran-3,4-diol (IV-B, 2.55 g, 82%) as a yellow oil.

[0255] To a mixture of cis-tetrahydrofuran-3,4-diol (IV-B, 1.65 g, 15.9 mmol) and benzyl bromide (BnBr) (2.85 mL, 23.8 mmol) in N,N-dimethylformamide (DMF) (18 mL), potassium carbonate (KCO) (3.29 g, 23.8 mmol) was added, and the reaction mixture was stirred at room temperature overnight. After completion, the reaction was quenched with ice-water (50 mL) and extracted with ethyl acetate (100 mL × 3). The organic layer was collected, dried over NaSO, concentrated under reduced pressure, and then subjected to silica gel column chromatography eluted with ethyl acetate / petroleum ether (0% to 30%) to give cis-4-(benzyloxy)tetrahydrofuran-3-ol (IV-C, 2.26 g, 73%) as a colorless oil.

[0256] To a solution of cis-4-(benzyloxy)tetrahydrofuran-3-ol (IV-C, 2.26 g, 11.6 mmol) in dichloromethane (30 mL) was carefully added Dess-Martin periodinane (9.86 g, 23.3 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. After completion, saturated sodium thiosulfate solution (20 mL) and saturated sodium carbonate solution (20 mL) were added at 0 °C to quench the reaction, and the mixture was extracted with dichloromethane (100 mL × 2). The organic layer was collected, dried over Na2SO4, and concentrated under reduced pressure to give a residue, which was separated using silica gel column chromatography eluted with ethyl acetate / petroleum ether (0–20%) to give 4-(benzyloxy)dihydrofuran-3(2H)-one (IV-D, 1.35 g, 61%) as a colorless oil. 1 H NMR (500MHz, DMSO-d6)δ 7.41-7.29(m,5H), 4.76(d,J=11.7Hz, 1H), 4.62(d,J=11.7Hz, 1H), 4.35-4.28(m,1H), 4.2 0(t,J=7.1Hz, 1H), 4.07-4.00(m,1H), 3.96(d,J=17.4Hz, 1H), 3.82(dd,J=9.6, 7.1Hz, 1H).

[0257] To a solution of 4-(benzyloxy)dihydrofuran-3(2H)-one (IV-D, 1.12 g, 5.80 mmol) in dry THF (10 mL) was added methylmagnesium bromide (1 M in THF, 11.7 mL) at −20° C. under N protection. The reaction mixture was stirred at 0° C. for 1 h. After completion, saturated NH4Cl solution (10 mL) was added at 0° C. to quench the reaction. The mixture was extracted with ethyl acetate (100 mL × 2). The organic layer was collected, dried over Na2SO4, concentrated under reduced pressure, and then separated using silica gel column chromatography to give cis-4-(benzyloxy)-3-methyltetrahydrofuran-3-ol (IV-E, 321 mg, 23%) as a colorless oil. 1H NMR (500MHz, DMSO-d6)δ 7.40-7.32(m,4H), 7.32-7.26(m,1H), 4.69(d,J=12.1Hz, 1H), 4.61(s,1H), 4.55(d,J=12.2Hz, 1H) , 3.96-3.87(m,1H), 3.67-3.58(m,2H), 3.54(d,J=8.3Hz, 1H), 3.45(d,J=8.3Hz, 1H), 1.22(s,3H).

[0258] To a solution of cis-4-(benzyloxy)-3-methyltetrahydrofuran-3-ol (IV-E, 321 mg, 1.54 mmol) in methanol (20 mL) was added palladium (10% on carbon, 100 mg) and acetic acid (1 drop). The reaction mixture was stirred overnight under 1 atmosphere of H. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give cis-3-methyltetrahydrofuran-3,4-diol (Intermediate IV, 158 mg, 87%) as a colorless oil.

[0259] Synthesis of cis-tetrahydro-2H-pyran-3,4-diol (intermediate V) [ka] To a solution of (cyclopent-3-en-1-yloxy)tris(propan-2-yl)silane (VA, 1.50 g, 6.24 mmol) in tert-butanol (5 mL) was added potassium osmate (22 mg, 0.06 mmol), 4-methylmorpholine N-oxide (NMO) (195 mg, 1.67 mmol), pyridine (96 μL, 1.20 mmol), and water (1.5 mL). The reaction mixture was stirred at 85° C. for 5 hours. The reaction mixture was concentrated to give a residue, which was separated using silica gel column chromatography eluting with methanol / dichloromethane (0-10%) to give cis-tetrahydro-2H-pyran-3,4-diol (Intermediate V, 1.30 g, 76%) as a yellow oil. 1H NMR (500MHz, CDCl3)δ 3.89-3.82(m,3H), 3.78-3.76(m,1H), 3.56-3.52(m,1H), 3.48-3.43(m,1H), 3.03(s,2H), 1.90-1.83(m,1H), 1.80-1.75(m,1H).

[0260] Synthesis of cis-5,5-difluoro-1-methylcyclohexane-1,2-diol (Intermediate VI) [ka] To a solution of pent-4-enal (VI-A, 10.0 g, 119 mmol) in THF (100 mL) was added (2-methylallyl)magnesium bromide (0.5 M in THF, 286 mL, 143 mmol) at 0 °C. The reaction mixture was stirred at 25 °C under a N atmosphere for 1 h. After completion, the reaction mixture was quenched with HO (200 mL) at 0 °C and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine (50 mL), dried over NaSO, and concentrated under reduced pressure to give 2-methylocta-1,7-dien-4-ol (VI-B, 16.2 g, 97%) as a colorless oil.

[0261] To a solution of 2-methylocta-1,7-dien-4-ol (VI-B, 16.2 g, 116 mmol) in dichloromethane (500 mL), tert-butyldiphenylchlorosilane (TBDPSCl) (47.6 g, 173 mmol) and N,N-dimethylpyridin-4-amine (DMAP) (28.2 g, 231 mmol) were added, and the reaction mixture was stirred at room temperature overnight. After completion, the reaction mixture was diluted with HO (300 mL) and extracted with dichloromethane (200 mL × 3). The combined organic layers were washed with brine (200 mL), dried over NaSO, and concentrated under reduced pressure to give a residue. The residue was separated using silica gel column chromatography to give tert-butyl[(2-methylocta-1,7-dien-4-yl)oxy]diphenylsilane (VI-C, 39.1 g, 89%) as a colorless oil. 1H NMR (400MHz, CDCl3)δ 7.61-7.0(m,4H), 7.30-7.26(m,6H), 5.60-5.53(m,1H), 4.82-4.75(m,2H), 4.56-4.51(m,2H), 3.7 9-3.16(m,1H), 2.08-2.04(m,2H), 2.04-1.98(m,2H), 1.40-1.35(m,2H), 1.32(s,3H), 0.97(s,9H).

[0262] To a solution of tert-butyl[(2-methylocta-1,7-dien-4-yl)oxy]diphenylsilane (VI-C, 39.1 g, 103 mmol) in dichloromethane (500 mL) was added Grubbs' catalyst II (4.38 g, 5.16 mmol). The reaction mixture was stirred overnight at 40 °C under a N atmosphere. After completion, the reaction mixture was diluted with HO (100 mL) and extracted with dichloromethane (100 mL × 3). The combined organic layers were washed with brine (100 mL), dried over NaSO, and concentrated under reduced pressure. The resulting residue was separated using silica gel column chromatography to give tert-butyl[(3-methylcyclohex-3-en-1-yl)oxy]diphenylsilane (VI-D, 32.1 g, 89%) as a colorless oil. 1 H NMR (400MHz, CDCl3)δ 7.70-7.67(m,4H), 7.42-7.35(m,6H), 5.29(s,1H), 3.96-3.94(m,1H), 2.12-2.0 3(m,3H), 1.86-1.85(m,1H), 1.66-1.61(m,1H), 1.58-1.52(m,4H), 1.07(s,9H).

[0263] To a solution of tert-butyl[(3-methylcyclohex-3-en-1-yl)oxy]diphenylsilane (VI-D, 32.1 g, 91.4 mmol) in THF (300 mL) and HO (30 mL), potassium dioxide dioxoosmium dihydrate (1.68 g, 4.56 mmol) and 4-methylmorpholine N-oxide (NMO) (12.9 g, 110 mmol) were added, and the reaction mixture was stirred overnight at 25° C. After completion, the reaction mixture was quenched with saturated NaHSO solution (50 mL) and HO (150 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine (100 mL), dried over NaSO, and concentrated under reduced pressure to give a residue, which was separated using silica gel column chromatography to give cis-5-((tert-butyldiphenylsilyl)oxy)-1-methylcyclohexane-1,2-diol (VI-E, 30.3 g, 86%) as a colorless oil.

[0264] To a mixture of cis-5-((tert-butyldiphenylsilyl)oxy)-1-methylcyclohexane-1,2-diol (VI-E, 30.3 g, 78.8 mmol) and (dimethoxymethyl)benzene (24.0 g, 157 mmol) in dichloromethane (300 mL), pyridinium p-toluenesulfonate (PPTS) (3.96 g, 15.8 mmol) was added, and the reaction mixture was stirred overnight at 25 °C. After completion, the reaction mixture was diluted with HO (100 mL) and extracted with dichloromethane (100 mL × 3). The combined organic layers were washed with brine (100 mL), dried over NaSO, and concentrated under reduced pressure to give a residue. The residue was separated using silica gel column chromatography to obtain cis-tert-butyl((3a-methyl-2-phenylhexahydrobenzo[d][1,3]dioxol-5-yl)oxy)diphenylsilane (VI-F, 25.2 g, 67%) as a colorless oil. 1H NMR (400MHz, CDCl3)δ 7.66-7.65(m,4H), 7.43-7.26(m,11H), 5.93-5.89(m,1H), 4.21-4.14(m,1H), 3.95-3.90(m,1H), 2.16- 2.10(m,1H), 1.95-1.92(m,1H), 1.85-1.76(m,2H), 1.62-1.55(m,4H), 1.38-1.36(m,1H), 1.08(s,9H).

[0265] To a solution of cis-tert-butyl((3a-methyl-2-phenylhexahydrobenzo[d][1,3]dioxol-5-yl)oxy)diphenylsilane (VI-F, 25.2 g, 53.3 mmol) in THF (300 mL), tetrabutylammonium fluoride (TBAF) (20.9 g, 80.0 mmol) was added, and the reaction mixture was stirred at 70 °C for 2 h. After completion, the reaction mixture was diluted with HO (100 mL) and extracted with EtOAc (120 mL × 3). The combined organic layers were washed with brine (100 mL × 5), dried over NaSO, and concentrated under reduced pressure to give a residue that was subjected to silica gel column chromatography to give cis-3a-methyl-2-phenyl-hexahydro-2H-1,3-benzodioxol-5-ol (VI-G, 12.1 g, 97%) as a colorless oil.

[0266] To a solution of cis-3a-methyl-2-phenyl-hexahydro-2H-1,3-benzodioxol-5-ol (VI-G, 12.1 g, 51.6 mmol) in dichloromethane (200 mL) was added sodium bicarbonate (8.68 g, 103 mmol) and Dess-Martin (32.9 g, 77.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature under N for 2 h. After completion, the reaction mixture was quenched with a saturated solution of NaSO (100 mL) and extracted with dichloromethane (100 mL × 2). The combined organic layers were washed with brine (100 mL), dried over NaSO, and concentrated under reduced pressure. The resulting residue was separated using silica gel column chromatography to give cis-3a-methyl-2-phenyltetrahydrobenzo[d][1,3]dioxol-5(4H)-one (VI-H, 10.4 g, 87%) as a colorless oil. 1 H NMR (400MHz, CDCl3)δ 7.42-7.37(m,5H), 5.80(s,1H), 4.26(s,1H), 2.79-2.75(m,1H), 2.60-2.42(m,2H), 2.28-2.24(m,2H), 2.03-1.95(m,1H), 1.48(s,3H).

[0267] To a solution of cis-3a-methyl-2-phenyltetrahydrobenzo[d][1,3]dioxol-5(4H)-one (VI-H, 5.00 g, 21.5 mmol) in dichloromethane (20 mL) was added diethylaminosulfur trifluoride (DAST) (20 mL) at 0 °C. The reaction mixture was stirred overnight at room temperature under N. After completion, the reaction was quenched with water (50 mL) and extracted with ethyl acetate (50 mL × 2). The combined organic layers were washed with brine (20 mL), dried over NaSO, and concentrated under reduced pressure to give a residue that was separated using silica gel column chromatography to give cis-5,5-difluoro-3a-methyl-2-phenylhexahydrobenzo[d][1,3]dioxole (VI-I, 3.50 g, 64%) as a colorless oil.

[0268] To a solution of cis-5,5-difluoro-3a-methyl-2-phenylhexahydrobenzo[d][1,3]dioxole (VI-I, 3.50 g, 13.8 mmol) in ethyl acetate (100 mL) was added palladium (10% on carbon, 500 mg), and the reaction mixture was stirred overnight at room temperature under H (1 atm). Upon completion, the mixture was filtered through a short pad of Celite®, and the filtrate was concentrated under reduced pressure to give a residue. The residue was separated using silica gel column chromatography to give cis-5,5-difluoro-1-methylcyclohexane-1,2-diol (Intermediate VI, 1.80 g, 79%) as a white solid. 1 H NMR (400MHz, DMSO-d6)δ 4.62-4.61(m,1H), 4.23(s,1H), 3.37-3.36(m,1H), 2.02-1.98(m,1H), 1.85-1.73(m,4H), 1.59-1.57(m,1H), 1.11(s,3H). 19 F NMR (400MHz, DMSO-d6) δ -86.9 &-87.6(d), -89.3 &-89.9(d).

[0269] Synthesis of oxepane-4,5-diol (intermediate VII) [ka] To a solution of oxan-4-one (VII-A, 1.53 g, 15.3 mmol) in THF (10 mL) was added ethyl diazoacetate (1.62 mL, 15.4 mmol) and boron trifluoride ethyl etherate (1.80 mL, 15.3 mmol) over 15 min at −30 °C. The reaction was stirred at that temperature for 1 h. It was then slowly quenched with 30% aqueous Na2CO3 solution. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (100 mL × 3). The combined organic extracts were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified using silica gel column chromatography eluted with petroleum ether / ethyl acetate (1:0 to 5:1) to give ethyl 5-oxooxepane-4-carboxylate (VII-B, 1.36 g, 48%) as a colorless oil. LC-MS(ESI):m / z 187.1[M+H]+ .

[0270] To a solution of ethyl 5-oxoxepane-4-carboxylate (VII-B, 3.70 g, 19.9 mmol) in EtOH (25 mL) at 0 °C, Raney nickel (430 mg, 1.99 mmol) was added. The resulting mixture was stirred at 50 °C for 12 h. Then, it was filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was subjected to silica gel column chromatography to obtain ethyl 5-hydroxyoxepane-4-carboxylate (VII-C, 3.40 g, 91%) as a colorless oil. LC-MS (ESI): m / z 189.1 [M+H] + . 1 H NMR (500MHz, CDCl3)δ 4.31-4.29(m,1H), 4.20(q, J=7.0Hz, 2H), 3.89-3.84(m,1H), 3.80-3.71(m,2H), 3.68-3.64(m,1H), 3.13(br s,1H), 2.81-2.78(m,1H), 2.47-2.40(m,1H), 2.00-1.95(m,1H), 1.91-1.80(m,2H), 1.30(t,J=7.0Hz, 3H).

[0271] To a solution of ethyl 5-hydroxyoxepane-4-carboxylate (VII-C, 2.82 g, 15.0 mmol) in dry dichloromethane (30 mL) at 0 °C, triethylamine (3.0 mL) and methanesulfonyl chloride (2.0 mL, 22.5 mmol) were added. The mixture was stirred at room temperature for 5 h. The reaction was quenched with saturated NaHCO3 solution (50 mL) and extracted with dichloromethane (100 mL × 3). The combined organic extracts were dried over Na2SO4 and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give ethyl 5-((methylsulfonyl)oxy)oxepane-4-carboxylate (VII-D, 3.67 g, 92%) as a colorless oil. LC-MS (ESI): m / z 267.1 [M+H] + .

[0272] To a solution of ethyl 5-((methylsulfonyl)oxy)oxepane-4-carboxylate (VII-D, 3.87 g, 14.5 mmol) in THF (30 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (3.0 mL) at room temperature. The reaction mixture was stirred for 4 h, then diluted with EtOAc (50 mL) and washed with brine (100 mL). The organic layer was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give ethyl 2,3,6,7-tetrahydrooxepin-4-carboxylate (VII-E, 1.27 g, 51%) as a colorless oil. 1 H NMR (500MHz, CDCl3)δ 7.22(t,J=6.0Hz, 1H), 4.21(q,J=7.0Hz, 2H), 3.72-3.70(m,4H), 2.78-2.75(m,2H), 2.52-2.49(m,2H), 1.31(t,J=6.0Hz, 3H).

[0273] A mixture of ethyl 2,3,6,7-tetrahydrooxepin-4-carboxylate (VII-E, 1.07 g, 6.29 mmol), potassium osmate dihydrate (120 mg, 0.37 mmol), 4-methylmorpholine N-oxide (NMO) (1.20 g, 10.3 mmol), pyridine (0.8 mL), HO (7 mL), and t-BuOH (20 mL) was stirred overnight at 80 °C under a N atmosphere. Upon completion, the mixture was cooled to room temperature and filtered through a Celite pad, and the pad was washed with methanol (HPLC grade, 30 mL). The filtrate was concentrated under reduced pressure to give a residue that was separated using silica gel column chromatography to give cis-ethyl 4,5-dihydroxyoxepane-4-carboxylate (VII-F, 1.01 g, 78%). 1H NMR (500MHz, CDCl3)δ 4.32(q, J=7.0Hz, 2H), 4.20(d,J=10Hz, 1H), 3.84-3.80(m,2H), 3.78-3.71(m,2H), 3.56(s,1H), 2 .45-2.39(m,1H), 2.20-2.5(m,2H), 1.85-1.81(m,1H), 1.75-1.71(m,1H), 1.34(t,J=7.0Hz, 3H).

[0274] To a mixture of cis-ethyl 4,5-dihydroxyoxepane-4-carboxylate (VII-F, 710 mg, 3.50 mmol), imidazole (790 mg, 11.6 mmol), and triethylamine (1.2 mL) in dichloromethane (30 mL) was added tert-butyldimethylchlorosilane (TBDMSCl) (1.26 g, 8.38 mmol) at 0 °C. The reaction mixture was warmed and stirred at 80 °C for 12 h, after which it was quenched with saturated NaHCO solution (50 mL) and extracted with dichloromethane (60 mL × 3). The combined organic extracts were dried over NaSO and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give ethyl 5-[(tert-butyldimethylsilyl)oxy]-4-hydroxyoxepane-4-carboxylate (VII-G, 0.74 g, 68%). 1 H NMR (500MHz, CDCl3)δ 4.27(q, J=7.0Hz, 2H), 4.16-4.09(m,1H), 3.84-3.78(m,2H), 3.74-3.68(m,2H), 3.33(br s,1H), 2.52-2.44(m,1H), 2.20-2.15(m,1H), 1.79-1.75(m,1H), 1.65-1 .61(m,1H), 1.32(t,J=7.0Hz, 3H) 0.86(s,9H), 0.08(s,3H), 0.01(s,3H).

[0275] To a mixture of cis-ethyl 5-[(tert-butyldimethylsilyl)oxy]-4-hydroxyoxepane-4-carboxylate (VII-G, 1.33 g, 4.20 mmol) and CaCl (930 mg, 8.40 mmol) in THF (12 mL) at 0 °C was added NaBH (560 mg, 16.7 mmol). The mixture was stirred for 15 min, then gradually warmed to room temperature and stirred for 12 h. The reaction was quenched with saturated NaHCO solution (10 mL) and extracted with dichloromethane (60 mL × 3). The combined organic extracts were dried over NaSO and concentrated under reduced pressure to give a residue that was separated using silica gel column chromatography to give 5-[(tert-butyldimethylsilyl)oxy]-4-(hydroxymethyl)oxepan-4-ol (VII-H, 1.12 g, 97%). LC-MS(ESI):m / z 277.2[M+H] + .

[0276] To a solution of 5-[(tert-butyldimethylsilyl)oxy]-4-(hydroxymethyl)oxepan-4-ol (VII-H, 64 mg, 0.23 mmol) in acetonitrile (1 mL) and HO (0.1 mL) was added NaIO (50 mg, 0.23 mmol), and the mixture was stirred at room temperature for 3 h. Next, ethyl acetate (15 mL) and a saturated aqueous solution of NaSO (8 mL) were added. The mixture was vigorously stirred for 15 min, and then the two phases were separated using a separatory funnel. The aqueous solution was extracted with ethyl acetate (50 mL × 2). The combined organic layers were washed with brine (20 mL), dried over anhydrous MgSO, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give 5-[(tert-butyldimethylsilyl)oxy]oxepan-4-one (VII-I, 46 mg, 81%). 1H NMR (500MHz, CDCl3)δ 4.39(dd,J=7.0, 2.0Hz, 1H), 4.10-4.05(m,1H), 3.99-3.95(m,1H), 3.92-3.89(m,2H), 2.85-2. 80(m,1H), 2.72-2.66(m,1H), 1.91-1.84(m,1H), 1.80-1.74(m,1H), 0.95(s,9H), 0.11(s,6H).

[0277] To a solution of 5-[(tert-butyldimethylsilyl)oxy]oxepan-4-one (VII-I, 85 mg, 0.35 mmol) in THF (1 mL) was added DIBAL-H (1 M in hexane, 1.04 mL, 1.04 mmol) at 0 °C. The mixture was warmed to room temperature and stirred for 2 h. The resulting solution was filtered through Celite, washed with dichloromethane (20 mL), and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give 5-((tert-butyldimethylsilyl)oxy)oxepan-4-ol (VII-J, 75 mg, 87%). 1 H NMR (500MHz, CDCl3)δ 3.85-3.80(m,1H), 3.78-3.72(m,1H), 3.71-3.62(m,4H), 2.10-2.01(m,1H), 1.97-1.91(m,1H), 1.83-1.74(m,2H), 0.92(s,9H), 0.12(s,3H), 0.11(s,3H).

[0278] To a solution of 5-[(tert-butyldimethylsilyl)oxy]oxepan-4-ol (VII-J, 23 mg, 0.09 mmol) in dry THF (1 mL) was added TBAF (1 M in THF, 90 μL, 0.09 mmol) at 0° C. The resulting solution was stirred for 45 minutes, allowing the mixture to warm to room temperature. The resulting solution was diluted with dichloromethane (20 mL) and quenched with water (5 mL). The organic layer was washed with brine (5 mL), dried over NaSO, and concentrated under reduced pressure. The crude product was separated using silica gel column chromatography to give oxepane-4,5-diol (Intermediate VII, 12 mg, 90%) as a mixture of isomers. LC-MS (ESI): m / z 133.1 [M+H]+ .

[0279] Synthesis of cis-oxepane-3,4-diol (intermediate VIII) [ka] Oxan-4-one (VIII-A, 20.0 g, 200 mmol) and potassium hydroxide (22.4 g, 400 mmol) were dissolved in methanol (320 mL) under a nitrogen atmosphere. The resulting solution was cooled to 0 °C, and a solution of iodine (45.6 g, 180 mmol) in methanol (320 mL) was added dropwise over a period of 2 h. The reaction mixture was then warmed to room temperature and stirred for 1 h. The solvent was then removed under reduced pressure, and the residue was suspended in ethyl acetate (500 mL). After filtration, the filtrate was concentrated to give the crude product, which was separated using silica gel column chromatography eluted with petroleum ether / ethyl acetate (10:1 to 0:1) to give 4,4-dimethoxytetrahydro-2H-pyran-3-ol (VIII-B, 13.4 g, 41%) as a yellow oil. 1 H NMR (500MHz, CDCl3) δ 3.85-3.78(m,2H), 3.73-3.66(m,2H), 3.52-3.47(m,1H), 3.28(s,3H), 3.26(s,3H), 1.98-1.92(m,1H), 1.79-1.75(m,1H).

[0280] To a solution of 4,4-dimethoxytetrahydro-2H-pyran-3-ol (VIII-B, 2.70 g, 16.7 mmol) in tetrahydrofuran (50 mL) was added sodium hydride (0.87 g, 21.6 mmol) at 0 °C. To the mixture, (bromomethyl)benzene (2.38 mL, 20.0 mmol) was added dropwise, and the reaction mixture was stirred at room temperature for 12 hours. Then, it was quenched with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were concentrated to give a residue, which was separated using silica gel column chromatography eluted with petroleum ether / ethyl acetate (20:1 to 1:1) to give 3-(benzyloxy)-4,4-dimethoxytetrahydro-2H-pyran (VIII-C, 4.20 g, 100%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.42-7.28(m,5H), 4.77(d,J=12.1Hz, 1H), 4.64(d,J=12.1Hz, 1H), 3.99(dd,J=12.3, 3.0Hz, 1H), 3.85-3.81(m,1H), 3. 63-3.60(m,1H), 3.56-3.51(m,1H), 3.44-3.42(m,1H), 3.24(s,3H), 3.22(s,3H), 2.12-2.07(m,1H), 1.79-1.75(m,1H).

[0281] To a solution of 3-(benzyloxy)-4,4-dimethoxytetrahydro-2H-pyran (VIII-C, 4.20 g, 16.7 mmol) in tetrahydrofuran (40 mL), hydrochloric acid (2 M solution, 41.6 mL) was added, and the mixture was stirred at room temperature for 12 hours. The resulting mixture was adjusted to pH 7 with saturated sodium carbonate and extracted with ethyl acetate (50 mL × 3). The combined organic layers were concentrated to give a residue, which was separated using silica gel column chromatography eluted with petroleum ether / ethyl acetate (50:1 to 1:1) to give 3-(benzyloxy)tetrahydro-4H-pyran-4-one (VIII-D, 2.90 g, 84%) as a yellow oil. 1H NMR (500MHz, CDCl3)δ 7.40-7.30(m,5H), 4.87(d,J=11.9Hz, 1H), 4.56(d,J=11.9Hz, 1H), 4.21-4.17(m,1H), 4.17 -4.07(m,1H), 4.02-3.99(m,1H), 3.76-3.71(m,1H), 3.62-3.58(m,1H), 2.62-2.60(m,2H).

[0282] To a solution of 3-(benzyloxy)tetrahydro-4H-pyran-4-one (VIII-D, 2.30 g, 11.2 mmol) in dichloromethane (40 mL) was added BF3-ether complex (5.6 mL, 44.6 mmol) and (trimethylsilyl)diazomethane solution (2 M in hexane, 16.7 mL, 33.5 mmol) at −78 °C. The reaction mixture was stirred at −78 °C for 1 h, quenched with saturated sodium bicarbonate solution (2.6 mL) and water (20 mL), and extracted with dichloromethane (20 mL × 3). The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to give a residue. The residue was redissolved in methanol (4 mL), and to the resulting solution was added pyridin-1-ium 4-methylbenzenesulfonate (4.20 g, 16.7 mmol). After stirring at 25°C for 1 hour, the reaction mixture was concentrated under reduced pressure, followed by the addition of water (50 mL) and subsequent extraction with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to give a residue. The residue was separated using silica gel column chromatography eluted with petroleum ether / ethyl acetate (20:1 to 0:1) to give 3-(benzyloxy)oxepan-4-one (VIII-E, 390 mg, 16%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.42-7.32(m,5H), 4.74(d,J=11.8Hz, 1H), 4.52(d,J=11.8Hz, 1H), 4.12(t,J=5.1Hz, 1H), 3.96-3.93( m,1H), 3.85-3.78(m,3H), 2.79-2.73(m,1H), 2.57-2.48(m,1H), 2.03-1.92(m,1H), 1.91-1.81(m,1H).

[0283] To a solution of 3-(benzyloxy)oxepan-4-one (VIII-E, 1.40 g, 6.36 mmol) in methanol (20 mL) was added sodium borohydride (430 mg, 12.7 mmol) at 0 °C, and the mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated to give a residue, which was separated using silica gel column chromatography eluted with petroleum ether / ethyl acetate (10:1 to 1:1) to give cis-3-(benzyloxy)oxepan-4-ol (VIII-F, 660 mg, 47%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 7.41-7.30(m,5H), 4.69-4.58(m,2H), 4.13-4.08(m,1H), 3.79-3.66(m,4H), 3.59-3.61 (m,1H), 2.52(d,J=4.3Hz, 1H), 2.11-2.01(m,2H), 1.74-1.70(m,1H), 1.62-1.56(m,1H).

[0284] To a solution of cis-3-(benzyloxy)oxepan-4-ol (VIII-F, 700 mg, 3.15 mmol) in methanol (2 mL), palladium (10% on carbon, 335 mg) was added, and the mixture was stirred at room temperature for 1 h. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was separated using silica gel column chromatography eluted with petroleum ether / ethyl acetate (10:1 to 0:1) to give cis-oxepane-3,4-diol (Intermediate VIII, 320 mg, 77%) as a yellow oil. 1 H NMR (500MHz, CDCl3)δ 3.85(s,1H), 3.79-3.73(m,4H), 3.63-3.60(m,1H), 2.71-2.70(m,1H), 2. 70-2.56(m,1H), 1.91-1.84(m,2H), 1.80-1.74(m,1H), 1.70-1.63(m,1H).

[0285] Synthesis of cis-3-fluoro-1-(methylsulfonyl)piperidin-4-amine (Intermediate IX) [ka] To a mixture of cis-tert-butyl (3-fluoropiperidin-4-yl)carbamate (IX-A, 480 mg, 2.20 mmol) and triethylamine (667 mg, 6.60 mmol) in dichloromethane (10 mL) was added methanesulfonyl chloride (298 mg, 2.60 mmol) at 0 °C. The reaction mixture was stirred at room temperature under N for 1 h. The reaction mixture was diluted with H O (50 mL) and extracted with dichloromethane (50 mL × 2). The combined organic layers were washed with brine (30 mL), dried over Na SO , and concentrated under reduced pressure. The resulting residue was separated using silica gel column chromatography to give cis-tert-butyl (3-fluoro-1-(methylsulfonyl)piperidin-4-yl)carbamate (IX-B, 603 mg, 93%) as a white solid. LC-MS (ESI): m / z 297.1 [M+H] + .

[0286] To a solution of cis-tert-butyl (3-fluoro-1-(methylsulfonyl)piperidin-4-yl)carbamate (IX-B, 603 mg, 2.00 mmol) in dichloromethane (6 mL) was added trifluoroacetic acid (0.6 mL) at 0 °C. The reaction mixture was stirred overnight at room temperature under N2. After completion, the reaction mixture was concentrated under reduced pressure to give cis-3-fluoro-1-(methylsulfonyl)piperidin-4-amine (Intermediate IX, 380 mg, 61%) as a TFA salt. LC-MS (ESI): m / z 197.1 [M+H] + .

[0287] Synthesis of 1-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-amine (Intermediate X) [ka] To a mixture of tert-butyl N-(piperidin-4-yl)carbamate (1.11 g, 5.50 mmol) and triethylamine (2.3 mL, 16.5 mmol) in dichloromethane (20 mL) was added 1-methyl-1H-pyrazole-4-sulfonyl chloride (XA, 1.00 g, 5.50 mmol) at 0 °C. The reaction mixture was stirred at room temperature under a N atmosphere for 1 h. After completion, the mixture was diluted with HO (40 mL) and extracted with dichloromethane (40 mL × 2). The combined organic layers were washed with brine (30 mL), dried over NaSO, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give tert-butyl (1-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)carbamate (XB, 1.70 g, 89%) as a white solid. LC-MS(ESI):m / z 345.1[M+H] + .

[0288] To a solution of tert-butyl (1-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)carbamate (XB, 1.70 g, 4.94 mmol) in dioxane (20 mL) was added HCl (4 M in dioxane, 20 mL) at 0° C., and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give 1-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-amine (Intermediate X, 1.10 g, 80%) as the HCl salt. LC-MS (ESI): m / z 245.1 [M+H] + .

[0289] Synthesis of 4-amino-N-(oxetan-3-yl)benzenesulfonamide (Intermediate XI) [ka] To a solution of 4-nitrobenzenesulfonyl chloride (300 mg, 1.35 mmol) in dichloromethane (5 mL) was added oxetan-3-amine (XI-A, 0.10 mL, 1.35 mmol) and triethylamine (0.60 mL, 4.06 mmol). The reaction mixture was stirred at room temperature for 2 hours. Then, it was poured into ice water (10 mL) and extracted with dichloromethane (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give 4-nitro-N-(oxetan-3-yl)benzenesulfonamide (XI-B, 250 mg, 72%) as a white solid. LC-MS (ESI): m / z 259.0 [M+H] + .

[0290] To a mixture of 4-nitro-N-(oxetan-3-yl)benzenesulfonamide (XI-B, 250 mg, 0.97 mmol) and iron powder (65 mg, 9.68 mmol) in EtOH (7 mL) and HO (3 mL), NHCl (1026 mg, 19.4 mmol) was added, and the reaction mixture was stirred at 60 °C overnight. The reaction mixture was filtered through a short pad of Celite®, and the filter cake was washed with EtOAc (30 mL). The filtrate was concentrated under reduced pressure, and the residue was separated using silica gel column chromatography to give 4-amino-N-(oxetan-3-yl)benzenesulfonamide (Intermediate XI, 200 mg, 91%) as a brown solid. LC-MS (ESI): m / z 229.1 [M+H] + .

[0291] Synthesis of 4-amino-3-fluoro-N-(methyl-d3)benzenesulfonamide (Intermediate XII) [ka] To a mixture of methyl-d3-amine hydrochloride (397 mg, 5.63 mmol) and potassium carbonate (1.56 g, 11.3 mmol) in dichloromethane / water (15 mL / 5 mL) was added 3-fluoro-4-nitrobenzene-1-sulfonyl chloride (XII-A, 900 mg, 3.76 mmol). The mixture was stirred at room temperature for 2 hours, then diluted with water (20 mL), and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine and concentrated under reduced pressure to give 3-fluoro-N-(methyl-d3)-4-nitrobenzenesulfonamide (XII-B, 1.00 g, crude) as a yellow oil. 1 H NMR (500MHz, CDCl3) δ 8.22 (dd, J=8.8, 6.9Hz, 1H), 7.95-7.61 (m, 2H), 4.70 (s, 1H).

[0292] A mixture of 3-fluoro-N-(methyl-d3)-4-nitrobenzenesulfonamide (XII-B, 1.00 g, crude product from the last step) and palladium (10% on carbon, 0.45 g) in methanol (15 mL) was stirred under 1 atmosphere of H2 at room temperature for 12 hours. The reaction mixture was then filtered, and the filtrate was concentrated to give a residue, which was separated using silica gel column chromatography eluted with petroleum ether / ethyl acetate (10:1 to 1:1) to give 4-amino-3-fluoro-N-(methyl-d3)benzenesulfonamide (Intermediate XII, 480 mg) as a yellow solid. 1 H NMR (500MHz, CDCl3) δ 7.54-7.43(m,2H), 6.84(t,J=8.3Hz, 1H), 4.22(s,3H).

[0293] Synthesis of 4-amino-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (Intermediate XIII) [ka] To a mixture of tetrahydro-2H-pyran-4-amine (XIII-A, 505 mg, 5.00 mmol) and 4-nitrobenzenesulfonyl chloride (1.10 g, 5.00 mmol) in dichloromethane (20 mL) was added triethylamine (1.38 mL, 10.0 mmol). The mixture was stirred at room temperature for 2 hours. It was concentrated under reduced pressure to give 4-nitro-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (XIII-B, crude), which was used in the next step without further purification.

[0294] To a solution of 4-nitro-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (XIII-B, crude product from the previous step) in methanol (20 mL) was added palladium (10% on carbon, 200 mg). The mixture was stirred overnight at room temperature under 1 atmosphere of H2. It was then filtered, and the filtrate was concentrated under reduced pressure to give 4-amino-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (intermediate XIII, 1.04 g, 82% from XIII-A). LC-MS (ESI): m / z 257.1 [M+H] + .

[0295] Synthesis of 4-amino-N-(3-methyloxetan-3-yl)benzenesulfonamide (Intermediate XIV) [ka] To a mixture of 3-methyloxetan-3-amine HCl salt (XIV-A, 0.41 g, 3.28 mmol) and triethylamine (1.4 mL, 10.1 mmol) in dichloromethane (30 mL) was added 4-nitrobenzene-1-sulfonyl chloride (0.75 g, 3.37 mmol). The reaction mixture was stirred at room temperature for 3 hours, then poured into water (200 mL) and filtered. The filter cake was washed with dichloromethane (30 mL). The filtrate was then concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give N-(3-methyloxetan-3-yl)-4-nitrobenzenesulfonamide (XIV-B, 0.89 g, 99%). LC-MS (ESI): m / z 271.0 [MH]- .

[0296] To a solution of N-(3-methyloxetan-3-yl)-4-nitrobenzene-1-sulfonamide (XIV-B, 0.89 g, 3.27 mmol) in methanol (10 mL) was added palladium (10% on carbon, 0.32 g). The reaction mixture was stirred at room temperature for 2 hours. Then, it was filtered through a short pad of Celite®. The filter cake was washed with EtOAc (30 mL), and the filtrate was concentrated under reduced pressure. The resulting residue was separated using silica gel column chromatography to give 4-amino-N-(3-methyloxetan-3-yl)benzene-1-sulfonamide (Intermediate XIV, 0.45 g, 57%). 1 H NMR (500MHz, DMSO-d6)δ 7.79(s,1H), 7.89(d,J=8.5Hz, 2H), 6.62(d,J=8.5Hz, 2H), 5.97(s,2H), 4.92(d,J=6.0Hz, 2H), 4.04(d,J=6.0Hz, 2H), 1.43(s,3H).

[0297] Example 1. Synthesis of 4-((5-cyano-4-(cyclopentylmethoxy)pyrimidin-2-yl)amino)benzenesulfonamide (1) [ka] To a mixture of 2,4-dichloropyrimidine-5-carbonitrile (1A, 2.00 g, 11.5 mmol) and 4-aminobenzene-1-sulfonamide (2.18 g, 12.7 mmol) in anhydrous N,N-dimethylformamide (DMF) (20 mL) was added N,N-diisopropylethylamine (DIEA) (4.46 g, 34.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 10 minutes, and then poured into water (200 mL). The formed precipitate was filtered, washed with water (30 mL × 2), and dried to give 4-((4-chloro-5-cyanopyrimidin-2-yl)amino)benzenesulfonamide (1B, 1.60 g, 45%) as a yellow solid. LC-MS (ESI): m / z 310.0 [M+H] + .1 H NMR (400MHz, DMSO-d6) δ 11.15(s,1H), 8.98(s,1H), 7.90-7.76(m,4H), 7.29(s,2H).

[0298] To a solution of 4-((4-chloro-5-cyanopyrimidin-2-yl)amino)benzenesulfonamide (1B, 60 mg, 0.19 mmol) and cyclopentylmethanol (58 mg, 0.58 mmol) in dimethyl sulfoxide (DMSO) (3 mL), potassium tert-butoxide (t-BuOK) (65 mg, 0.58 mmol) was added, and the reaction mixture was stirred at 90 °C for 2 h. Then, it was poured into a cold saturated solution of NH Cl (15 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na SO , and concentrated under reduced pressure to give a residue. The residue was separated using preparative HPLC to give 4-((5-cyano-4-(cyclopentylmethoxy)pyrimidin-2-yl)amino)benzenesulfonamide (1, 16 mg, 23%). LC-MS(ESI):m / z 374.1[M+H] + . 1 H NMR (400MHz, DMSO-d6)δ 10.65(br s,1H), 8.75(s,1H), 7.90(d,J=8.8Hz, 2H), 7.79(d,J=8.8Hz, 2H), 7.26(s,2H), 4.39(d,J =7.2Hz, 2H), 2.45-2.39(m,1H), 1.79-1.77(m,2H), 1.65-1.55(m,4H), 1.36-1.26(m,2H).

[0299] Example 2. Synthesis of cis-4-((5-cyano-4-((2-hydroxycyclohexyl)oxy)pyrimidin-2-yl)amino)benzenesulfonamide (2) [ka] To a solution of 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzenesulfonamide (1B, 140 mg, 0.45 mmol) in DMSO (3 mL), t-BuOK (152 mg, 1.36 mmol) and cis-cyclohexane-1,2-diol (158 mg, 1.36 mmol) were added, and the reaction mixture was stirred at 90° C. for 1 h. After completion, it was poured into an ice-cold saturated solution of NH4Cl (15 mL) and then extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over NaSO, and concentrated under reduced pressure to give a residue that was separated using silica gel column chromatography to give cis-4-((4-((2-hydroxycyclohexyl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzenesulfonamide (2) in racemic form, which was further separated by chiral SFC to give:

[0300] Enantiomer 1 (2a, 97.9% ee); retention time: 3.93min. LC-MS(ESI):m / z 390.1[M+H] + ; 1 H NMR (400MHz, DMSO-d6)δ 10.60(s,1H), 8.73(s,1H), 7.86(d,J=9.0Hz, 2H), 7.77(d,J=8.9Hz, 2H), 7.26(s,2H), 5.33(s, 1H), 4.85(d,J=4.7Hz, 1H), 3.90(s,1H), 1.95(d,J=4.1Hz, 1H), 1.75-1.53(m,5H), 1.34(m,2H).

[0301] Enantiomer 2 (2b, 99% ee); Retention time: 4.76min; LC-MS(ESI): m / z 390.0[M+H] + .

[0302] Analytical method: Column: ChiralCel OD, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH (0.05% DEA); Gradient: 8 min @ B 40%; Flow rate: 2.0 mL / min; Back pressure: 100 bar, Column temperature: 35 °C.

[0303] SFC method: Instrument: Waters Thar 80 Preparative SFC; Column: ChiralCel OD, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH + 0.1% NH3·H2O; Gradient: B 40%; Flow rate: 50 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0304] Example 3. Synthesis of cis-4-((2-hydroxy-2-methylcyclopentyl)oxy)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (3) [ka] To a solution of 2,4-dichloropyrimidine-5-carbonitrile (1A, 400 mg, 2.30 mmol) in t-BuOH (100 mL) was added 1-(methylsulfonyl)piperidin-4-amine (410 mg, 2.23 mmol) and DIEA (900 mg, 6.89 mmol), and the reaction mixture was stirred at 85° C. for 2 hours. After completion, the reaction mixture was concentrated under reduced pressure, and the residue was triturated in dichloromethane (20 mL). The precipitate was collected and dried to give 4-chloro-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (3A, 400 mg, 37%) as a white solid. LC-MS (ESI): m / z 316.1 [M+H] + .

[0305] To a mixture of 4-chloro-2-[(1-methanesulfonylpiperidin-4-yl)amino]pyrimidine-5-carbonitrile (3A, 40 mg, 0.06 mmol) and cis-1-methylcyclopentane-1,2-diol (Intermediate I, 11 mg, 0.10 mmol) in DMSO (1 mL) was added t-BuOK (18 mg, 0.16 mmol). The reaction mixture was stirred at 55 °C for 1.5 hours. After completion, the resulting mixture was poured into ice water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layer was washed with brine (10 mL), dried over NaSO, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography eluting with petroleum ether / ethyl acetate (1:0 to 1:2) to give cis-4-((2-hydroxy-2-methylcyclopentyl)oxy)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (3) as a racemate, which was further separated by chiral SFC to give the following:

[0306] Enantiomer 1 (3a, 100% ee); retention time: 3.16min. LC-MS(ESI):m / z 396.2[M+H] + .

[0307] Enantiomer 2 (3b, 100% ee); retention time: 3.67min. LC-MS(ESI):m / z 396.2[M+H] + . 1 H NMR (400MHz, DMSO-d6) (tautomer ratio approximately 1:1)δ 8.51&8.44(s,1H), 8.24&8.05(d,J=8.0Hz, 1H), 5.14-5.09(m,1H), 4.47(d,J=6.5Hz, 1H), 3.94-3.82(m,1H), 3.56-3.33( m,2H), 2.91-2.81(m,5H), 2.12-2.05(m,1H), 2.00-1.87(m,2H), 1.82-1.70(m,3H), 1.62-1.51(m,4H), 1.22&1.20(s,3H).

[0308] Analytical method: Column: ChiralPak AD, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH (0.05% DEA); Gradient: 8 min @ B 30%; Flow rate: 2.0 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0309] SFC method: Instrument: MG II preparative SFC (SFC-14); Column: ChiralPak AS, 250 x 30 mm ID, 10 μm; Mobile phase: A is CO2 and B is ethanol; Gradient: B 30%; Flow rate: 70 mL / min; Back pressure: 100 bar; Wavelength: 220 nm; Cycle time: approximately 4 min; Column temperature: 38 °C.

[0310] Example 4. Synthesis of cis-4-((2-hydroxy-2-methylcyclopentyl)oxy)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (4) [ka] A mixture of 4-chloro-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (3A, 60 mg, 0.19 mmol), cis-4,4-difluoro-1-methylcyclopentane-1,2-diol (Intermediate II, 35 mg, 0.23 mmol), and t-BuOK (43 mg, 0.38 mmol) in DMSO (1 mL) was stirred at 50° C. for 30 minutes. The resulting mixture was adjusted to pH 7 with formic acid and then separated using preparative HPLC to give cis-4-((4,4-difluoro-2-hydroxy-2-methylcyclopentyl)oxy)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (4, 47 mg, 57%) in racemic form, which was further separated by chiral SFC to give:

[0311] Enantiomer 1 (4a, 96.3% ee); retention time: 1.22min. LC-MS(ESI):m / z 432.2[M+H] + . 1H NMR (400MHz, DMSO-d6) (tautomer ratio approximately 1:1)δ 8.55&8.49(s,1H), 8.25&8.16(d,J=8.0Hz, 1H), 5.36-5.22(m,1H), 5.13&5.12(s,1H), 3.99-3.80(m,1H), 3.56 -3.53(m,2H), 2.88-2.82(m,6H), 2.44-2.20(m,3H), 1.98-1.81(m,2H), 1.62-1.52(m,2H), 1.31&1.30(s,3H).

[0312] Enantiomer 2 (4b, 95.5% ee); retention time: 1.45min. LC-MS(ESI):m / z 432.2[M+H] + .

[0313] Analytical method: Column: Chiralpak AS-3, 150 x 4.6 mm ID, 3 μm; Mobile phase: 25% ethanol (0.05% DEA) in CO2; Flow rate: 2.5 mL / min; Column temperature: 35 °C.

[0314] SFC method: Instrument: MG II preparative SFC (SFC-14); Column: ChiralPak AS, 250 x 30 mm ID, 10 μm; Mobile phase: A is CO2 and B is isopropanol; Gradient: B 25%; Flow rate: 70 mL / min; Back pressure: 100 bar; Column temperature: 38 °C.

[0315] Example 5. Synthesis of cis-4-((2-hydroxy-2-methylcyclopentyl)oxy)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (5) [ka] A mixture of 4-chloro-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (3A, 50 mg, 0.16 mmol), cis-1-methylcyclopentane-4,4-d-1,2-diol (Intermediate III, 21 mg, 0.17 mmol), and t-BuOK (36 mg, 0.32 mmol) in DMSO (1 mL) was stirred at 80° C. for 30 minutes. The reaction mixture was then adjusted to pH 7 with formic acid. The mixture was separated using preparative HPLC to give cis-4-((2-hydroxy-2-methylcyclopentyl-4,4-d)oxy)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (5, 31 mg, 49%) in racemic form, which was further separated by chiral SFC to give:

[0316] Enantiomer 1 (5a, 100% ee); retention time: 3.22min. LC-MS(ESI):m / z 398.2[M+H] + . 1 H NMR (400MHz, DMSO-d6) (tautomer ratio approximately 1:1)δ 8.51&8.44(s,1H), 8.24&8.05(d,J=8.0Hz, 1H), 5.14-5.17(m,1H), 4.48&4.47(s,1H), 3.94-3.82(m,1H), 3.55-3.51(m, 2H), 2.89-2.81(m,5H), 2.08-1.98(m,1H), 1.95-1.83(m,2H), 1.80-1.64(m,2H), 1.60-1.52(m,3H), 1.21&1.19(s,3H).

[0317] Enantiomer 2 (5b, 100% ee); retention time: 3.74min. LC-MS(ESI):m / z 398.2[M+H] + .

[0318] Analytical method: Column: ChiralPak IH, 100 × 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is methanol (0.05% DEA); Gradient: 0.0 min-1.0 min @ 10% B, 1.0 min-4.5 min gradient (10-40% B), 4.5 min-7.0 min @ 40% B, 7.0 min-8.0 min @ 10% B; Flow rate: 2.5 mL / min; Column temperature: 40 °C.

[0319] SFC method: Equipment: IMADZU PREP SOLUTION SFC; Column: ChiralPAK IH, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MEOH + 0.1% NH3·H2O; Gradient: B 40%; Flow rate: 40 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0320] Example 6. Synthesis of 2-((3-fluoro-1-(methylsulfonyl)piperidin-4-yl)amino)-4-((2-hydroxy-2-methylcyclopentyl)oxy)pyrimidine-5-carbonitrile (6) [ka] To a mixture of 4-chloro-2-(methylsulfanyl)pyrimidine-5-carbonitrile (6A, 1.00 g, 5.40 mmol) and cis-1-methylcyclopentane-1,2-diol (Intermediate I, 0.75 g, 6.50 mmol) in DMF (10 mL) was added CsCO (3.51 g, 10.8 mmol). The reaction mixture was stirred at room temperature under N for 1 h. After completion, the reaction mixture was diluted with HO (50 mL) and extracted with EtOAc (50 mL × 2). The combined organic layers were washed with brine (20 mL), dried over NaSO, and concentrated under reduced pressure. The resulting residue was separated using silica gel column chromatography to give cis-4-((2-hydroxy-2-methylcyclopentyl)oxy)-2-(methylthio)pyrimidine-5-carbonitrile (6B, 1.30 g, 91%) as an oil. LC-MS(ESI):m / z 266.2[M+H] + .

[0321] To a solution of cis-4-((2-hydroxy-2-methylcyclopentyl)oxy)-2-(methylthio)pyrimidine-5-carbonitrile (6B, 800 mg, 3.00 mmol) in dichloromethane (8 mL) was added m-CPBA (1.04 g, 6.00 mmol) at 0 °C. The reaction mixture was stirred at room temperature under N for 2 h. Then, the TFA salt of cis-3-fluoro-1-(methylsulfonyl)piperidin-4-amine (Intermediate IX, 643 mg, 2.07 mmol) and triethylamine (1.27 g, 12.6 mmol) were added at 0 °C. The reaction mixture was stirred at room temperature under N for 15 min. After completion, the reaction mixture was diluted with HO (30 mL) and extracted with dichloromethane (50 mL × 2). The combined organic layers were washed with brine (30 mL), dried over NaSO, and concentrated under reduced pressure. The resulting residue was separated using silica gel column chromatography and preparative HPLC to give cis-2-((3-fluoro-1-(methylsulfonyl)piperidin-4-yl)amino)-4-((2-hydroxy-2-methylcyclopentyl)oxy)pyrimidine-5-carbonitrile (6) in the form of a stereoisomeric mixture, which was further separated by chiral SFC to give the following:

[0322] Isomer 1 (6a, 100% ee); retention time: 3.45min. LC-MS(ESI):m / z 414.2[M+H] + ; 1 H NMR (400MHz, CD3OD) (tautomer ratio=1:1)δ 8.40&8.36(s,1H), 5.28-5.19(m,1H), 5.00-4.80(m,1H), 4.30-4.03(m,2H), 3.89-3.85(m,1H), 3.30-3.00(m,2) H), 2.93&2.91(s,3H), 2.25-2.15(m,1H), 2.10-1.95(m,1H), 1.95-1.80(m,4H), 1.75-1.60(m,2H), 1.30(s,3H).

[0323] Isomer 2 (6b, 99.6% ee); retention time: 3.58 min. LC-MS (ESI): m / z 414.2 [M+H] + .

[0324] Isomer 3 (6c, 96.2% ee); retention time: 4.23min. LC-MS(ESI):m / z 414.2[M+H] + .

[0325] Isomer 4 (6d, 100% ee); retention time: 4.41 min. LC-MS (ESI): m / z 414.2 [M+H] + .

[0326] Analytical method: Column: Chiralpak AS-3, 150 x 4.6 mm ID, 3 μm; Mobile phase: A:CO2 B:ethanol (0.05% DEA); Gradient: 5% to 40% B in 5 min and hold at 40% for 2.5 min, then 5% B for 2.5 min; Flow rate: 2.5 mL / min; Column temperature: 35 °C.

[0327] SFC method: Instrument: Waters Thar 80 Preparative SFC; Column: Chiralpak AS, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH + 0.1% NH3·H2O; Gradient: B 40%; Flow rate: 40 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0328] Example 7. Synthesis of 4-((4,4-difluoro-2-hydroxy-2-methylcyclohexyl)oxy)-2-((1-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (7) [ka] To a mixture of 1-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-amine hydrochloride (Intermediate X, 1.30 g, 4.63 mmol) and 2,4-dichloropyrimidine-5-carbonitrile (3A, 1.20 g, 6.90 mmol) in t-BuOH (10 mL) was added diisopropylethylamine (3 mL, 16.0 mmol). The reaction mixture was stirred at 50° C. under N for 0.5 h. After completion, the reaction mixture was diluted with HO (30 mL) and extracted with ethyl acetate (30 mL×3). The combined organic layers were washed with brine (20 mL), dried over NaSO, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography and preparative HPLC to give 4-chloro-2-((1-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (7A, 800 mg, 45%) as a white solid. LC-MS (ESI): m / z 382.1 [M+H] + .

[0329] To a mixture of 4-chloro-2-((1-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (7A, 200 mg, 0.52 mmol) and cis-5,5-difluoro-1-methylcyclohexane-1,2-diol (Intermediate VI, 131 mg, 0.79 mmol) in DMSO (2 mL) was added t-BuOK (176 mg, 1.57 mmol). The reaction mixture was stirred at 50 °C under N for 2 h. After completion, the mixture was diluted with HO (20 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine (20 mL), dried over NaSO, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography and preparative HPLC to give cis-4-((4,4-difluoro-2-hydroxy-2-methylcyclohexyl)oxy)-2-((1-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)amino)pyrimidine-5-carbonitrile (7) as a racemate, which was further separated by chiral SFC to give the following:

[0330] Enantiomer 1 (7a, 100% ee); retention time: 2.73min. LC-MS(ESI):m / z 512.2[M+H] + ; 1 H NMR (400MHz, DMSO-d6) (tautomer ratio approximately 1:1)δ 8.50&8.46(s,1H), 8.34&8.32(s,1H), 8.27&8.12(d,J=8.0Hz, 1H), 7.78&7.77(s,1H), 5.20-5.12(m,1H), 4.92&4.82(s,1H), 3 .90(s,3H), 3.79-3.78(m,1H), 3.55-3.48(m,2H), 2.51-2.49(m,2H), 2.40-1.89(m,8H), 1.64-1.58(m,2H), 1.20&1.18(s,3H).

[0331] Enantiomer 2 (7b, 100% ee); retention time: 4.71min. LC-MS(ESI):m / z 512.2[M+H] + .

[0332] Analytical method: Column: ChiralPak IH, 100 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is methanol (0.05% DEA); Gradient: 8 min @ 20% B; Flow rate: 2.5 mL / min; Column temperature: 40 °C.

[0333] SFC method: Instrument: Waters Thar 80 Preparative SFC; Column: ChiralPak IH, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH + 0.1% NH3·H2O; Gradient: B 30%; Flow rate: 40 mL / min; Back pressure: 100 bar; Column temperature: 35 °C; Wavelength: 254 nm; Cycle time: 8 min, Elution time: 2.3 hr.

[0334] Example 8. Synthesis of 2-((1-((1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)amino)-4-((1-methylcyclopentyl)methoxy)pyrimidine-5-carbonitrile (8) [ka] To a mixture of tert-butyl 4-aminopiperidine-1-carboxylate (500 mg, 2.50 mmol) and N,N-diisopropylethylamine (1.2 mL, 7.50 mmol) in DMF (2 mL) was added a solution of 2,4-dichloropyrimidine-5-carbonitrile (1A, 435 mg, 2.50 mmol) in DMF (1 mL) dropwise at 0 °C. The mixture was then stirred at room temperature for 1 h. Upon completion, the mixture was separated using preparative HPLC to give tert-butyl 4-((4-chloro-5-cyanopyrimidin-2-yl)amino)piperidine-1-carboxylate (8A, 420 mg, 50%). LC-MS (ESI): m / z 338.1 [M+H] + .

[0335] To a mixture of tert-butyl 4-((4-chloro-5-cyanopyrimidin-2-yl)amino)piperidine-1-carboxylate (8A, 216 mg, 0.56 mmol) and (1-methylcyclopentyl)methanol (96 mg, 0.84 mmol) in dry DMSO (2 mL) was added t-BuOK (125 mg, 1.12 mmol). The mixture was stirred at 80 °C for 30 min. Then, the mixture was cooled to room temperature, diluted with water (10 mL), and extracted with ethyl acetate (50 mL × 2). The organic layer was collected, washed with brine, dried over NaSO, and concentrated under reduced pressure. The resulting residue was separated using silica gel column chromatography to give tert-butyl 4-((5-cyano-4-((1-methylcyclopentyl)methoxy)pyrimidin-2-yl)amino)piperidine-1-carboxylate (8B, 200 mg, 86%). LC-MS(ESI):m / z 416.3[M+H] + .

[0336] To a solution of tert-butyl 4-((5-cyano-4-((1-methylcyclopentyl)methoxy)pyrimidin-2-yl)amino)piperidine-1-carboxylate (8B, 200 mg, 0.48 mmol) in methanol (3 mL) was added HCl (4 M in dioxane, 1 mL). The reaction mixture was stirred at 40° C. for 1 h and then concentrated under reduced pressure to give 4-((1-methylcyclopentyl)methoxy)-2-(piperidin-4-ylamino)pyrimidine-5-carbonitrile (8C, 155 mg, 92%) as the HCl salt. LC-MS (ESI): m / z 316.2 [M+H] + .

[0337] To a mixture of 4-((1-methylcyclopentyl)methoxy)-2-(piperidin-4-ylamino)pyrimidine-5-carbonitrile (8C, 100 mg, 0.28 mmol) and N,N-diisopropylethylamine (140 uL, 0.85 mmol) in dry dichloromethane (2 mL) was carefully added a solution of 1-benzyl-1H-pyrazole-4-sulfonyl chloride (73 mg, 0.28 mmol) in dry dichloromethane (2 mL) at 0 °C. The mixture was stirred at room temperature for 1 hour. After completion, the mixture was concentrated under reduced pressure and the residue was separated using silica gel column chromatography to give 2-((1-((1-benzyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)amino)-4-((1-methylcyclopentyl)methoxy)pyrimidine-5-carbonitrile (8D, 100 mg, 66%) as a white solid. LC-MS(ESI):m / z 536.2[M+H] + .

[0338] To a solution of 2-((1-((1-benzyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)amino)-4-((1-methylcyclopentyl)methoxy)pyrimidine-5-carbonitrile (8D, 90 mg, 0.17 mmol) in DMSO (1 mL) was added t-BuOK (57 mg, 0.51 mmol) and the mixture was stirred at room temperature overnight. After completion, the mixture was filtered and the filtrate was separated using preparative HPLC to afford 2-((1-((1H-pyrazol-4-yl)sulfonyl)piperidin-4-yl)amino)-4-((1-methylcyclopentyl)methoxy)pyrimidine-5-carbonitrile (8, 24.2 mg, 29%) as a white solid. LC-MS (ESI): m / z 446.2 [M+H] + . 1 H NMR (500MHz, DMSO-d6)δ 8.49&8.45(s,1H), 8.30&8.16(d,J=7.6Hz, 1H), 8.09(s,2H), 4.14(d,J=14.4Hz, 2H), 3.87-3.64(m,1H), 3.51 -3.43(m,2H), 2.48-2.34(m,2H), 1.96-1.87(m,2H), 1.67-1.43(m,8H), 1.38-1.30(m,2H), 1.05&1.03(s,3H).

[0339] Example 9. Synthesis of 4-((5-cyano-4-(piperidin-1-yl)pyrimidin-2-yl)amino)benzenesulfonamide (65) [ka] A solution of 4-((4-chloro-5-cyanopyrimidin-2-yl)amino)benzenesulfonamide (1B, 50 mg, 0.16 mmol), piperidine (20 uL, 0.21 mmol), and N,N-diisopropylethylamine (33 mg, 0.26 mmol) in dioxane (2 mL) was stirred at 60° C. for 2 hours. The reaction mixture was diluted with water (3 mL), and a precipitate formed. The mixture was filtered, and the filter cake was triturated in methanol (5 mL). The solid was collected and dried to give 4-((5-cyano-4-(piperidin-1-yl)pyrimidin-2-yl)amino)benzenesulfonamide (65, 20 mg, 35%). LC-MS (ESI): m / z 359.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6)δ 10.04(br s,1H), 8.34(s,1H), 7.72(d,J=8.8Hz, 2H), 7.64(d,J=8.8Hz, 2H), 7.10(s,2H), 3.76-3.74(m,4H), 1.56-1.51(m,6H).

[0340] Example 10. Synthesis of 4-((5-cyano-4-(piperidin-1-yl)pyrimidin-2-yl)amino)-N-(oxetan-3-yl)benzenesulfonamide (66) [ka] To a solution of 2,4-dichloro-5-iodopyrimidine (66A, 10.0 g, 36.4 mmol) in dioxane (90 mL) was added piperidine (3.41 g, 40.0 mmol) and diisopropylethylamine (14.1 g, 109 mmol). The reaction mixture was stirred at 25 °C for 15 h. After completion, the mixture was diluted with HO (80 mL) and extracted with EtOAc (80 mL × 3). The combined organic layers were washed with brine (60 mL), dried over NaSO, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give 2-chloro-5-iodo-4-(piperidin-1-yl)pyrimidine (66B, 10.0 g, 85%) as a white solid. LC-MS (ESI): m / z 324.1 [M+H] + .

[0341] A mixture of 2-chloro-5-iodo-4-(piperidin-1-yl)pyrimidine (66B, 3.00 g, 9.27 mmol), Zn(CN) (2.18 g, 18.5 mmol), Zn (606 mg, 9.27 mmol), Pd(PPh) (1.07 g, 0.93 mmol), and 1,1′-bis(diphenylphosphino)ferrocene (dppf) (1.03 g, 1.85 mmol) in dioxane (15 mL) was purged with N and then subjected to microwave conditions with stirring at 60° C. for 1.5 hours. Upon completion, the mixture was filtered through a short pad of Celite®, and the filtrate was concentrated under reduced pressure. The resulting residue was separated using flash chromatography to give 2-chloro-4-(piperidin-1-yl)pyrimidine-5-carbonitrile (66C, 0.9 g, 43%) as a white solid. LC-MS (ESI): m / z 223.1 [M+H] + .

[0342] To a mixture of 2-chloro-4-(piperidin-1-yl)pyrimidine-5-carbonitrile (66C, 30 mg, 0.13 mmol), 4-amino-N-(oxetan-3-yl)benzenesulfonamide (Intermediate XI, 46 mg, 0.20 mmol), CsCO (132 mg, 0.41 mmol), and Xantphos (16 mg, 0.03 mmol) in dioxane (3 mL) was added Pd(OAc) (5 mg, 0.01 mmol), and the reaction mixture was stirred overnight at 100° C. under a N atmosphere. After cooling to room temperature, it was filtered, and the filtrate was concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give 4-((5-cyano-4-(piperidin-1-yl)pyrimidin-2-yl)amino)-N-(oxetan-3-yl)benzenesulfonamide (66, 12 mg, 22%). LC-MS (ESI): m / z 415.1 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ 10.23(br s,1H), 8.48(s,1H), 8.37(br s,1H), 7.88(d,J=8.8Hz, 2H), 7.71(d,J=8.8Hz, 2H), 4.49(t,J=6.8Hz, 2H), 4. 40-4.31(m,1H), 4.24(t,J=6.4Hz, 2H), 3.90-3.86(m,4H), 1.68-1.64(m,6H).

[0343] Example 11. Synthesis of 4-((5-cyano-4-(4-hydroxyphenyl)pyrimidin-2-yl)amino)benzenesulfonamide (92) [ka] To a mixture of 4-((4-chloro-5-cyanopyrimidin-2-yl)amino)benzenesulfonamide (1B, 50 mg, 0.16 mmol) and (4-hydroxyphenyl)boronic acid (27 mg, 0.19 mmol) in dioxane (4 mL) was added a solution of KCO (116 mg, 0.83 mmol) in HO (1 mL). The reaction mixture was degassed and backfilled with N three times. Pd(t-BuP) (8 mg, 0.02 mmol) was added, and the resulting mixture was stirred at 90 °C under a N atmosphere for 3 h. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure. The resulting residue was separated using preparative HPLC to give 4-((5-cyano-4-(4-hydroxyphenyl)pyrimidin-2-yl)amino)benzenesulfonamide (92, 11 mg, 19%). LC-MS(ESI):m / z 368.1[M+H] + . 1 H NMR (400MHz, DMSO-d6)δ 10.73(br s,1H), 8.94(s,1H), 7.96(d,J=8.8Hz, 2H), 7.95(d,J=8.8Hz, 2H), 7.79(d,J=8.8Hz, 2H), 7.25(s,2H), 6.98(d,J=8.8Hz, 2H).

[0344] Example 12. Synthesis of cis-4-((4-((2-hydroxycyclopentyl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzenesulfonamide (99) [ka] To a solution of 2,4-dichloro-5-(trifluoromethyl)pyrimidine (99A, 2.00 g, 9.22 mmol) in t-BuOH (50 mL) was added 4-aminobenzene-1-sulfonamide (1.59 g, 9.22 mmol) and N,N-diisopropylethylamine (4.5 mL, 27.7 mmol). The reaction mixture was stirred at 30° C. for 16 hours. Upon completion, the reaction mixture was concentrated under reduced pressure and the residue was triturated with dichloromethane (30 mL). The product was collected and dried to give 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzenesulfonamide (99B, 0.70 g, 22%) as a white solid. LC-MS (ESI): m / z 353.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 11.0(s,1H), 8.89(s,1H), 7.88(d,J=8.0Hz, 2H), 7.80(d,J=8.0Hz, 2H), 7.28(s,2H).

[0345] To a mixture of 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzenesulfonamide (99B, 200 mg, 0.57 mmol) and t-BuOK (127 mg, 1.13 mmol) in DMSO (3 mL) was added cis-cyclopentane-1,2-diol (64 mg, 0.62 mmol). The reaction mixture was stirred at 90 °C for 20 min. After completion, the reaction mixture was poured into an ice-cold saturated solution of NH Cl (15 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na SO and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give cis-4-((4-((2-hydroxycyclopentyl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzenesulfonamide (99) as a racemate, which was further separated by chiral SFC to give the following:

[0346] Enantiomer 1 (99a, 92.9% ee); retention time: 3.19min. LC-MS(ESI):m / z 419.1[M+H] + ; 1 H NMR (400MHz, DMSO-d6)δ 10.40(s,1H), 8.56(s,1H), 7.90(d,J=8.0Hz, 2H), 7.77(d,J=8.0Hz, 2H), 7.22(s,2H), 5.40-5.32(m,1 H), 4.71(d,J=4.0Hz, 1H), 4.28-4.22(m,1H), 2.10-1.92(m,1H), 1.92-1.67(m,3H), 1.74-1.45(m,2H).

[0347] Enantiomer 2 (99b, 91.1% ee); retention time: 4.21min. LC-MS(ESI):m / z 419.1[M+H] + .

[0348] Analytical method: Column: ChiralPak AD, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is methanol (0.05% DEA); Gradient: 10 min @ 40%; Flow rate: 2.0 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0349] SFC Method: Instrument: Waters UPC2 analytical SFC; Column: ChiralPAK AD, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is methanol (0.05% DEA); Gradient: 10 min @ 40%; Flow rate: 40 mL / min; Column temperature: 35 °C.

[0350] Example 13. Synthesis of cis-4-((4-((3-hydroxytetrahydro-2H-pyran-4-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (100) [ka] To a mixture of methyl-d3-amine monohydrochloride (100A, 1.00 g, 14.8 mmol) and 4-nitrobenzenesulfonyl chloride (4.00 g, 17.8 mmol) in dichloromethane (100 mL) was added sodium carbonate (1 M aqueous solution, 45 mL, 45 mmol). The mixture was stirred at room temperature for 2 hours. After completion, the mixture was extracted with dichloromethane (200 mL × 2). The extracts were combined, dried over Na2SO4, and concentrated under reduced pressure to give N-(methyl-d3)-4-nitrobenzenesulfonamide (100B, 2.97 g, 91%).

[0351] To a solution of N-(methyl-d3)-4-nitrobenzenesulfonamide (100B, 2.97 g, 13.6 mmol) in methanol (30 mL) was added palladium (10% on carbon, 300 mg). The mixture was stirred at room temperature under 1 atmosphere of H2 for 5 hours. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give 4-amino-N-(methyl-d3)benzenesulfonamide (100C, 2.40 g, 94%) as a white solid. LC-MS (ESI): m / z 190.1 [M+H] + .

[0352] To a mixture of 4-amino-N-(methyl-d3)benzenesulfonamide (100C, 2.40 g, 12.7 mmol) and 2,4-dichloro-5-(trifluoromethyl)pyrimidine (99A, 3.30 g, 15.2 mmol) in t-BuOH (60 mL) was added N,N-diisopropylethylamine (4.92 g, 38.1 mmol). The reaction mixture was stirred overnight at 80 °C under N2. After completion, the mixture was concentrated under reduced pressure to give a residue. The residue was diluted with HO (60 mL) and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure (until 2–3 mL of the mixture remained). The mixture was filtered and the filter cake was triturated in dichloromethane (10 mL) to form a yellow solid, which was collected and dried to give 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (100D, 2.12 g, 45%). LC-MS (ESI): m / z 370.1 [M+H] + .

[0353] To a solution of 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (100D, 150 mg, 0.41 mmol) in DMSO (2 mL) was added cis-tetrahydro-2H-pyran-3,4-diol (Intermediate V, 96 mg, 0.81 mmol) and t-BuOK (137 mg, 1.20 mmol). The reaction mixture was stirred at 90 °C for 2 h. After completion, the reaction mixture was diluted with HO (50 mL) and extracted with EtOAc (50 mL × 2). The combined organic layers were washed with brine (50 mL), dried over NaSO, and concentrated under reduced pressure to give a residue that was separated using silica gel column chromatography to give cis-4-((4-((3-hydroxytetrahydro-2H-pyran-4-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d)benzenesulfonamide (100) in racemic form, which was further separated by chiral SFC to give:

[0354] Enantiomer 1 (100a, 99% ee); retention time: 4.20min. LC-MS(ESI):m / z 452.2[M+H] + ; 1 H NMR (400MHz, DMSO-d6)δ 10.50(s,1H), 8.60(s,1H), 7.92(d,J=8.8Hz, 2H), 7.73(d,J=8.7Hz, 2H), 7.27(s,1H), 5.62- 5.56(m,1H), 5.05(d,J=4.9Hz, 1H), 3.94-3.85(m,1H), 3.69-3.49(m,4H), 2.10-1.81(m,2H).

[0355] Enantiomer 2 (100b, 98.6% ee); retention time: 5.41 min. LC-MS (ESI): m / z 452.2 [M+H] + .

[0356] Analytical method: Column: ChiralCel OD, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH (0.05% DEA); Gradient: 8 min @ B 30%; Flow rate: 2.0 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0357] SFC method: Instrument: Waters Thar 80 Preparative SFC; Column: ChiralCel OD, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH + 0.1% NH3·H2O; Gradient: B 25%; Flow rate: 50 mL / min; Back pressure: 100 bar; Column temperature: 35 °C; Wavelength: 256 nm; Cycle time: 8 min; Elution time: 1.5 hr.

[0358] Example 14. Synthesis of cis-3-fluoro-4-((4-((3-hydroxytetrahydro-2H-pyran-4-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (101) [ka] To a mixture of 4-amino-3-fluoro-N-(methyl-d3)benzenesulfonamide (Intermediate XII, 100 mg, 0.48 mmol) and N,N-diisopropylethylamine (0.17 mL, 0.97 mmol) in t-BuOH (1 mL) was added dropwise a solution of 2,4-dichloro-5-(trifluoromethyl)pyrimidine (99A, 98 uL, 0.72 mmol) in t-BuOH (0.1 mL) at 80 °C. The mixture was stirred at 80 °C for 2 hours. Then, a second batch of 2,4-dichloro-5-(trifluoromethyl)pyrimidine (99A, 98 uL, 0.72 mmol) in t-BuOH (0.1 mL) was added dropwise at 80 °C. The mixture was stirred at 80 °C for an additional 12 hours. After completion, the mixture was separated using preparative HPLC to give 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3-fluoro-N-(methyl-d3)benzenesulfonamide (101A, 45 mg, 24%) as a yellow solid. 1 H NMR (500MHz, DMSO-d6) δ 10.71(s,1H), 8.84(s,1H), 7.93(t,J=7.9Hz, 1H), 7.72-7.62(m,2H), 7.53(s,1H).

[0359] To a mixture of 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3-fluoro-N-(methyl-d3)benzenesulfonamide (101A, 80 mg, 0.21 mmol) and cis-tetrahydro-2H-pyran-3,4-diol (Intermediate V, 49 mg, 0.42 mmol) in dimethyl sulfoxide (1 mL) was added t-BuOK (70 mg, 0.62 mmol). The mixture was stirred at 90° C. for 1 hour. The reaction mixture was adjusted to pH 7 with formic acid and then separated using preparative HPLC to give cis-3-fluoro-4-((4-((3-hydroxytetrahydro-2H-pyran-4-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (101, 27 mg, 28%) in racemic form, which was further separated by chiral SFC to give:

[0360] Enantiomer 1 (101a, 100% ee); retention time: 4.73min. LC-MS(ESI):m / z 470.1[M+H] + ; 1 H NMR (400MHz, DMSO-d6) (tautomer ratio=1:1)δ 10.05(s,1H), 8.55(s,1H), 8.03(t,J=8.4Hz, 1H), 7.82-7.62(m,2H), 7.50(s,1H), 5.45-5. 41(m,1H), 5.02(d,J=4.9Hz, 1H), 3.84-3.81(m,1H), 3.61-3.54(m,4H), 2.01-1.78(m,2H).

[0361] Enantiomer 2 (101b, 100% ee); retention time: 5.39min. LC-MS(ESI):m / z 470.1[M+H] + .

[0362] Analytical method: Column: ChiralPak C-IG, 100 × 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is methanol (0.05% DEA); Gradient: 0.0 min-1.0 min @ 10% B, 1.0 min-4.5 min gradient (10-40% B), 4.5 min-7.0 min @ 40% B, 7.0 min-8.0 min @ 10% B; Flow rate: 2.5 mL / min; Column temperature: 40 °C.

[0363] SFC method: Equipment: IMADZU PREP SOLUTION SFC; Column: ChiralPak C-IG, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MEOH + 0.1% NH3·H2O; Gradient: B 40%; Flow rate: 40 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0364] Example 15. Synthesis of 4-((4-((5-hydroxyoxepan-4-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (102) [ka] To a mixture of oxepane-4,5-diol (Intermediate VII, 16 mg, 0.12 mmol) and 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (100D, 15 mg, 0.04 mmol) in DMSO (1 mL) was added t-BuOK (14 mg, 0.12 mmol) at 0 °C. The reaction mixture was stirred at 80 °C for 12 h. After cooling to room temperature, the solution was poured into a saturated solution of NH4Cl (15 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give 4-((4-((5-hydroxyoxepan-4-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (102), which was further separated by chiral SFC to give the following:

[0365] Diastereomer 1 (102a, 96.7% ee); Retention time: 1.37 min. LC-MS (ESI): m / z 466.3 [M+H] + .

[0366] Diastereomer 2 (102b, 100% ee); Retention time: 1.45 min. LC-MS (ESI): m / z 466.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6)δ 10.51(br s,1H), 8.60(s,1H), 7.95(d,J=8.0Hz, 2H), 7.74(d,J=8.0Hz, 2H), 7.29(s,1H), 5.43-5.39(m,1H), 5.06(d,J =4.0Hz, 1H), 4.02-3.93(m,1H), 3.75-3.60(m,4H), 2.21-2.15(m,1H), 2.00-1.94(m,2H), 1.81-1.74(m,1H).

[0367] Diastereomer 3 (102c, 95.3% ee); Retention time: 1.69 min. LC-MS (ESI): m / z 466.2 [M+H]+ .

[0368] Diastereomer 4 (102d, 100% ee); retention time: 1.89 min. LC-MS (ESI): m / z 466.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6)δ 10.51 (br, s, 1H), 8.60 (s, 1H), 7.95 (d, J=8.0Hz, 2H), 7.74 (d, J=8.0Hz, 2H), 7.29 (s, 1H), 5.42-5.39 (m, 1H), 5.06 (d,J=4.0Hz, 1H), 3.97-3.93(m,1H), 3.75-3.61(m,4H), 2.24-2.15(m,1H), 2.00-1.94(m,2H), 1.81-1.76(m,1H).

[0369] Analytical method: Instrument: Waters UPC2 analytical SFC (SFC-H); Column: ChiralPak AD, 150 x 4.6 mm ID, 3 μm; Mobile phase: A is CO2 and B is ethanol (0.05% DEA); Gradient: B 40%; Flow rate: 2.5 mL / min; Back pressure: 100 bar; Column temperature: 35 °C; Wavelength: 220 nm.

[0370] SFC method: Run 1: Instrument: MG II Preparative SFC (SFC-14); Column: ChiralPak AD, 250 × 30 mm ID, 10 μm; Mobile phase: A is CO₂ and B is isopropanol (0.1% NH₃·H₂O); Gradient: B 35%. Flow rate: 80 mL / min; Back pressure: 100 bar; Column temperature: 38 °C.

[0371] Second run: Instrument: MG II Preparative SFC (SFC-14); Column: ChiralPak AD, 250 × 30 mm ID, 10 μm; Mobile phase: A is CO2 and B is ethanol (0.1% NH3·H2O); Gradient: B 35%; Flow rate: 80 mL / min; Back pressure: 100 bar; Column temperature: 38 °C.

[0372] Example 16. Synthesis of cis-4-((4-((3-hydroxyoxepan-4-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (103) [ka] To a mixture of 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (100D, 100 mg, 0.27 mmol) and cis-oxepane-3,4-diol (Intermediate VIII, 42 mg, 0.33 mmol) in DMSO (1 mL) was added t-BuOK (91 mg, 0.81 mmol). The mixture was stirred at 80° C. for 2 h. It was adjusted to pH 7 with formic acid and then separated using preparative HPLC to give cis-4-((4-((3-hydroxyoxepan-4-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (103, 27 mg, 28%) in racemic form, which was further separated by chiral SFC to give:

[0373] Enantiomer 1 (103a, 100% ee); retention time: 4.67min. LC-MS(ESI):m / z 466.2[M+H] + . 1 H NMR (400MHz, DMSO-d6)δ 10.52(s,1H), 8.60(s,1H), 7.94(d,J=8.8Hz, 2H), 7.73(d,J=8.8Hz, 2H), 7.30(s,1H), 5.29(s,1H), 5.16(d,J=5.6Hz, 1H), 3.81-3.72(m,3H), 3.65-3.62(m,2H), 2.11-1.94(m,2H), 1.88-1.78(m,2H).

[0374] Enantiomer 2 (103b, 95.1% ee); retention time: 5.08min. LC-MS(ESI):m / z 466.2[M+H] + .

[0375] Analytical method: Column: ChiralPak C-IG, 100 × 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is methanol (0.05% DEA); Gradient: 0.0 min-1.0 min @ 10% B, 1.0 min-4.5 min gradient (10-40% B), 4.5 min-7.0 min @ 40% B, 7.0 min-8.0 min @ 10% B; Flow rate: 2.5 mL / min; Column temperature: 40 °C.

[0376] SFC method: Equipment: IMADZU PREP SOLUTION SFC; Column: ChiralPak C-IG, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH + 0.1% NH3·H2O; Gradient: B 40%; Flow rate: 40 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0377] Example 17. Synthesis of cis-3-methyl-4-((2-((1-(methylsulfonyl)piperidin-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)oxy)tetrahydrofuran-3-ol (104) [ka] To a mixture of 2,4-dichloro-5-(trifluoromethyl)pyrimidine (99A, 651 mg, 3.00 mmol) and 1-(methylsulfonyl)piperidin-4-amine (534 mg, 3.00 mmol) in t-BuOH (10 mL) was added N,N-diisopropylethylamine (1.48 mL, 9.00 mmol). The mixture was stirred at 80° C. for 3 hours. After completion, the mixture was concentrated under reduced pressure and the residue was subjected to preparative HPLC separation to give 4-chloro-N-(1-(methylsulfonyl)piperidin-4-yl)-5-(trifluoromethyl)pyrimidin-2-amine (104A, 367 mg, 30%). LC-MS (ESI): m / z 359.0 [M+H] + .

[0378] To a mixture of 4-chloro-N-(1-(methylsulfonyl)piperidin-4-yl)-5-(trifluoromethyl)pyrimidin-2-amine (104A, 88 mg, 0.25 mmol) and cis-3-methyltetrahydrofuran-3,4-diol (Intermediate IV, 59 mg, 0.50 mmol) in DMSO (3 mL) was added t-BuOK (83 mg, 0.74 mmol). The reaction mixture was stirred at 90° C. for 30 minutes. Upon completion, the mixture was cooled to room temperature and then subjected to preparative HPLC separation to give cis-3-methyl-4-((2-((1-(methylsulfonyl)piperidin-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)oxy)tetrahydrofuran-3-ol (104, 34 mg, 28%) in racemic form, which was further separated by chiral SFC to give:

[0379] Enantiomer 1 (104a, 99.6% ee); retention time: 1.14min. LC-MS(ESI):m / z 441.2[M+H] + ; 1 H NMR (400MHz, DMSO-d6) (tautomer ratio approximately 1:1)δ 8.35&8.31(s,1H), 7.99&7.78(d,J=8.0Hz, 1H), 5.32-5.22(m,1H), 4.83&4.81(s,1H), 4.22-4.16(m,1H), 3.91-3.88(m, 1H), 3.77-3.75(m,1H), 3.57-3.53(m,4H), 2.90-2.84(m,5H), 2.04-1.91(m,2H), 1.57-1.51(m,2H), 1.33&1.23(s,3H).

[0380] Enantiomer 2 (104b, 98.7% ee); Retention time: 1.43 min. LC-MS (ESI): m / z 441.2 [M+H] + .

[0381] Analytical method: Column: Chiralpak AD-3, 150 x 4.6 mm ID, 3 um; Mobile phase: 30% ethanol (0.05% DEA) in CO2; Flow rate: 2.5 mL / min; Column temperature: 35°C.

[0382] SFC method: Instrument: MG II preparative SFC (SFC-14); Column: ChiralPak AD, 250 × 30 mm ID, 10 μm; Mobile phase: A is CO2 and B is ethanol (0.1% NH3·H2O); Gradient: B 25%; Flow rate: 70 mL / min; Back pressure: 100 bar; Column temperature: 38 °C.

[0383] Example 18. Synthesis of 4-((5-chloro-4-((2-hydroxycyclopentyl)oxy)pyrimidin-2-yl)amino)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (130) [ka] To a mixture of 2,4,5-trichloropyrimidine (130A, 0.68 g, 3.68 mmol) and cis-cyclopentane-1,2-diol (0.39 g, 3.86 mmol) in DMSO (10 mL) was added t-BuOK (0.43 g, 3.86 mmol) at 0 °C, and the reaction mixture was stirred at 80 °C for 2 h. The reaction mixture was then poured into a cold saturated solution of NH4Cl (15 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give cis-2-((2,5-dichloropyrimidin-4-yl)oxy)cyclopentan-1-ol (130B, 0.38 g, 41%) as a white solid. LC-MS (ESI): m / z 249.0 [M+H] + .

[0384] To a mixture of 2-[(2,5-dichloropyrimidin-4-yl)oxy]cyclopentan-1-ol (130B, 58 mg, 0.23 mmol) and 4-amino-N-(oxan-4-yl)benzene-1-sulfonamide (63 mg, 0.24 mmol) in anhydrous t-BuOH (1 mL) was added hydrogen chloride (4 M in dioxane, 0.12 mL, 0.47 mmol). The reaction mixture was stirred at 80 °C for 2 h. After cooling to room temperature, it was poured into a saturated aqueous solution of NH Cl (15 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na SO , and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give cis-4-((5-chloro-4-((2-hydroxycyclopentyl)oxy)pyrimidin-2-yl)amino)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (130) in racemic form, which was further separated by chiral SFC to give the following:

[0385] Enantiomer 1 (130a, 98.3% ee); Retention time: 4.07 min. LC-MS (ESI): m / z 469.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6)δ 10.06(br s,1H), 8.35(s,1H), 7.88(d,J=9.0Hz, 2H), 7.72(d,J=8.9Hz, 2H), 7.59(d,J=7.0Hz, 1H), 5.27-5.21(m,1H), 4.72(d,J=4.8Hz, 1H), 4.29-4.19 (m,1H), 3.74-3.66(m,2H), 3.33-3.20(m,3H), 1.89-1.82(m,1H), 1.87 -1.78(m,3H), 1.71-1.61(m,1H), 1.59-1.49(m,3H), 1.40-1.28(m,2H).

[0386] Enantiomer 2 (130b, 98.7% ee); retention time: 5.95min. LC-MS(ESI):m / z 469.2[M+H] + ; 1H NMR (400MHz, DMSO-d6)δ 10.07(br s,1H), 8.35(s,1H), 7.88(d,J=8.9Hz, 2H), 7.72(d,J=8.9Hz, 2H), 7.59(d,J=7.2Hz, 1H) , 5.28-5.23(m,1H), 4.72(d,J=4.8Hz, 1H), 4.30-4.20(m,1H), 3.75-3.67(m,2H), 3.24- 3.19(m,3H), 2.07-2.01(m,1H), 1.88-1.78(m,3H), 1.70-1.60(m,1H), 1.55-1.45(m,3H), 1.37-1.29(m,2H).

[0387] Analytical method: Column: ChiralCel OD, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH (0.05% DEA); Gradient: 8 min @ 40% B; Flow rate: 2.0 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0388] SFC method: Instrument: Waters UPC2 analytical SFC; Column: ChiralPak AD, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is methanol (0.05% DEA); Gradient: 10 min @ 40%; Flow rate: 2.0 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0389] Example 19. Synthesis of cis-4-((5-bromo-4-((2-hydroxycyclopentyl)oxy)pyrimidin-2-yl)amino)-N-(3-methyloxetan-3-yl)benzenesulfonamide (131) [ka] To a mixture of 5-bromo-2,4-dichloropyrimidine (131A, 113 mg, 0.50 mmol) and cis-cyclopentane-1,2-diol (50 mg, 0.50 mmol) in DMSO (2 mL) was added t-BuOK (67 mg, 0.60 mmol), and the mixture was stirred at room temperature for 2 hours. After completion, the mixture was separated using preparative HPLC to give cis-2-((5-bromo-2-chloropyrimidin-4-yl)oxy)cyclopentan-1-ol (131B, 108 mg, 74%) as a white solid. LC-MS (ESI): m / z 293.0 [M+H] + .

[0390] To a mixture of cis-2-[(5-bromo-2-chloropyrimidin-4-yl)oxy]cyclopentan-1-ol (131B, 92 mg, 0.31 mmol) and 4-amino-N-(3-methyloxetan-3-yl)benzene-1-sulfonamide (Intermediate XIV, 76 mg, 0.31 mmol) in anhydrous dioxane (1 mL) under a nitrogen atmosphere, Pd(OAc) (4 mg, 0.02 mmol), Xantphos (18 mg, 0.03 mmol), and CsCO (204 mg, 0.63 mmol) were added. The reaction mixture was stirred at 100 °C for 4 h under a nitrogen atmosphere. After cooling to room temperature, the mixture was diluted with ethyl acetate (20 mL), filtered through a Celite pad, and washed with ethyl acetate (10 mL). The filtrate was concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give cis-4-({5-bromo-4-[(2-hydroxycyclopentyl)oxy]pyrimidin-2-yl}amino)-N-(3-methyloxetan-3-yl)benzene-1-sulfonamide (131) in racemic form, which was further separated by chiral SFC to give the following:

[0391] Enantiomer 1 (131a, 94.2% ee); retention time: 4.39 min. LC-MS (ESI): m / z 499.1 and 501.1 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ 10.10(br s,1H), 8.43(s,1H), 8.14(br s,1H), 7.90(d,J=8.8Hz, 2H), 7.72(d,J=8.8Hz, 2H), 5.33-5.19(m,1H), 4.71(d,J=4.8Hz, 1H), 4.53(d,J=5.6Hz, 2H) ), 4.32-4.22(m,1H), 4.08(d,J=6.0Hz, 2H), 2.11-1.97(m,1H), 1.91-1.77(m,3H), 1.67-1.55(m,2H), 1.43(s,3H).

[0392] Enantiomer 2 (131b, 93.9% ee); retention time: 7.54 min. LC-MS (ESI): m / z 499.1 and 501.1 [M+H] + .

[0393] Analytical method: Column: ChiralCel OD, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is methanol (0.05% DEA); Gradient: 10 min @ 40%; Flow rate: 40 mL / min; Column temperature: 35 °C.

[0394] SFC method: Instrument: Waters UPC2 analytical SFC; Column: ChiralPak AD, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is methanol (0.05% DEA); Gradient: 10 min @ 40%; Flow rate: 2.0 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0395] Example 20. Synthesis of cis-4-((4-((2-hydroxycyclopentyl)oxy)-5-methylpyrimidin-2-yl)amino)benzenesulfonamide (132) [ka] To a solution of cis-cyclopentane-1,2-diol (100 mg, 0.98 mmol) in THF (3 mL) was added NaH (60% in mineral oil, 78 mg, 1.96 mmol) at 0 °C, and the reaction mixture was heated to 40 °C. Next, a solution of 2,4-dichloro-5-methylpyrimidine (132A, 144 mg, 0.88 mmol) in THF (3 mL) was added dropwise. After completion, the reaction mixture was poured into an ice-cold saturated solution of NH4Cl (15 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was then separated using silica gel column chromatography to give cis-2-((2-chloro-5-methylpyrimidin-4-yl)oxy)cyclopentan-1-ol (132B, 150 mg, 75%) as a white solid. LC-MS(ESI):m / z 229.0[M+H] + .

[0396] A mixture of cis-2-((2-chloro-5-methylpyrimidin-4-yl)oxy]cyclopentan-1-ol (132B, 100 mg, 0.44 mmol), 4-aminobenzene-1-sulfonamide (114 mg, 0.66 mmol), Cs2CO3 (427 mg, 1.31 mmol), Pd(OAc)2 (10 mg, 0.04 mmol), and Xantphos (51 mg, 0.09 mmol) in dioxane (3 mL) was degassed and flushed with N2 three times. The mixture was filled in a tube, then sealed and stirred at 100° C. under microwave conditions for 1 h. After completion, the reaction mixture was concentrated under reduced pressure and the residue was separated using silica gel column chromatography to give cis-4-((4-((2-hydroxycyclopentyl)oxy)-5-methylpyrimidin-2-yl)amino)benzene-1-sulfonamide (132) in racemic form, which was further separated by chiral SFC to give:

[0397] Enantiomer 1 (132a, 96.1% ee); retention time: 3.20min. LC-MS(ESI):m / z 365.1[M+H] + ; 1H NMR (400MHz, DMSO-d6)δ 9.69(s,1H), 8.08(s,1H), 7.88(d,J=8.9Hz, 2H), 7.69(d,J=8.8Hz, 2H), 7.13(s,2H), 5.27-5.19(m,1H), 4.62(d ,J=5.0Hz, 1H), 4.26-4.17(m,1H), 2.06-1.97(m,4H), 1.88-1.75(m,3H), 1.72-1.62(m,1H), 1.61-1.50(m,1H).

[0398] Enantiomer 2 (132b, 93.4% ee); retention time: 3.76min. LC-MS(ESI):m / z 365.0[M+H] + .

[0399] Analytical method: Column: ChiralCel OJ, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH (0.05% DEA); Gradient: 8 min @ B 40%; Flow rate: 2.0 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0400] SFC method: Instrument: Waters Thar 80 Preparative SFC; Column: ChiralCel OJ, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH + 0.1% NH3·H2O; Gradient: B 40%; Flow rate: 50 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0401] Example 21. Synthesis of cis-4-((5-ethyl-4-((2-hydroxycyclopentyl)oxy)pyrimidin-2-yl)amino)benzenesulfonamide (133) [ka] To a mixture of 2,4-dichloro-5-ethylpyrimidine (133A, 2.98 g, 19.6 mmol) and cis-cyclopentane-1,2-diol (2.00 g, 19.6 mmol) in DMSO (60 mL) was added t-BuOK (6.60 g, 58.9 mmol) portionwise at 0 °C. The reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was poured into an ice-cold saturated solution of NH4Cl (60 mL) and extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. The resulting residue was separated using silica gel column chromatography to give cis-2-((2-chloro-5-ethylpyrimidin-4-yl)oxy)cyclopentan-1-ol (133B, 1.80 g, 38%) as a white solid. LC-MS(ESI):m / z 243.0[M+H] + .

[0402] A mixture of cis-2-((2-chloro-5-ethylpyrimidin-4-yl)oxy)cyclopentan-1-ol (133B, 510 mg, 2.10 mmol), 4-aminobenzenesulfonamide (360 mg, 2.10 mmol), CsCO (2.05 g, 6.30 mmol), Pd(OAc) (140 mg, 0.63 mmol) and Xantphos (370 mg, 0.63 mmol) in dioxane (5 mL) was purged with N and then subjected to microwave conditions with stirring at 100 °C for 1.5 h. After completion, the reaction mixture was concentrated under reduced pressure and the residue was separated using silica gel column chromatography to give cis-4-((5-ethyl-4-((2-hydroxycyclopentyl)oxy)pyrimidin-2-yl)amino)benzenesulfonamide (133) in racemic form, which was further separated by chiral SFC to give the following:

[0403] Enantiomer 1 (133a, 91.1% ee); retention time: 4.64min. LC-MS(ESI):m / z 379.1[M+H] + ; 1H NMR (400MHz, DMSO-d6)δ 9.71(s,1H), 8.08(s,1H), 7.90(d,J=8.8Hz, 2H), 7.71(d,J=8.8Hz, 2H), 7.13(s,2H), 5.26(d,J=4.4Hz, 1H), 4.65(d,J=4.4Hz, 1H), 4.23(t,J=4.4Hz, 1H), 2.47-2.42(m,2H), 2.05-1.98(m,1H), 1.91-1.75(m,3H), 1.71-1.55(m,2H), 1.16(t,J=7.2Hz, 3H).

[0404] Enantiomer 2 (133b, 90.5% ee); retention time: 5.72min. LC-MS(ESI):m / z 379.1[M+H] + .

[0405] Analytical method: Column: ChiralPak IA, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH (0.05% DEA); Gradient: 8 min @ 40% B; Flow rate: 1.8 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0406] SFC method: Instrument: Waters Thar 80 Preparative SFC; Column: ChiralCel IA, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH + 0.1% DEA; Gradient: B 40%; Flow rate: 50 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0407] Example 22. Synthesis of cis-4-((5-cyclopropyl-4-((2-hydroxycyclopentyl)oxy)pyrimidin-2-yl)amino)-N-isopropylbenzenesulfonamide (134) [ka] To a mixture of 2,4-dichloro-5-iodopyrimidine (66A, 5.40 g, 19.6 mmol) and cis-cyclopentane-1,2-diol (2.00 g, 19.6 mmol) in DMSO (60 mL) was added t-BuOK (6.60 g, 58.9 mmol) portionwise at 0 °C. The reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was poured into an ice-cold saturated solution of NH4Cl (60 mL) and extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give cis-2-((2-chloro-5-iodopyrimidin-4-yl)oxy)cyclopentan-1-ol (134A, 4.5 g, 67%) as a white solid. LC-MS(ESI):m / z 341.0[M+H] + .

[0408] A mixture of cis-2-((2-chloro-5-iodopyrimidin-4-yl)oxy)cyclopentan-1-ol (134A, 500 mg, 1.46 mmol), cyclopropylboronic acid (250 mg, 2.92 mmol), KCO (607 mg, 4.40 mmol), and Pd(dppf)Cl (107 mg, 0.14 mmol) in 1,4-dioxane (8 mL) and HO (2 mL) was degassed and backfilled with N three times. The reaction mixture was stirred at 100 °C under a N atmosphere for 5 h. After completion, the reaction mixture was concentrated under reduced pressure, and the residue was separated using silica gel column chromatography to give cis-2-((2-chloro-5-cyclopropylpyrimidin-4-yl)oxy)cyclopentan-1-ol (134B, 210 mg, 56%) as a white solid. LC-MS(ESI):m / z 255.0[M+H] + .

[0409] A mixture of cis-2-((2-chloro-5-cyclopropylpyrimidin-4-yl)oxy)cycloclopentan-1-ol (134B, 130 mg, 0.51 mmol), 4-amino-N-isopropylbenzenesulfonamide (101 mg, 0.51 mmol), CS2CO3 (497 mg, 1.53 mmol), Pd(OAc)2 (34 mg, 0.15 mmol) and Xantphos (88 mg, 0.15 mmol) in dioxane (5 mL) was purged with N2 before it was subjected to microwave conditions with stirring at 100 °C for 1 h. After completion, the reaction mixture was concentrated under reduced pressure and the residue was separated using silica gel column chromatography to give cis-4-((5-cyclopropyl-4-((2-hydroxycyclopentyl)oxy)pyrimidin-2-yl)amino)-N-isopropylbenzenesulfonamide (134) in racemic form, which was further separated by chiral SFC to give the following:

[0410] Enantiomer 1 (134a, 97.2% ee); retention time: 3.23min. LC-MS(ESI):m / z 433.0[M+H] + ; 1 H NMR (400MHz, DMSO-d6)δ 9.75(s,1H), 7.94(s,1H), 7.90(d,J=8.8Hz, 2H), 7.67(d,J=8.8Hz, 2H), 7.32( d,J=7.2Hz, 1H), 5.26-5.22(m,1H), 4.65(d,J=4.8Hz, 1H), 4.32-4.16(m,1H), 3.25-3.17(m,1H), 2.10-1.97(m,1H), 1.90-1.75(m,4H), 1.74-1.64(m,1H), 1 .63-1.50(m,1H), 0.94(d,J=6.5Hz, 6H), 0.86-0.76(m,3H), 0.74-0.67(m,1H).

[0411] Enantiomer 2 (134b, 97.6% ee); retention time: 4.34min. LC-MS(ESI):m / z 433.1[M+H] + .

[0412] Analytical method: Column: ChiralCel OD, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is EtOH (0.05% DEA); Gradient: 8 min @ 40% B; Flow rate: 1.8 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0413] SFC method: Instrument: Waters Thar 80 Preparative SFC; Column: ChiralCel OD, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH + 0.1% NH3·H2O; Gradient: B 40%; Flow rate: 50 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0414] Example 23. Synthesis of cis-4-((5-(1-fluorovinyl)-4-((2-hydroxycyclopentyl)oxy)pyrimidin-2-yl)amino)-N-(methyl-d3)benzenesulfonamide (135) [ka] To a solution of 1-(2,4-dichloropyrimidin-5-yl)ethan-1-one (135A, 950 mg, 5.00 mmol) in dichloromethane (20 mL) was added bis(2-methoxyethyl)aminosulfur trifluoride (BAST) (3.32 g, 15.0 mmol) dropwise at 0 °C. The reaction mixture was then stirred at room temperature for 16 h. After completion, the mixture was carefully poured into ice water (20 mL) and extracted with dichloromethane (20 mL × 3). The organic layers were combined, dried over anhydrous NaSO, and then evaporated under reduced pressure. The residue was separated using silica gel column chromatography to give 2,4-dichloro-5-(1,1-difluoroethyl)pyrimidine (135B, 890 mg, 84%) as a pale yellow oil. LC / MS (ESI) m / z: 213.1 [M+H] + .

[0415] To a mixture of 2,4-dichloro-5-(1,1-difluoroethyl)pyrimidine (135B, 680 mg, 3.21 mmol) and cis-cyclopentane-1,2-diol (360 mg, 3.53 mmol) in N,N-dimethylformamide (10 mL) at −30°C under a N atmosphere with stirring, NaHMDS (1 M in THF, 3.85 mL, 3.85 mmol) was added to the mixture, with the temperature maintained between −30°C and −20°C. After the addition, the mixture was stirred at −30°C for an additional 20 minutes. The reaction was quenched with saturated NH4Cl solution (3 mL) and HO (5 mL) and extracted with EtOAc (15 mL × 3). The organic layers were combined, dried over anhydrous Na2SO4, and then concentrated under reduced pressure. The residue was separated using silica gel column chromatography to give cis-2-((2-chloro-5-(1,1-difluoroethyl)pyrimidin-4-yl)oxy)cyclopentan-1-ol (135C, 320 mg, 36%) as a white solid. LC / MS (ESI) m / z: 279 [M+H] + .

[0416] cis-2-((2-chloro-5-(1,1-difluoroethyl)pyrimidin-4-yl)oxy)cyclopentan-1-ol (135C, 278 mg, 1.00 mmol), 4-amino-N-isopropylbenzenesulfonamide (227 mg, 1.20 mmol), C in dioxane (10 mL). S2 A mixture of CO (975 mg, 3.00 mmol), Pd(OAc) (67 mg, 0.30 mmol), and XantPhos (174 mg, 0.30 mmol) was purged with N. The reaction was stirred at 100 °C under microwave irradiation for 1 h. Upon completion, the reaction mixture was concentrated under reduced pressure, and the residue was separated using silica gel column chromatography to give cis-4-((5-cyclopropyl-4-((2-hydroxycyclopentyl)oxy)pyrimidin-2-yl)amino)-N-isopropylbenzenesulfonamide (135) in racemic form, which was further separated by chiral SFC to give:

[0417] Enantiomer 1 (135a, 98.8% ee); retention time: 5.25min. LC-MS(ESI):m / z 412.2[M+H] + ; 1 H NMR (400MHz, DMSO-d6)δ 10.24(s,1H), 8.44(s,1H), 7.96(d,J=8.8Hz, 2H), 7.71(d,J=8.8Hz, 2H), 7.23(s,1H), 5.58-5.34(m,2H), 5.01(d,J HF =19.2Hz, 1H), 4.86(d,J=4.5Hz, 1H), 4.32-4.16(m,1H), 2.18-2.03(m,1H), 1.97-1.73(m,3H), 1.68-1.56(m,2H).

[0418] Enantiomer 2 (135b, 99.6% ee); retention time: 8.76min. LC-MS(ESI):m / z 412.2[M+H] + .

[0419] Analytical method: Column: ChiralPak IA, 250 x 4.6 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH (0.05% DEA); Gradient: 8 min @ 40% B; Flow rate: 2.0 mL / min; Back pressure: 100 bar; Column temperature: 35 °C.

[0420] SFC method: Instrument: Waters Thar 80 Preparative SFC; Column: ChiralPak IA, 250 x 21.2 mm ID, 5 μm; Mobile phase: A is CO2, B is MeOH + 0.1% NH3·H2O; Gradient: B 50%; Flow rate: 40 mL / min; Back pressure: 100 bar; Column temperature: 35 °C; Wavelength: 220 nm; Cycle time: 5 min; Elution time: 1.2 hr.

[0421] The compounds of the present disclosure can be synthesized by one of ordinary skill in the art in light of the present disclosure....

Claims

1. A compound of formula I, or a pharma- ceutically acceptable salt thereof: 【Chemistry 1】 (In the formula: L 1 is optionally substituted phenylene, optionally substituted 5- or 6-membered heteroarylene, optionally substituted 4- to 8-membered heterocyclylene, or optionally substituted C 3~8 is a carbocyclylene; R 1 But, SO 2 R 10 , S.O. 2 N.R. 11 R 12 ,S(O)(NH)R 10 or C(O)NR 11 R 12 and X is N or CR 13 and L 2 is a bond or -O-; L 3 is a bond, optionally substituted C 1~4 Alkylene, or optionally substituted C 1~4 is heteroalkylene; R 2 but, 【Chemistry 25】 or R 2 is selected from 【Chemistry 26】 or R 2 is selected from 【Chemical 27】 is selected from R 3 is hydrogen, halogen, CN, C(O)NR 11 R 12 , optionally substituted C 1~6 Alkyl, optionally substituted C 2~4 Alkenyl, optionally substituted C 2~4 Alkynyl, optionally substituted C 1~4 Heteroalkyl, OR A , C.O.R. B , COOR A , N.R. 11 R 12 , optionally substituted C 3~8 carbocyclyl, optionally substituted 4- to 10-membered heterocyclyl, or optionally substituted 5- to 10-membered heteroaryl; R 4 is hydrogen, halogen, optionally substituted C 1~6 Alkyl or NR 11 R 12 and Where: R 10 is optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted 4-10 membered heterocyclyl; R 11 and R 12 Each occurrence is independently selected from hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted 4-10 membered heterocyclyl; or a nitrogen protecting group; or R 11 and R 12 may be joined to form an optionally substituted 4-10 membered heterocyclyl or 5- or 6-membered heteroaryl; R A is hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted 4-10 membered heterocyclyl; or an oxygen protecting group; R B is hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted 4-10 membered heterocyclyl, or optionally substituted heteroaryl; R 13 is hydrogen, F, CN, —OH, optionally substituted C 1~4 Alkyl, optionally substituted C 1~4 Heteroalkyl, optionally substituted C 3~8 carbocyclyl, or optionally substituted 4-10 membered heterocyclyl.

2. R 2 is 【Chemistry 27-1】 2. The compound of claim 1, selected from:

3. L 1 -R 1 is 【Chemistry 2-1】 is selected from During the ceremony: Where valences permit, n is 0, 1, 2, 3, or 4; R 100 each occurrence independently represents halogen, CN, OH, optionally substituted C 1~4 Alkyl, optionally substituted C 1~4 Alkoxy, and optionally substituted C 1~4 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt thereof, wherein: R is selected from the group consisting of aryl, ...

4. 4. The compound of claim 3, or a pharma- ceutically acceptable salt thereof, wherein n is 0.

5. R 1 SO 2 N.R. 11 R 12 where R 11 and R 12 are independently hydrogen, optionally substituted C 1~4 Alkyl, optionally substituted C 3~6 5. The compound according to any one of claims 1 to 4, which is cycloalkyl or an optionally substituted 4-8 membered heterocyclyl having 1 or 2 ring heteroatoms independently selected from N, O, and S, or a pharma- ceutically acceptable salt thereof.

6. R 1 But, SO 2 N.H. 2 or R 1 but, 【Chemistry 8】 or R 1 but, 【Chemistry 9】 6. The compound according to any one of claims 1 to 5, or a pharma- ceutically acceptable salt thereof, selected from:

7. L in Formula I 1 -R 1 but, 【Chemistry 13】 or L in formula I is selected from 1 -R 1 but, 【Chemistry 14】 3. The compound according to claim 1 or 2, or a pharma- ceutically acceptable salt thereof, selected from:

8. 8. The compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, wherein X is N.

9. L 2 is -O-, and L 3 is optionally substituted with one or more substituents independently selected from a bond, F, OH, and a protected OH; 1~4 The compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt thereof, which is alkylene.

10. Formula I-1 or I-2 【Chemistry 15】 10. The compound according to claim 9, wherein:

11. R 3 is hydrogen, F, Cl, Br, or C optionally substituted with F and / or deuterium; 1~4 11. The compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, wherein R is 0, R is 1, R is 2, R is 3, R is 4, R is 5, R is 6, R is 7, R is 8, R is 9, R is 10, R is 11, R is 12, R is 13, R is 14, R is 15, R is 16, R

12. R 3 but, 【Chemistry 35】 12. The compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, selected from:

13. R 4 The compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

14. A compound of formula II, or a stereoisomer or a pharma- ceutically acceptable salt thereof: 【Chemical 37】 (In the formula: L 1 is optionally substituted phenylene, optionally substituted 5- or 6-membered heteroarylene, optionally substituted 4- to 8-membered heterocyclylene, or optionally substituted C 3~8 is a carbocyclylene; R 1 But, SO 2 R 10 , S.O. 2 N.R. 11 R 12 or S(O)(NH)R 10 and X is N or CR 13 and Ring A is an optionally substituted carbocycle or an optionally substituted heterocycle having one or more ring heteroatoms independently selected from O, N, and S; Q is OH, F, CN, C(O)H, C(O)-(C 1-4 alkyl optionally substituted with F), CH 2 OH, C 1-4 alkyl optionally substituted with F, or C 1-4 alkoxy optionally substituted with F; R 3 is hydrogen, halogen, CN, C(O)NR 11 R 12 , optionally substituted C 1~6 Alkyl, optionally substituted C 2~4 Alkenyl, optionally substituted C 2~4 Alkynyl, optionally substituted C 1~4 Heteroalkyl, OR A , C.O.R. B , COOR A , N.R. 11 R 12 , optionally substituted C 3~8 carbocyclyl, optionally substituted 4- to 10-membered heterocyclyl, or optionally substituted 5- to 10-membered heteroaryl; R 4 is hydrogen, halogen, optionally substituted C 1~6 Alkyl or NR 11 R 12 and Where: R 10 is optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted 4-10 membered heterocyclyl; R 11 and R 12 Each occurrence is independently selected from hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted 4-10 membered heterocyclyl; or a nitrogen protecting group; or R 11 and R 12 may be joined to form an optionally substituted 4-10 membered heterocyclyl or 5- or 6-membered heteroaryl; R A is hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted 4-10 membered heterocyclyl; or an oxygen protecting group; R B is hydrogen, optionally substituted C 1~6 Alkyl, optionally substituted C 3~8 carbocyclyl, optionally substituted phenyl, optionally substituted 4-10 membered heterocyclyl, or optionally substituted heteroaryl; R 13 is hydrogen, F, CN, —OH, optionally substituted C 1~4 Alkyl, optionally substituted C 1~4 Heteroalkyl, optionally substituted C 3~8 carbocyclyl, or optionally substituted 4-10 membered heterocyclyl.

15. 15. The compound of claim 14, or a stereoisomer or pharma- ceutically acceptable salt thereof, wherein X is N. Claim 16: In formula II 【Chemical 38】 but, 【Chemistry 39-1】 16. The compound of claim 14 or 15, or a stereoisomer or a pharma- ceutically acceptable salt thereof, selected from:

17. In formula II 【Chemical 38】 but, 【Chemical 39】 or in formula II 【Chemistry 40】 but, 【Chemistry 41】 16. The compound of claim 14 or 15, or a stereoisomer or a pharma- ceutically acceptable salt thereof, selected from: Claim 18: In formula II 【Chemical 38】 but, 【Chemistry 41-1】 16. The compound of claim 14 or 15, or a stereoisomer or a pharma- ceutically acceptable salt thereof, selected from:

19. The following formula II-1 or II-2: 【Chemistry 42】 (In the formula: n1 and n2 are independently 0, 1, 2, or 3; Z is CR 21 R 22 , O, or NR 23 and Where valences permit, p is 0, 1, 2, 3, or 4; L 1 is optionally substituted phenylene, optionally substituted 5- or 6-membered heteroarylene, optionally substituted 4-8-membered heterocyclylene, or optionally substituted C 3-8 carbocyclylene; R 1 is SO 2 R 10 , SO 2 NR 11 R 12 , S(O)(NH)R 10 , or C(O)NR 11 R 12 ; Q is OH, F, CN, C(O)H, C(O)-(C 1-4 alkyl optionally substituted with F), CH 2 OH, C 1-4 alkyl optionally substituted with F, or C 1-4 alkoxy optionally substituted with F; R 3 is hydrogen, halogen, CN, C(O)NR 11 R 12 , optionally substituted C 1-6 alkyl, optionally substituted C 2-4 alkenyl, optionally substituted C 2-4 alkynyl, optionally substituted C 1-4 heteroalkyl, OR A , COR B , COOR A , NR 11 R 12 , optionally substituted C 3-8 carbocyclyl, optionally substituted 4-10 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl; R 4 is hydrogen, halogen, optionally substituted C 1-6 alkyl, or NR 11 R 12 ; Where: R 10 is optionally substituted C 1-6 alkyl, optionally substituted C 3-8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted 4-10 membered heterocyclyl; each of R 11 and R 12 at each occurrence is independently hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 3-8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted 4-10 membered heterocyclyl; or a nitrogen protecting group; R 11 and R 12 may be joined to form an optionally substituted 4-10 membered heterocyclyl or 5- or 6-membered heteroaryl; R A is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 3-8 carbocyclyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted 4-10 membered heterocyclyl; or an oxygen protecting group; R B is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 3-8 carbocyclyl, optionally substituted phenyl, optionally substituted 4-10 membered heterocyclyl, or optionally substituted heteroaryl; R 20 Each occurrence independently represents oxo, halogen, CN, G 1 , C(O)H, C(O)G 1 , O.H., O.G. 1 , N.H. 2 , NH(G 1 ), and N(G 1 ) (G 1 ), where G 1 each occurrence independently represents F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 1~4 Alkyl, or F, CN, OH, and C 1~4 C optionally substituted with 1 to 3 substituents independently selected from heteroalkyl 3~6 is cycloalkyl, or two geminal R 20 form an oxo group, or two R 20 together with the intervening atoms form an optionally substituted ring system; R 21 and R 22 are each independently hydrogen or R 20 and Or R 21 and R 22 together form an oxo group or an optionally substituted ring structure, Or R 21 and R 22 and one R 20 the groups, together with the intervening atoms, form a ring structure which is optionally substituted; R 23 is hydrogen or R 20 and Or R 23 and one R 20 The radicals, together with the intervening atoms, form a ring structure which is optionally substituted. or a stereoisomer or a pharma- ceutically acceptable salt thereof.

20. 20. The compound of claim 19, or a stereoisomer or pharma- ceutically acceptable salt thereof, wherein Z is O.

21. n2 is 1, n1 is 0, 1, 2, or 3; 21. The compound of claim 19 or 20, wherein p is 0, or a stereoisomer or a pharma- ceutically acceptable salt thereof.

22. L in Formula II, Formula II-1, or Formula II-2 1 -R 1 but, 【Chemistry 45】 or L in formula II, formula II-1, or formula II-2 is selected from 1 -R 1 but, 【Chemistry 46】 22. The compound according to any one of claims 14 to 21, or a stereoisomer or a pharma- ceutically acceptable salt thereof, selected from:

23. R 3 is hydrogen, F, Cl, Br, or C optionally substituted with F and / or deuterium; 1~4 23. The compound according to any one of claims 14 to 22, or a stereoisomer or a pharma- ceutically acceptable salt thereof, wherein R is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23

24. R 3 but, 【Chemistry 47】 24. The compound according to any one of claims 14 to 23, or a stereoisomer or a pharma- ceutically acceptable salt thereof, selected from:

25. R 4 The compound according to any one of claims 14 to 24, or a stereoisomer or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

26. A compound, or a pharma- ceutically acceptable salt thereof, The compound is selected from: 【Chemistry 101-1】 【change】 【change】 【change】 【change】 【change】 or, The compound is selected from: 【Chemistry 102-1】 【change】 【change】 【change】 【change】 【change】 or, The compound is selected from 【Chemistry 103-1】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 A compound, or a pharma- ceutically acceptable salt thereof.

27. A compound, or a pharma- ceutically acceptable salt thereof, comprising: The compound is selected from 【Chemistry 104】 【change】 A compound, or a pharma- ceutically acceptable salt thereof.

28. A compound, or a pharma- ceutically acceptable salt thereof, comprising: The compound is represented by the following formula: 【Chemistry 105】 A compound, or a pharma- ceutically acceptable salt thereof.

29. A compound, or a pharma- ceutically acceptable salt thereof, comprising: The compound is represented by the following formula: 【Chemistry 106】 A compound, or a pharma- ceutically acceptable salt thereof.

30. A compound, or a pharma- ceutically acceptable salt thereof, comprising: The compound is represented by the following formula: 【Chemistry 107】 A compound, or a pharma- ceutically acceptable salt thereof.

31. A compound represented by the following: 【Chemistry 108】

32. A compound represented by the following: 【Chemistry 109】

33. A compound represented by the following formula: 【Chemistry 110】

34. A pharmaceutical composition comprising a compound according to any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof, or a compound according to claims 31 to 33, and a pharma- ceutically acceptable excipient.

35. 1. A pharmaceutical product for use in a method of treating cancer in a subject in need thereof, comprising: The medicament comprises a compound according to any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof, or a compound according to claims 31 to 33, or a pharmaceutical composition according to claim 34; 40. The pharmaceutical composition of claim 34, wherein the method comprises administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 39, or a pharma- ceutically acceptable salt thereof, or a compound according to claims 31 to 33, or a pharmaceutical composition according to claim 34.

36. 36. The pharmaceutical product of claim 35, wherein the cancer is breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, liver cancer, pancreatic cancer, stomach (i.e. gastric) cancer and / or thyroid cancer.

37. The pharmaceutical agent of claim 3599, wherein the cancer is a breast cancer selected from ER positive / HR positive, HER2 negative breast cancer; ER positive / HR positive, HER2 positive breast cancer; triple negative breast cancer (TNBC); inflammatory breast cancer, endocrine therapy resistant breast cancer, trastuzumab resistant breast cancer, or breast cancer exhibiting primary or acquired resistance to CDK4 / CDK6 inhibition.

38. 36. The pharmaceutical product of claim 35, wherein the cancer is advanced or metastatic breast cancer, lung cancer, or ovarian cancer.

39. The method of any one of claims 35 to 38, wherein the cancer is characterized by amplification or overexpression of cyclin E1 and / or cyclin E2.

40. Use of a compound according to any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof, or a compound according to claims 31 to 33, or a pharmaceutical composition according to claim 34, in the preparation of a medicament for use in a method of treating cancer in a subject in need thereof.

41. The use of claim 40, wherein the cancer is breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, renal cancer, liver cancer, pancreatic cancer, stomach (i.e. gastric) cancer and / or thyroid cancer.

42. The use of claim 40, wherein the cancer is a breast cancer selected from ER positive / HR positive, HER2 negative breast cancer; ER positive / HR positive, HER2 positive breast cancer; triple negative breast cancer (TNBC); inflammatory breast cancer, endocrine therapy resistant breast cancer, trastuzumab resistant breast cancer, or breast cancer exhibiting primary or acquired resistance to CDK4 / CDK6 inhibition.

43. The use described in claim 40, wherein the cancer is advanced or metastatic breast cancer, lung cancer, or ovarian cancer.

44. The use according to any one of claims 40 to 43, wherein the cancer is characterized by amplification or overexpression of cyclin E1 and / or cyclin E2.